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ABSTRACT
The growth of chronic myeloid leukaemic (CML) and acute myeloid 
leukaemic (AML) cells in vitro and their response to various cytokines were 
studied and compared to normal peripheral blood and bone marrow cells.
In normal mononuclear cells (MNC) the three cytokines [granulocyte 
colony-stimulating factor (G-CSF), granulocyte-macrophage colony stimulating 
factor (GM-CSF) and interleukin-3 (IL-3)] had no appreciable difference at 
stimulating (colony-forming unit granulocyte-macrophage) CFU-GM-formation. 
By contrast, G-CSF was a more potent stimulator of CFU-CML, than GM-CSF 
or IL-3. Interleukin-4 (IL-4) augmented G-CSF-induced colony formation of 
CML chronic phase cells. Transforming growth factor j3l (TGF/3X) reduced G- 
CSF-induced CFU-CML from CML chronic phase (p< 0.005) and blast 
transformation MNC, but had no effect on normal CFU-GM stimulated by G- 
CSF.
The growth of CML mononuclear cells in vitro could not be correlated to 
the white cell count or percentage of CD34+ cells present. The mechanisms for 
the inhibitory effects of TGFft on CML cells were studied using in-situ 
hybridisation techniques to demonstrate the expression of the G-CSF and IL-4 
receptors. The results suggest that this response is more likely to be due to a 
difference in signal transduction or protein synthesis rather in transcription.
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CHAPTER 1
INTRODUCTION
Blood is a suspension of differentiated, mainly non-dividing cells. It is 
produced by undifferentiated haemopoietic cells with a high replicative 
potential, belonging to the marrow and reticuloendothelial system. In recent 
years much time has been devoted to the study of the haemopoietic system 
and the factors regulating it. This has been facilitated by the relatively easy 
access to blood and bone marrow cells.
In-vitro, the progenitor cells of the haemopoietic system require colony 
stimulating factors (CSFs) to proliferate and differentiate. A  significant 
number of these haemopoietic growth factors have now been cloned and 
sequenced and their effects have been well characterised. However their 
mechanisms of action and biological effects in vivo are unclear and whether 
they play a role in the pathogenesis of haemopoietic malignancies is unproven. 
Advances in recombinant DNA technology has lead to the molecular cloning 
of genes that encode CSFs and a series of other polypeptides released in the 
inflammatory response, many of which also affect haemopoietic cells. 
Collectively these peptides have been termed cytokines.
The aim of this thesis was to study the proliferative response of normal 
and leukaemic cells to various cytokines and to determine whether a 
combination of cytokines could be of benefit in the treatment of leukaemia. 
The main cytokines used were transforming growth factor (TGF^),
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granulocyte colony-stimulating factor (G-CSF) and interleukin-4 (IL-4). 
Attempts were made to elucidate the cause of the different effects that TGF/^ 
had on normal and leukaemic cells using in situ hybridisation techniques.
The haemopoietic system
Embiyology
The three primary germ layers of the human embryo are the ectoderm, 
mesoderm and the endoderm. The first haemopoietic stem cells arise from the 
mesoderm of the yolk sac. These mesoblastic cells generate nucleated 
erythroblasts that synthesize "embryonic" haemoglobin during the first week 
of life. The production of nucleated red cells by the yolk sac declines sharply 
at 6 weeks and terminates by 10 weeks. From the second to the seventh month 
of life the liver is the primary site of haemopoiesis, supported in this role to 
a lesser extent by the spleen from the third to the sixth month (Lewis, 1989). 
The transfer of responsibility for haematopoiesis from the liver to the bone 
marrow begins at three months and is usually complete at birth. The liver 
produces a small number of haemopoietic cells for a short while after birth. 
A  few precursor cells may persist in the spleen even in adulthood.
The human yolk sac and early embryo initially produce red cells and a 
small percentage of mainly pre-B lymphocytes. Megakaryocytes first appear 
after three months. It is only in the second half of gestation that myelopoiesis 
begins and granulocytes are formed (Jandl, 1989).
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Sites of haemopoiesis
Bone marrow: In adults the bone marrow is the major site of
haemopoiesis. The human skeleton contains approximately 600 grams of bone 
marrow. Over 70% of the bone marrow is located in the pelvis, vertebrae and 
sternum (Jandl, 1989). Progenitor cells with the ability to generate erythroid, 
leucocyte and megakaryocyte precursors are located within the bone marrow. 
Among the progenitor cells are mature blood cells and non-haemopoietic cells, 
all of which are supported by a reticulin framework. This reticulin framework 
or bone marrow stroma is an ill-defined entity that consists of endothelial 
cells, fibroblasts, fat cells and macrophages. The stromal cells collectively 
support haemopoiesis but the precise contributions of the different 
components are unknown (Lewis, 1989).
Spleen: The spleen is an intra-peritoneal organ located in the left
hypochondrium. In healthy adults the spleen weighs between 150 and 200 
grams, and measures approximately 4 x 8 x 1 2  cm. The spleen is normally not 
palpable on physical examination of healthy individuals. It consists of three 
compartments: the white pulp, the marginal zone and the red pulp. The white 
pulp consists of lymphoid follicles contained within a reticular framework. The 
lymphoid follicles are the sites of lymphocyte production. The marginal zone 
is the junctional area between the red and white pulp. It is composed of a 
more heterogenous population of cells but is particularly rich in monocytes. 
The red pulp contains both erythroid and myeloid progenitor cells (Lewis, 
1989).
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Lymph nodes: The lymph nodes contain lymphoid follicles which are
sites of lymphopoiesis. Lymphocytes, plasma cells, macrophages and 
occasionally mast cells are present in lymph nodes. Granulocytes and erythroid 
cells are not normally found (Hess, 1987).
Peyers patches: These are lymphoid aggregates found in close
association with the epithelium of the small bowel. They are similar in 
structure to the lymphoid follicles found in the spleen and lymph nodes and 
are sites of lymphopoiesis (Hess, 1987).
Thymus: The thymus is a bi-lobed lymphoepithelial gland located in
the anterior and superior mediastinum. Development begins at about the 
eighth week of gestation. The gland continues to increase in weight until 
puberty after which it atrophies and is replaced mainly by fat and fibrous 
tissue. The main cellular components of the thymus are T-lymphocytes and 
epithelial cells (Hess, 1987)
Haemopoietic cell populations
The 3 main classes of mature blood cells are erythrocytes (red cells), 
leucocytes (white cells) and platelets. Both erythrocytes and platelets lack a 
nucleus, a feature that is not seen in any other cell type in the human body. 
They are therefore incapable of cell division. The main function of 
erythrocytes is O2/CO2  transport, and that of platelets is clotting. Leucocytes 
comprise of neutrophils, eosinophils, basophils, lymphocytes and monocytes. 
Though they have many diverse functions they are generally responsible for
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aspects of humoral and cell-mediated immunity.
Haemopoietic stem cells
Mammalian blood cells have a finite life span which is considerably 
shorter than the life span of the organism. The maintenance of constant 
numbers of cells in the peripheral blood is achieved by the proliferation and 
differentiation of precursor cells which are located primarily in the bone 
marrow. These precursors are all derived from a common self-maintaining 
population of stem cells established during embryogenesis (Metcalf and 
Moore, 1971). Potten and Loeffler in 1990, defined stem cells as "capable of 
1) proliferation, 2) self-maintenance, 3) production of large numbers of 
differentiated functional progeny, 4) regenerating the tissue after injury and 
5) flexibility in the use of these options". Although several aspects of 
haemopoiesis are yet to be defined, some general principles have been 
established:- (Metcalf, 1984; Testa and Dexter, 1990; Metcalf, 1991; Wright 
and Lord, 1992).
- The pluripotent stem cell is the most "senior" cell in the bone marrow 
hierarchy and has a finite capacity for renewal.
- Once committed to a given lineage, stem cells differentiate 
unidirectionally, this being associated with a restriction of the cell’s 
capacity for renewal.
- Local and systemic growth factors and inhibitors regulate the 
proliferation of stem cells.
20
- Contact with marrow stromal cells is important for stem cell 
proliferation.
The probability of stem cell renewal at the single cell level is thought 
to be a random process and hence it is not possible to predict whether an 
individual stem cell will self-renew or differentiate (Till et al, 1964). In 
contrast, at the stem cell population level self-renewal and differentiation 
appear to be tightly controlled so that demands for the production of 
differentiated cells and for the expansion of the stem cell population are met 
when necessary. The commitment to a particular lineage of differentiation may 
be stochastic (i.e. the probability of entering a particular lineage is random), 
predetermined or as a response to growth factors or microenvironmental cues 
(Gordon, 1993).
Haemopoietic tissue can therefore be broadly divided into 3 types of 
cell populations: multipotent progenitors or stem cells, committed progenitors 
and maturing/mature cells. Two functional qualities characterise a stem cell: 
self-renewal by self-replication, and the production of more differentiated 
cells. Committed progenitor cells are derived from stem cells, and are 
committed to cell division and differentiation along one or more maturation 
pathways. A  system of hierarchy therefore exists with a small number of 
"committed" cells with a high replicative potential giving rise to cells of a 
particular type which possess a varying capacity to divide. The process of 
haemopoiesis should therefore be considered as a continuum with a series of 
compartments of increasing maturity, and decreasing potential for self-renewal,
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which is frequently displayed as a unidirectional linear branching hierarchy.
Progenitor cells are detected by their ability to give rise to colonies of 
morphologically recognizable differentiation progeny in semi-solid cultures 
(Pluznik and Sachs, 1965; Bradley and Metcalf, 1966). The 3rd stage of 
haemopoiesis encompasses the bulk (approximately 95%) of the cells. It 
represents the proliferative amplification of differentiated cells as they mature 
to become fully functional blood cells. These cells are recognizable and 
classified by their morphological characteristics. When mature the cells leave 
the marrow environment via the central venous sinus and enter the peripheral 
circulation where they carry out appropriate functions. The differentiation 
pathway leading to each mature cell type is illustrated in Figure 1. In addition 
to giving rise to mature haemopoietic cells it now seems clear that osteoclasts 
(Ash et al, 1980), epidermal Langerhan cells (Katz et al, 1979), and tissue 
mast cells (Kitamura et al; 1977, Kitamura et al, 1981) are also derived from 
bone marrow cells.
In normal human bone marrow less than 1% of the stem cells are in the 
peripheral circulation at any one time (Gordon, 1994). Stem cells can be 
induced to circulate by haemopoietic growth factors and cytotoxic drugs. 
Brecher and Cronkite in 1951 provided evidence for circulating stem cells in 
mice. In 1976, Richman et al showed that there was an increase in the number 
of circulating progenitor cells during the recovery phase from chemotherapy. 
In 1988, it was reported that administration of haemopoietic growth factors 
(G-CSF and GM-CSF) resulted in mobilization of progenitor cells into the
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circulation (Durstein et al, 1988; Socinski et al, 1988).
In, in vivo studies of murine haemopoiesis the spleen colony-forming 
units (CFU-S) have been widely regarded as cells most closely fitting stem 
cells due to their proliferative potential, self-renewal characteristics and 
capacity for multi-lineage differentiation (Till and McCulloch, 1961).
Spleen colony-forming unit (CFU-S) assay
The spleen colony-forming technique was developed in 1961 by Till and 
McCulloch. It was the first quantitative assay for measuring the numbers of 
haemopoietic stem cells. Mice were lethally irradiated (8-9 Gy) to destroy 
endogenous stem cells. They were then injected intravenously with bone 
marrow cells. Post mortem analysis performed between 7 and 12 days after 
injection of donor bone marrow cells revealed macroscopic colonies in the 
spleen. The colonies consisted mainly of maturing cells of erythroid, 
megakaryocytic and granulocytic lineages, though some undifferentiated cells 
were present. The numbers of spleen colony-forming units (CFU-S) can be 
directly related to the total number of injected cells by a seeding factor f. Thus 
CFU-S = CFC-S x f. The value of f is approximately 0.1.
Growth of haemopoietic progenitor cells in vitro
In recent years techniques have been developed to study the behaviour 
of haemopoietic progenitor cells in culture. The first of these in vitro cloning 
techniques was introduced by Pluznik and Sachs in 1965 and Bradley and
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Metcalf in 1966. At this stage only mixed colonies consisting of granulocyte 
and macrophage were grown and their growth depended on the presence of 
a colony-stimulating activity (CSA) derived from a variety of cell or tissue 
sources. Variations in the culture conditions and in the source of CSA 
gradually extended the technique and it is now possible to demonstrate the 
growth of clones of the different committed precursors cells in semi-solid gels 
of agar or methylcellulose. Types of colony-forming units (CFU) are named 
according to the mature cell types arising in the colonies. Thus CFU-GEMM  
or CFU-mix describes mixed colonies containing granulocytic, megakaryocytic 
and erythroid progeny and BFU-E, CFU-GM and CFU-MEG describes 
progenitor cells committed to erythrocyte, granulocyte and megakaryocyte 
differentiation respectively. An important step forward came with the ability 
to grow bone marrow in long-term culture. Initially described by Dexter in 
1977 and subsequently refined, the technique in its present form is capable of 
supporting the growth of a wide spectrum of bone marrow cells, including the 
stem cell population, through numerous generations over a period of many 
months.
Mature haemopoietic cells
There are 8 commonly recognised mature blood cell types that are 
derived from the pluripotent stem cell. They are neutrophils, eosinophils, 
basophils, monocytes, T and B lymphocytes, erythroid cells and platelets.
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Neutrophil maturation and morphology
The mature neutrophil represents 60 to 70% of the total leucocyte 
count. The maturation of the neutrophil goes through 5 recognisable stages, 
from the myeloblast, to promyelocyte, myelocyte, metamyelocyte and finally 
to a mature segmented neutrophil.
Myeloblast: The myeloblast is the earliest identifiable precursor of the 
mature neutrophil. It is usually found in small numbers in the bone marrow 
but is absent from the peripheral blood in healthy individuals. The cell is of 
variable size (10-18pm) and has a large round/oval nucleus with one to five 
pale nucleoli, the cytoplasm is scanty and basophilic and in the more mature 
myeloblast may contain a few azurophilic or primary granules. Occasionally in 
acute leukaemia some of the primary granules coalesce to form one or more 
rod-like cytoplasmic inclusions known as Auer rods. These Auer rods are 
regarded as being diagnostic of leukaemic myeloblasts.
Promyelocyte: As the cytoplasm of the maturing myeloblast becomes 
more abundant a new type of granule known as the secondary granule 
appears. These granules stain darkly with May-Grunwald Giemsa and he over 
the nucleus as well as in the cytoplasm.
Myelocyte: The myelocyte is slightly smaller than the myeloblast, but 
it has a more prominent cytoplasm. The nucleus is still rounded or slightly 
indented but nucleoli are absent. Using a May-Grunwald Giemsa stain the 
cytoplasm has lost some of its basophilia, it becomes more pink and contains
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increasing numbers of specific granules which can be identified as neutrophilic, 
eosinophilic or basophilic.
Metamyelocyte: The development of nuclear indentation marks the 
transition from myelocyte to metamyelocyte. The nucleus becomes more 
kidney shaped and the cytoplasm acquires more granules. As the nucleus 
elongates further and bends the cell is known as a band form.
Neutrophil: The mature neutrophil is approximately 10-14 |im in size. 
The nuclear material is divided into 3 or 4 segments which are joined by thin 
strands of chromatin. The mature neutrophil spends about 11 days in the 
marrow whilst its time in the circulation is extremely short with a half life of 
6 to 8 hours. Neutrophils can adhere to and penetrate the endothelial lining 
of the blood vessels and are thus also found in extravascular sites. Neutrophils 
phagocytose and kill micro-organisms. Ingested organisms are contained within 
vacuoles (phagosomes) into which are released a battery of enzymes normally 
contained within the cytoplasmic granules. These enzymes include lysozyme, 
myeloperoxidase and acid hyaluronidase.
Other cells included in the granulocyte category are:
Eosinophils; these normally comprise 2 to 3% of the mature leucocytes. The 
eosinophil is characterised by the presence of large granules that fill the 
cytoplasm and stain a bright orangish-red colour with Wright’s stain. 
Eosinophils contain about a third of the histamine found in normal blood. 
Eosinophils participate in hypersensitivity reactions and play a role in 
immunity to helminth infections (Jandl, 1989).
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Basophils; are the least common of the granulocyte family, representing 0.2% 
of blood leucocytes. Adult forms are readily distinguished by the presence of 
huge metachromatic purple/black granules in the cytoplasm. They contain half 
the histamine found in man, nearly all of which is released during an 
anaphylactic reaction. Their exact function is unclear, but they appear in 
tissues during hypersensitivity states and anaphylactic reactions.
Other cells in the leucocyte compartment
B-lymphocytes: These cells possess cytoplasmic and later in their
development, surface-bound immunoglobulin. They are responsible for 
antibody production. B-cells that are actively producing antibody are 
morphologically distinct and are called plasma cells.
T-fymphocytes: These cells comprise 60-85% of the circulating
lymphocytes and are sub-divided on the basis of surface markers into several 
sub-populations with distinct functions. These include the augmentation of 13- 
cell antibody production, suppression of both T- and B-cell responses, and also 
non-specific cytotoxicity.
Monocytes/macrophages: These cells are part of the mononuclear
phagocyte system. Their primary function is phagocytosis of micro-organisms 
and the removal of damaged tissue fragments, dead cells, and inert particles 
produced in infected and inflammatory states. They are vital to the response 
of lymphocytes to antigenic stimulation. They also make soluble mediators, 
such as CSA with regulatory or modulatory roles and are involved in cell to 
cell interactions of several kinds.
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Figure 1: D ifferentiation pathways o f the haem opoietic  
system
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The eight major mature cell types of the blood are all derived from the 
pluripotent stem cell compartment. From stem cells derive progenitor cells, which 
are committed to divide and differentiate along one or more differentiation 
pathways. In the presence of appropriate growth factors, these progenitors can 
be grown in semi-solid culture medium to form colonies and are therefore known 
as colony-forming units (CFU). Types of colony-forming cell are named according 
to the mature cell types arising in the colonies:
granulocyte/erythroid/macrophage/megakaryocyte (CFU-GEMM); erythroid burst- 
forming unit (BFU-E);erythroid colony-forming unit (CFU-E); granulocyte- 
macrophage (CFU-GM);megakaryocyte (CFU-MEG);eosinophil (CFU-Eo). 
Other abbreviations are n, neutrophil; e, eosinophil; b; basophil.
Chronic myeloid leukaemia
Chronic myeloid leukaemia (CML) is a clonal cancer arising from 
neoplastic transformation of the haemopoietic stem cell ( Kurzrock et al,
1988). The Philadelphia (Ph) chromosome is the hallmark of the disease and 
is the result of a reciprocal translocation between chromosome 9 and 22. This 
cytogenetic aberration is seen in greater than 90% of cases of CML (Rowley, 
1973).
Epidemiology
CML occurs with an annual incidence of about 1 case per 100,000 of 
the population (Goldman, 1989b). Approximately 650 cases per year are 
diagnosed in the United Kingdom. There is a slight male preponderance, the 
male to female ratio being 1.4:1. The diagnosis is most commonly made in the 
5th and 6th decades of life, however the disease can affect both neonates and 
the elderly.
The only known predisposing cause is ionising radiation. This was 
clearly demonstrated in the survivors exposed to the high gamma irradiation 
from the atomic bombings at Hiroshima and Nagasaki. The incidence of CML 
in this group of patients was not age related. The leukaemia excesses have 
now disappeared and the leukaemia rates in the survivors today are no 
different to the general population of Japan (Cartwright and Staines, 1992).
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Pathogenesis
In 1960, Nowell and Hungerford working in Philadelphia reported that 
myeloid cells from patients with CML had a deletion of a portion of the long 
arm of the G group of chromosomes. This was subsequently shown to involve 
a G group pair other than the pair implicated in Downs Syndrome (trisomy 
21) and was hence designated chromosome 22. The abnormal chromosome 
was called the Philadelphia chromosome (Ph).
In 1973, Rowley examined banded preparations of chromosomes from 
patients with CML and noted that cells with the Ph chromosome had 
elongation of the long arm of one member of the number 9 pair of 
chromosomes. It later transpired that the Ph chromosome is the reciprocal 
translocation between chromosome 9 and 22. The resultant chromosomal 
fusion creates a chimeric gene composed of 5’ sequences of the breakpoint 
cluster region (bcr) fused to the 3’ sequences of the Abelson proto-oncogene 
(abl), (Heisterkamp et al, 1984). The rearrangement in chromosome 22, band 
q ll  has been shown to be localised in a breakpoint cluster region (Major or 
m-bcr), (Groffen et al, 1984), which is located within the bcr gene. The hybrid 
bcr/abl gene formed as a result of the translocation encodes a protein kinase 
of p210 kD which has increased tyrosine kinase activity (Kurzrock et al, 1988; 
Konopka et al; 1984, Konopka et al, 1985). The precise function of the p210 
protein kinase is not known but it may disturb the normal mechanisms that 
control haemopoiesis. A  CML like disease has been observed in mice whose 
haemopoietic cells have been genetically engineered to express various bcr/abl
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constructs. Thus providing further evidence that this hybrid gene plays a 
primary role in the pathogenesis of CML in humans (Daley et al, 1990; 
Elefanty et al, 1990; Kelliher et al, 1990).
Clinical features
In most patients the disease has a triphasic course ; the chronic phase, 
the accelerated phase and the acute phase or blast transformation.
Chronic phase
Patients in chronic phase commonly present with lethargy (due to 
anaemia) or abdominal discomfort (due to splenomegaly). Increased sweating 
and weight loss may also be common presenting complaints. Rarer symptoms 
include fever, spontaneous bruising, non-specific visual disturbances due to 
hyperviscosity and priapism. Between 20 to 30% of patients are asymptomatic 
when diagnosed. At diagnosis 70-85% of patients have splenomegaly, 50% 
have hepatomegaly and a smaller proportion have generalised 
lymphadenopathy.
The median duration of the chronic phase is 3.5 years, but it can range 
from 1 to more than 10 years (Goldman 1989b).
Accelerated phase
There is no strict definition of the accelerated phase but the following 
features may point to disease progression: a rapid leucocyte doubling time,
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greater than 12% blasts in peripheral blood, greater than 20% blasts plus 
promyelocytes in marrow, more than 20% basophils plus eosinophils, anaemia 
or thrombocytopenia despite treatment, thrombocytosis in the absence of 
splenectomy, chromosomal abnormalities (in addition to the Ph chromosome), 
marrow failure associated with myelofibrosis and a leucocyte count resistant 
to treatment (Goldman, 1988).
Blast transformation
The evolution from chronic phase to blast transformation usually occurs 
over a period of weeks or months but on rare occasions can happen 
precipitously over a few days. Blast transformation is arbitrarily defined as the 
presence of more than 30% blasts or blasts plus promyelocytes in the 
peripheral blood or bone marrow. Symptoms, when present, include fever, 
weight loss, sweats, bone pain, pain in the splenic area, generalised 
lymphadenopathy and multiple subcutaneous nodules. Symptoms of 
hyperviscosity due to intracerebral or intrapulmonary leucostasis present less 
frequently. Additional cytogenetic abnormalities occur in over 80% of patients 
with CML approaching blast crisis (Kurzrock et al,1988) and commonly 
include trisomy 8, a second Ph chromosome and isochromosome 17q.
Haematological findings
The leucocyte count at diagnosis is typically between 100 x 109/1 and 300 
x 109/1, but can range from 20 x 109/1 to 1000 x 109/1. The white cell differential
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shows a full spectrum of immature and mature granulocytes with left-shifted 
myeloid maturation. Blasts may constitute 10 to 12% of the differential. The 
eosinophil and basophil count are frequently raised. The absolute lymphocyte 
count is normal. The amount of neutrophil alkaline phosphatase is greatly 
reduced or absent. Patients with a white cell count >150 x 109/1 are usually 
anaemic at diagnosis. The platelet count is usually between 300 and 700 x 109/1 
but rarely is over 106 x 109/L
The bone marrow at diagnosis is usually hypercellular, with loss of fat 
spaces and shows an increased myeloid population with left-shifted maturation. 
The number of megakaryocytes maybe increased. Erythroid activity is far less 
affected than myeloid maturation. Bone marrow biopsy confirms the lack of 
fat spaces and frequently reveals increased reticulin and diffuse fibrosis.
In patients with hepatosplenomegaly, histological examination shows 
infiltration of these organs by myeloid precursors and to a lesser extent 
megakaryocyte and erythroid precursors.
Disease progression maybe accompanied by an increased blast count, 
thrombocytosis, basophilia, eosinophilia, marrow fibrosis and less commonly 
thrombocytopenia. In 70% of cases of blast transformation the blasts have 
morphological and cell marker characteristics of myeloid cells, in 
approximately 20% the blasts are lymphoid in nature and in the remaining 5 
to 10% they have mixed lymphoid and myeloid features.
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Ph negative CML
Between 5 and 10% of patients with clinical and haematological 
features similar or identical to Ph positive CML lack the Ph chromosome.
The haematological features may initially be typical of Ph positive 
CML, however in some patients there maybe subtle clues that suggest Ph 
negativity such as a low platelet count, absence of the typical predominance 
of myelocytes in the leucocyte differential and the absence of an eosinophilia 
or basophilia. On molecular analysis of bone marrow cells some of these 
patients have the abnormal hybrid bcrfabl gene whilst in others no 
characteristic molecular abnormality has been defined. Initial studies suggested 
that patients with Ph negative CML had a worse prognosis. However more 
recent series where highly atypical CML’s have been excluded suggest, that for 
patients with a form of leukaemia close to classical CML, the only difference 
being the absence of the Ph chromosome, the prognosis is similar to Ph 
positive CML with a median survival of 3.5 years (Goldman, 1989b).
Therapeutic options
Although the prognosis for newly diagnosed patients with CML has not 
changed substantially in the past 10 years, the number of therapeutic options 
has increased significantly. Patients are now treated with chemotherapy, alpha- 
interferon, autologous bone marrow or peripheral stem rescue or allogeneic 
bone marrow transplantation (ABMT).
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Chemotherapy
Twenty years ago a newly diagnosed patient with CML was treated with 
busulphan without too much deliberation. This is no longer the case. Once the 
decision to treat has been reached, the choice lies between busulphan, 
hydroxyurea and alpha-interferon. The peripheral blood of patients with 
untreated CML contains large numbers of committed myeloid progenitor cells. 
Ideally therefore all new patients should be leukapheresed and have the buffy 
coat cells frozen prior to initiation of treatment. These cells could then be 
used to restore haemopoiesis following marrow aplasia secondary to either a 
failed bone marrow graft or inadvertent overtreatment with busulphan. The 
cells could also be used for autologous rescue, after high dose chemo- 
radiotherapy.
The two principal cytotoxic drugs used in treating CML are hydroxyurea 
and busulphan. Both drugs reverse symptoms, normalise spleen size and 
restore the blood count to normal. Busulphan however has a formidable list 
of long term side effects including interstitial pneumonitis, sterility, cutaneous 
pigmentation and a wasting condition. Erroneous administration can lead to 
severe or fatal marrow hypoplasia.
Hydroxyurea is a nucleotide reductase inhibitor. It acts on relatively 
mature myeloid cells, as reducing or stopping treatment leads to a rapid 
recurrence of leucocytosis. Hence unlike busulphan it has never been 
reported as causing an irreversible marrow hypoplasia (Goldman, 1990). 
Hydroxyurea is more likely than busulphan to cause immediate side effects
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which include rashes, fevers and non-specific gastro-intestinal symptoms. 
Unlike busulphan, hydroxyurea needs to be given daily if the leucocyte count 
is to be controlled. Hydroxyurea has now superseded busulphan as one of the 
drugs of choice for CML because of its beneficial effect on survival 
(Hehlmann et al, 1993).
Alpha-interferon
Since its introduction in the early 1980’s as treatment for CML, alpha- 
interferon has been used with increasing frequency. Not only does alpha- 
interferon control the spleen size and white cell count but it is also the first 
agent employed in treatment for CML that induces partial or even on occasion 
complete suppression of Ph positivity. Its exact mechanism of action is not 
clearly understood but it could act by suppressing more mature myeloid 
progenitor cells (Galvani and Cawley, 1989) or by inducing specific changes 
in the function or cellular composition of the marrow stroma (Dowding et al, 
1991). To induce Ph negativity alpha interferon needs to be given daily, sub- 
cutaneously for a period of 9 to 12 months. It is reasonable to stop treatment 
after this period if there is no reduction in Ph positivity. Treatment with alpha- 
interferon also prolongs the overall median survival. The duration of survival 
appears to correlate with the cytogenetic response achieved, if the response 
is greater than 65% Ph negative metaphases the actuarial survival at 5 years 
is approximately 90%. Unfortunately only a small proportion of patients 
(about 13%) respond in this way (Kloke et al, 1993).
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Autologous bone marrow rescue (ABMR)
The incurability of CML with conservative treatment, the favourable 
results of allogeneic transplants in the chronic phase of the disease, and the 
lack of suitable donors has generated considerable interest in ABMR for 
patients lacking a donor.
The presence of primitive haemopoietic cells in adult peripheral blood 
has been well recognized for 3 decades. Initial experiments showed that 
peripheral blood from a variety of species, including humans was capable of 
protecting recipients from lethal doses of whole body irradiation, by restoring 
blood cell formation from circulating donor cells (Goodman et al, 1962; 
Epstein et al, 1966). Subsequent studies lead to the demonstration and 
quantitation of specific progenitor populations detected by colony assays 
(McCreadie et al, 1971; Chervenick et al, 1971). More recently, identification 
of strategies for increasing the circulation of progenitors in the circulation, has 
heightened interest in the potential of peripheral blood harvests for clinical 
treatment protocols requiring haematologic rescue (Haylock et al, 1992 Gianni 
et al, 1989). Udomasakdi et al, in 1992a showed that peripheral blood of 
normal adults has a relatively small but readily detectable population of 
functionally defined primitive haemopoietic cells, that share properties with 
primitive marrow precursor cells, known as long term culture initiating cells 
(LTC-IC). They also showed that (Udomasakdi et al, 1992b) LTC-IC in CML 
patients, showed features of proliferating or activated cells. In marked contrast 
LTC-IC in normal donors exhibit features of a quiescent population.
37
Patients with CML have greatly increased numbers of pluripotent stem 
cells in their blood and bone marrow. These cells can be collected and 
cryopreserved prior to initiation of treatment and used at a latter date for 
autografting. Treatment involves high dose chemotherapy with or without 
radiation, followed by re-infusion of previously cryopreserved stem cells. 
Haemopoiesis in the first few months after autografting is often partially Ph 
negative, though the proportion of Ph positive marrow metaphases usually 
increases to 100% by 6 or 9 months after the autograft. One unrandomised 
study has shown autografting may increase survival, 56% of patients being 
alive at 5 years (Hoyle et al, 1994).
In 1983, Coulombel et al showed that in long-term bone marrow culture 
(LTBMC) Ph positive cells had a decreased survival, the survival of long-term 
culture initiating cells (putative stem cells) was undiminished, whereas the 
leukaemic cells were reduced by 30 fold. The same group, have recently shown 
that the in vitro purging procedure of LTBMC may be advantageous for those 
patients with CML, who have adequate numbers of long-term culture initiating 
cells (LTCIC) and concurrent loss of Ph positive leukaemic cells (Barnett et 
al,1994).
Bone marrow transplantation
In the past decade, it has become very clear that allogeneic bone 
marrow transplantation (BMT) can cure patients with CML. There is also 
general agreement, that bone marrow transplantation should be carried out 
whilst the patient is in chronic phase (Goldman, 1990). Thomas et al, in 1986
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reported that survival for patients with CML in chronic phase, transplanted 
with marrow from HLA-identical siblings was better if the procedure were 
performed within 1 year of diagnosis. As the risk of severe or fatal graft versus 
host disease (GVHD) is greater in older patients, this therapeutic option is 
generally only available for those patients under the age of 50 years. 
Unfortunately the number of patients below that age with an HLA- 
compatible-related donor probably only constitutes 10 to 15 % of new patients.
During the past 5 years interest has been focused on the possibility of 
using phenotypically matched unrelated donors. Preliminary results suggest, 
that the incidence of GVHD and graft failure is increased in these patients 
when compared with those who have had a sibling transplant (Goldman, 
1990). About 40% of these patients go on to be long term survivors (> 5 years) 
as compared to the 60 to 70% survival rate in patients who have a matched 
sibling BMT.
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Acute myeloid leukaemia 
Acute myeloid leukaemia (AML) is a malignant clonal disease, arising 
from transformation of a haemopoietic progenitor cell, and resulting in clonal 
proliferation of poorly or partly differentiated myeloid cells.
It is a heterogeneous disease, differing considerably among patients with 
respect to cytogenetic abnormalities, cellular phenotype and response to 
therapy (Champlin et al, 1987).
AML does not disturb haemopoiesis or produce symptoms until a 
substantial burden of leukaemic cells, usually between 109 and 1012, is present 
(Champlin et al, 1987).
Epidemiology
AML is predominantly a disease of adults. It accounts for approximately 
80% of adult leukaemias but only 20% of childhood leukaemias. There are no 
major differences in incidence according to sex or race. In the United 
Kingdom there are approximately 2000 new cases per year.
Leukaemogenic agents
Ionising radiation
X-rays and other ionising rays were the first identifiable agents 
associated with the induction of leukaemia. This first became apparent in the 
survivors of the atomic bomb explosions in Hiroshima and Nagasaki.
It is also now well documented, that patients treated by irradiation for 
other malignancies (eg Hodgkin’s Disease, myeloma, carcinoma of the breast
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and ovary) are at an increased risk of developing AML. The combination of 
irradiation and alkylating agents results in an even higher incidence of 
secondary AML.
Chemicals
The 2 main agents suspected of being leukaemogenic are alkylating 
drugs and benzene (Catovsky et al, 1989).
Alkylating agents: Patients who develop AML secondary to exposure 
to an alkylating agent usually have a slower evolution of the disease, a lesser 
degree of leukaemic infiltration, but a higher incidence of chromosomal 
abnormalities, in particular 5q- and monosomy 5 and/or 7. The main alkylating 
agents implicated are nitrogen mustard, lomustine and chlorambucil.
Benzene: Benzene constitutes 6 to 8% of the content of petroleum
and up to 30% of some liquid lacquers. It is known to produce chromosomal 
abnormalities. It has aetiologically been linked to the increased incidence of 
leukaemia in persons occupationally exposed to it.
Diagnosis
Patients usually present symptoms attributable to anaemia (tiredness), 
neutropenia (infections) and thrombocytopenia (bleeding/bruising).
The diagnosis is made by careful examination of the peripheral blood 
smear. The bone marrow is usually hypercellular but in 5 to 10% of cases it 
is hypocellular (Catovsky et al, 1989). Difficulties in diagnosis are encountered 
in cases presenting with a low white cell count, such as promyelocytic
41
leukaemia where dry aspirates maybe obtained due to rapid clot formation. If 
the percentage of myeloblasts in the bone marrow exceeds 30% the diagnosis 
is AML.
Classification
Bennett et al, in 1976 put forward a proposal for the classification 
of the acute leukaemias. The French-American-British (FAB) classification is 
now accepted internationally. A  revised classification (Bennett et al, 1985) was 
put forward by the same group and briefly is as follows:
MO - undifferentiated myeloblasts 
M l - myeloblasts without maturation 
M2 - myeloblasts with maturation 
M3 - hypergranular promyelocytes
M3 variant - hypogranular promyelocytes 
M4 - myelomonocytic
M5 - monocytic; monoblastic (M5a) and promonocytic (M5b)
M6 - erythroleukaemia with >50% erythroblasts and >30% 
myeloblasts.
M7 - megakaryoblastic
Bennett et al (1985) suggest that the initial assessment of the bone 
marrow aspirate (based on a 500 cell differential) should be to establish the 
percentage of erythroblasts. If the percentage of erythroblasts is >50% the 
diagnosis is AML M6 or myelodysplastic syndrome. A  diagnosis of AML M6
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is made if >30% of the non-erythroid cells are myeloblasts. Cases with fewer 
than 50% erythroblasts and greater than 30% myeloblasts will fall into the 
categories AML MO to M5 depending on the morphological nature of the 
blasts. Acute leukaemia with a megakaryoblastic component requires special 
methods for showing that the blast cells belong to the megakaryocytic lineage, 
for example platelet peroxidase reaction or platelet antibodies to platelet 
glycoprotein
Therapeutic options
The two major therapeutic options in AML are chemotherapy and 
BMT. The chemotherapeutic option is divided into 2 phases, remission 
induction and consolidation or post remission treatment. Other 
regimens/agents that are less commonly used are maintenance treatment and 
differentiation agents.
Chemotherapy
Remission induction treatment: The combination of drugs most
commonly used is cytosine arabinoside and an anthracycline.There is 
considerable controversy regarding which drug(s) is best combined with 
cytosine arabinoside. The anthracyclines most commonly used are 
daunorubicin, doxorubicin and more recently idarubicin. Combinations of 
cytosine with amsacrine (Louie and Issel, 1985; Arlin et al, 1984) or 
mitoxantrone (Shenkenberg et al, 1986) have also been used with some 
success. Adding additional drugs such as 6-thioguanine or etoposide is only of
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marginal benefit and does not improve survival (Foon and Gale, 1992) There 
are no convincing data that high dose cytosine at a dose of 1.5g-3.0g/m2 daily 
for 3 days, is superior to conventional dose cytosine (100-200mg/m2/day for 7 
days) in terms of either duration of remission or survival.
Post remission treatment: It is now generally accepted that further
cytoreductive treatment is required in patients who achieve remission to 
eradicate residual leukaemic cells and prevent relapse. Studies with the longest 
remissions have generally used 2 or more courses of post remission 
chemotherapy (Foon and Gale, 1992). Median remission duration range from 
1 to 2 years, with 5 year leukaemic free survival (LFS) in 15-30% in adults and 
35-60% in children (Creutzig et al, 1985; Weinstein et al, 1983). Most studies 
use consolidation chemotherapy similar to that used for remission induction 
(Foon and Gale, 1992).
Maintenance chemotherapy: This is rarely given. It involves giving
cyclical courses of intra-venous or sub-cutaneous cytosine together with 6- 
thioguanine or daunorubicin monthly. Numerous studies have failed to 
demonstrate a substantial benefit in patients receiving maintenance compared 
to those receiving induction and consolidation chemotherapy alone (Foon and 
Gale, 1992).
Differentiating agents: These agents attempt to induce maturation of
leukaemic cells. Agents used in vitro include phorbol esters, dimethysulphoxide 
(DMSO) and retinoids. All-trans retinoic acid (ATRA) has been used in 
clinical studies in patients with AML M3 with some considerable success. The
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results of a recent multi-centre randomised trial comparing standard 
chemotherapy and ATRA to chemotherapy alone has shown improved 
remission rates, reduced duration of coagulopathy and longer event-free 
survival in the ATRA group (Fenaux et al, 1993).
Bone marrow transplantation
In AML, BMT is used primarily as consolidation treatment for patients 
in remission or to induce remission in patients who have relapsed or have 
resistant disease (Champlin et al, 1987).
BMT provides an improved anti-leukaemic effect compared with 
chemotherapy alone. The major limitation of BMT is the transplant-related 
mortality usually due to pneumonitis or GVHD. The International Bone 
Marrow Transplant Registry (IBMTR, 1989) analyzed data from 704 recipients 
of HLA-identical sibling transplants for AML in first complete remission. The 
5 year leukaemia-free survival (LFS) was 48% and the leukaemia-relapse rate 
was 20%. Improved LFS was associated with younger age and lower white cell 
count at diagnosis. These results are similar to those reported after 
chemotherapy. Similarly there is no convincing data to show that autografts 
prolong LFS. Controversy therefore reigns as to whether chemotherapy, 
autografting or allogeneic BMT is the more effective treatment for AML in 
first remission. The most effective strategy maybe to reserve autografts, HLA- 
identical-sibling or unrelated BM Ts for people failing chemotherapy (Foon 
and Gale, 1992). Substantial improvements in the results of treatment of AML
45
require the development of new and more effective chemotherapeutic agents 
and innovative measures to overcome the major complications of BMT.
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Cytokines
Introduction
Cytokines are a group of hormone-like polypeptides of 60-160 amino 
acids that are released in inflammatory responses. Unlike classical endocrine 
hormones, cytokines usually exert their effects on cells in the immediate 
vicinity of their source, acting in a paracrine or autocrine fashion. The term 
"cytokine" encompasses growth factors, colony-stimulating factors and 
interleukins. With few exceptions, cytokines are released only following trauma 
or invasion by microorganisms, and their major function is to mobilize the 
defence and repair response of the body.
Over the past decade the following growth factors have been identified 
cloned and recombinant forms produced:
Name Molecular weight Gene site
Colony-stimulating factor-1 45-90,000 5q
Erythropoietin (Epo) 39,000 7q
Granulocyte-macrophage colony- 18 - 30,000 5q
stimulating factor (GM-CSF)
Granulocyte colony-stimulating- 20,000 i?q
factor (G-CSF)
Macrophage colony-stimulating- 70 - 90,000 5q
factor (M-CSF) 45 - 50,000
Interleukin-3 (also known as 15 - 30,000 5q
multipotent CSF)
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Name Mol wt Gene site
a-interferon 19-26,000 9
/3-interferon 20,000 9
"6 -interferon 17,000 12
Interleukin-1 17,000 2q
Interleukin-2 14-16,000 2q
Interleukin-4 16 - 20,000 2q
Interleukin-5 46,000 5q
Interleukin-6 19 - 21,000 7p
Interleukin-7 22-25,000 8q
Interleukin-8 8,000 4q
Interleukin-9 40,000 5q
Interleukin-10 17-21,000
Interleukin-11 23,000 19q
Platelet derived growth 31,000 7
factor I (PDGF I)
Platelet derived growth 28,000 7
factor II (PDGF II)
TGFa 5-20,000 2
TGFft 25,000 19q
Tumour necrosis factor (TNF) 17-50,000 6
Stem cell factor 30,000
Macrophage inflammatory 8,000
protein-la
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The growth factors mentioned above are glycoproteins, with polypeptide 
chains of similar length. The carbohydrate component of the molecule is not 
involved in its biological function but may protect the molecule from 
degradation and help to increase its half life in vivo (Metcalf, 1989b). The 
common characteristics of growth factors include a high biological activity but 
low tissue concentrations under basal conditions and a rapid increase in levels 
in response to inducing signals such as infections, blood loss or antigenic 
stimulation. Unlike classic polypeptide hormones they are produced by many 
different cell types including fibroblasts, endothelial cells and stromal cells.
Studies on the molecular control of neutrophilic granulocytes, monocyte 
and macrophage formation in vitro identified 4 glycoproteins capable of 
stimulating the formation of maturing colonies of these cells. The generic 
name colony-stimulating factor (CSF) was given to this group of regulators. A  
prefix indicates the main cell type stimulated by low concentrations of the 
CSF. Thus G-CSF is mainly a stimulus for granulocyte formation and GM- 
CSF for granulocyte and monocytes/macrophages. G-CSF, GM-CSF and IL-3 
are single chain polypeptides, whereas M-CSF is a dimer of two identical 
chains.
In humans the gene for GM-CSF, M-CSF, the M-CSF receptor 
(equivalent to the proto-oncogene c-fms), IL-4 and IL-5 are grouped together 
on the long arm of chromosome 5 and their transcription may be co-ordinated 
(Barlow et al, 1987; Young et al, 1988).
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Inhibitors of haemopoiesis
The study of molecules that inhibit haemopoiesis has lagged behind the 
study of stimulators of haemopoiesis. This may be because researchers tend 
to be cautious in their interpretation of inhibition which may be due to non- 
physiological toxic agents. Axelrad, 1990 defined negative regulators as growth 
inhibitory proteins or peptides of non-toxic nature that act within minutes or 
hours in a reversible manner and prevent stem cells from entering or being in 
S phase of the cell cycle. Molecules that conform to this definition are M IP-la  
and inhibin (Zipori and Honigwachs-Sha’anani, 1992). Cytokines such as TNF 
and interferons however are excluded by the above definition. The line drawn 
between "inhibitors" versus "stimulators" has further been blurred by the 
discovery of molecules like TGF/3 which is known to have both stimulatory and 
inhibitory effects depending on the target cell and growth conditions.
Granulocyte colony-stimulating-factor
Humans on average produce approximately 120 x 109 granulocytes per 
day, this number maybe increased 10 fold under stress due to an infection 
(Demetri and Griffen, 1991). G-CSF regulates the proliferation of neutrophils 
but may also play a role in their distribution within the body and their 
response to inflammatory stimuli (Demetri and Griffen, 1991).
G-CSF was identified by Burgess and Metcalf in 1980, from work done 
on a murine myelocytic cell line. In 1985, Nicola and Metcalf, identified a 
human analogue of the murine G-CSF. On the basis of biological activity and
50
receptor-binding studies human G-CSF was shown to be the same as CSF-/3, 
a stimulatory agent previously identified in human placenta-conditioned 
medium. (Nicola et al, 1985a). At the same time Welte et al purified to 
homogeneity a substance named human pluripotent colony-stimulating-factor 
also known as pluripoietin (Platzer et al, 1985). This was a colony-stimulating- 
factor that was secreted into the culture medium by the 5637 human bladder 
carcinoma cell line. Stromal cells, macrophages, fibroblasts, endothelial cells 
and the human bladder carcinoma cell line 5637 all produce G-CSF (Clark 
and Kamen, 1989).
In 1986, Souza cloned the cDNA encoding human G-CSF from the 
5637 cell line. The clone they derived encoded a protein of 174 amino acids. 
Nagata et al in 1986, cloned the cDNA for G-CSF using the squamous cell 
carcinoma cell line CHU2. The cDNA they obtained encoded a larger protein 
of 177 amino acids. This protein has less stimulatory activity than the smaller 
protein. Okabe et al, 1990, suggested that the amino acid terminus may play 
a role in the functional activity of G-CSF. Subsequently Nagata et al, 1986b 
cloned the cDNA encoding for the smaller protein from the same CHU2 cell 
line.
The chromosomal location of the G-CSF gene to chromosome 17 at 
17qll-12 raised speculation about whether the G-CSF gene was involved in 
the breakpoint of the t(15;17) translocation characteristic of acute 
promyelocytic leukaemia. The G-CSF gene however is located proximal to this 
breakpoint, and is not rearranged in the malignant clone that gives rise to
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AML M3 (Simmers et al, 1987).
The murine G-CSF gene is highly homologous with the human gene, 
with 69% nucleic acid sequence homology in both coding and non-coding 
regions and a 73% sequence homology in the amino acid sequence. Both the 
proliferation and differentiation-inducing activities of the murine and human 
G-CSF molecules cross species boundaries, unlike IL-3 and GM-CSF which 
are species specific. Nicola and Metcalf in 1985a, first described the existence 
of a high affinity receptor on granulocytes for G-CSF. Receptor numbers 
increase with leucocyte maturation, mature neutrophils having 2 to 3 times 
more receptors than mature metamyelocytes. However even neutrophils 
express a relatively low number of G-CSF receptors, approximately 50 to 500 
receptors per cell.
G-CSF receptors have also been described on a variety of other cells 
including human myeloid leukaemia cells, human placenta and vascular 
endothelium and human small cell cancer. The functional significance of 
G-CSF receptors on most non-haemopoietic cells remains unclear. In contrast 
G-CSF has been shown to act as a potent proliferative stimulus for some types 
of myeloid leukaemia. G-CSF receptors on myeloid leukaemic cells appear to 
have a similar affinity to receptors found on normal granulocytes (Budel et al,
1989). This has meant that there is a general reluctance to use G-CSF in acute 
myeloid leukaemia.
The primary effects of G-CSF on normal haemopoietic cells are on cells 
of the granulocytic lineage. In-vitro G-CSF stimulates proliferation and
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differentiation of neutrophil colony-forming cells. G-CSF acts on a relatively 
mature progenitor population that is primarily committed to neutrophil 
differentiation. Cultures of bone marrow progenitors enriched for the 
relatively primitive population expressing the CD34 antigen show minimal 
response to G-CSF when added alone (Demetri and Griffen, 1991).
The interaction of G-CSF with other growth factors in inducing 
proliferation of progenitor cells is complex. G-CSF appears to behave in a 
synergistic fashion with both GM-CSF and IL-3 (Vellenga et al, 1987a). 
Interleukin-4 however interacts in a more complex manner. Several studies 
have shown that IL-4 can augment G-CSF-induced proliferation of neutrophil 
colonies in vitro. Unlike GM-CSF or IL-3, IL-4 alone does not stimulate 
myelopoiesis. It also appears that IL-4 must be present early in cultures to 
have an enhancing effect. It could therefore be suggested that IL-4 sensitises 
committed cells to the effects of G-CSF (Sonoda et al, 1990).
The G-CSF receptor and the IL-4 receptor have 50% sequence 
homology (Fukunaga et al, 1990). There are possibly therefore similarities in 
signal transduction triggered by these 2 receptor-ligand systems.
Human myeloid leukaemia cells in culture exhibit a heterogenous 
response to G-CSF in combination with other cytokines. This reflects the 
variability inherent in the biology of the myeloid leukaemias (Kelleher et al, 
1987; Young et al, 1988; Nara et al, 1987). In some AML samples, IL-4 may 
augment G-CSF-induced proliferation of myeloblasts (Vellenga et al, 1990). 
A large proportion of the blasts from patients with AML fail to express G-
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CSF receptors. This is consistent with the observation that only about 50% of 
cases of AML proliferate when stimulated by G-CSF in vitro (Vellenga et al, 
1987a). There has been no clear relation between the number of G-CSF 
receptors on myeloblasts and their ability to proliferate in vitro when 
stimulated by exogenous G-CSF.
Granulocyte macrophage colony-stimulating factor
GM-CSF is a glycoprotein that stimulates the proliferation and 
differentiation of neutrophil, eosinophil and monocyte precursors in vitro. It 
is produced by monocytes, endothelial cells, fibroblasts and lymphocytes. The 
cDNA for human GM-CSF has been cloned (Wang et al, 1985). The cDNA  
encodes for the 144 amino acid precursor containing a 17 amino acid signal 
peptide. The 127 active amino acid product has 2 potential N-glycosylation 
sites and is homologous with the murine sequence. GM-CSF, unlike G-CSF 
is species specific in its activity.
The biological activities of GM-CSF are mediated through binding to 
a high affinity receptor. In the mouse the receptors are found on cells of the 
myelomonocytic lineage and both high and low affinity sites have been 
described (Walker et al, 1985a; Walker et al, 1985b). In man it appears that 
GM-CSF binds to a single class of receptor and that there are between 50 and 
1000 receptors per cell. The receptors are found on neutrophils, macrophages 
and eosinophils. Like G-CSF the number of receptors increase with 
maturation of the cell (Park et el, 1989). GM-CSF receptors have been
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described on leukaemic cells and, similar to G-CSF receptors on leukaemic 
cells, their numbers do not predict response to stimulation. Binding of GM- 
CSF results in internalisation of the receptor/ligand complex, however the 
receptors are recycled and appear again at the surface.
In clonogenic assays using human bone marrow mononuclear cells 
GM-CSF promotes growth of mixed colonies of granulocytes, 
macrophages/monocytes and eosinophils. With the addition of erythropoietin 
GM-CSF stimulates BFU-E and mixed colonies (CFU-GEMM). 
Megakaryocyte colonies are also produced but in lower numbers than with 
IL-3. In fully differentiated cells GM-CSF has important non-proliferative 
functions, for example, phagocytosis, chemotaxis and antibody-dependant 
cytotoxicity are all augmented by GM-CSF (DiPersio et al, 1990).
Interleukin-3
IL-3 was originally derived from the murine myelocytic cell line 
WEHI 3 (Ihle et al, 1983) and was called colony-forming unit stimulating 
activity (CFU-stimulating activity).
A  human analogue to murine IL-3 has been cloned (Otsuka et al, 
1988). Homology at the DNA level between murine and human IL-3 is 
approximately 45%, compared to 29% homology at the amino acid level. The 
human mRNA yields a 15-25 kD translation product.
Unlike G-CSF and GM-CSF receptors, the receptors for IL-3 are at 
their highest frequency on primitive cells, decreasing in number with increasing
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maturation. Receptors have been identified on myeloid and some pre-B cell 
precursors but not on the majority of lymphocytes or on cells of erythroid 
lineage. The IL-3 receptor has also been described on AML cells and normal 
monocytes (Budel et al, 1990).
With the exception of the WEHI 3 cell line and perhaps epidermal cells 
IL-3 is produced exclusively by activated T-lymphocytes (Luger et al, 1985).
Reported activities of IL-3 include stimulating the differentiation of 
neutrophils, macrophages, megakaryocytes and mast cells (Ihle et al, 1983) and 
stimulating the proliferation of mast cells (Ihle et al, 1981). Recently it has 
also been shown that IL-3 enhances IL-2-dependant growth of human T 
lymphocytes (Santoli et al, 1988; Schneider et el, 1988), induces IgG secretion 
of IL-2-activated B lymphocytes (Tadmori et al, 1989) and also potentiates the 
activities of eosinophils, basophils and monocytes (Hauck-Frendsch et al, 1987; 
Cannistra et al, 1988). IL-3 is less effective in promoting CFU-GM than GM- 
CSF but pre-treatment with IL-3 enhances colony formation when cells are 
subsequently exposed to GM-CSF. IL-3 also stimulates BFU-E but 
erythropoietin is required for erythrocyte maturation.
Stem cell factor
Stem cell factor (SCF) is a normal stromal cell derived cytokine which 
stimulates mast cells and is a ligand for the oncogene c-kit (Anderson et al,
1990). It is also known by the names c-kit ligand, mast cell growth factor, and 
steel locus factor. It has been called Steel locus factor because mice with
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mutations at the Steel locus, Sld exhibit defects in haemopoiesis, coat colour 
and fertility (Flanagan et al, 1991). Stem cell factor differs from IL-3, GM- 
CSF and G-CSF in that alone, it stimulates the growth of haemopoietic stem 
and progenitors only weakly and is relatively ineffective as a colony-stimulating 
factor (Moore, 1991; Metcalf, 1991). However, SCF exhibits a strong 
synergistic action on stem and progenitor cells in the presence of other 
haemopoietins like IL-3, G-CSF, GM-CSF or erythropoietin ( Metcalf, 1991; 
Moore, 1991). SCF also synergizes with cytokines such as IL-1,11^4, IL-6 and 
IL-7 that have little or no colony-stimulating activity or direct ability to 
stimulate the division of stem cells (Schrader, 1992).
The mechanisms causing the release of stem cells from the bone 
marrow are largely unexplained. One factor may be the action of cytokines 
like IL-3 and GM-CSF which down-regulate the expression of c-kit, the 
receptor for SCF. The cell bound, transmembrane form of SCF is expressed 
on stromal cells and can act as a cell-adhesion molecule. The binding of c-kit 
expressing haemopoietic cells to stromal cells may lead to disengagement of 
stem cells from their bone marrow microenvironment (Schrader, 1992).
Interleukin-4
Interleukin-4 (IL-4) was first described in 1982 by William Paul and 
called B-cell growth factor ( Paul and Ohara, 1987). It has also been called B 
cell-stimulatory factor (BSF-1), T-cell growth factor-2 (TCGF-2) and mast cell- 
growth factor (MCGF-2). When the cDNA for IL-4 was isolated and cloned
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it became clear that the molecule had diverse effects on B cells together with 
effects on lymphoid and non-lymphoid cells. It was then given interleukin 
status and called interleukin-4.
IL-4 is a small glycoprotein with a molecular weight of 15 to 19 kD. The 
cDNA for human IL-4 has been cloned and shown to code for a protein of 
153 amino acids which is cleaved between the glycine at position 24 and the 
histidine at position 25 to yield an active protein of 129 amino acids (Gallard,
1991). Human and murine clones share a 50% homology at the amino acid 
sequence. IL-4 however, is species specific in respect to its receptor binding 
and biological effects. There are 2 potential N-linked glycosylation sites, but 
glycosylation does not seem to be required for activity. The gene for IL-4 is 
located on chromosome 5q23-31 (Paul, 1991)
IL-4 is produced by activated T lymphocytes. It is also produced by 
some B-cell lymphomas, B cells from patients with systemic lupus 
erythematosus and bone marrow stromal cell lines.
The cDNA encoding for the IL-4 receptor was cloned in 1990. More 
recently several lines of investigation have suggested a second IL-4 receptor 
(Gallard, 1991). The cDNA for this receptor has not been isolated. 11^4 was 
initially described as a co-stimulator of DNA synthesis for B-cells stimulated 
with anti-IgM antibodies. Since then a wide range of biological functions have 
been attributed to 11^4 including increasing MHC class expression in resting 
B-cells and enhancing the production of IgGj and IgE isotypes following 
lipopolysaccharide (LPS) stimulation. IL-4 also acts to increase the viability
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and growth of normal resting T-cells and some T-cell lines, as well as to co- 
stimulate growth in some mast cell lines. IL-4 may also act as a autocrine 
growth factor for antigen specific T-cells in combination with IL-1 and 
enhance antigen presentation in bone marrow-derived macrophages (Kupper 
et al, 1987; Zlotnik et al, 1987). It augments the development of cytotoxic T- 
lymphocytes from resting murine cells and also induces lymphokine-activated 
killer (LAK) activity (Trenn et al, 1988; Peace et al, 1988). In contrast to these 
findings, it has been reported that IL-4 may actually inhibit human IL 2  
induced LAK cells in vitro. (Gerosa et al, 1988). IL-4 also enhances the 
proliferation of CFU-GM, BFU-E and CFU-Meg in response to G-CSF, Epo 
and IL1 respectively (Peschel et al, 1987).
Transforming growth factor p 1
Transforming growth factors (TGFa and TGF/3) belong to a family of 
polypeptide factors that share certain structures and functional characteristics. 
In 1978 DeLarco and Todaro reported that murine 3T3 cells transformed by 
a sarcoma virus produced polypeptide growth factors called sarcoma growth 
factors (SGFs). These polypeptides were secreted into the extracellular 
medium and had the unusual property of being able to cause anchorage- 
independent growth of normal rat kidney cells, clone 49F (NRK-49F). The 
transforming activity of SGFs on NRK cells was phenotypic, on removal of 
SGF from the NRK cells, they reverted back to their normal morphology and 
growth properties. Since then similar transforming activity has been reported
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in the conditioned medium of several neoplastic cell lines and a variety of 
murine cells transformed by a sarcoma virus. These transforming activities 
were also characterised by their ability to compete with epidermal growth 
factor (EGF) for binding to its receptor.
In 1980 Roberts extracted the transforming peptides from the tumour 
cells and the term "transforming growth factor" (TGF) was coined. Using the 
NRK 49F cell as an assay 2 principal types of TGFs were isolated and defined. 
Peptides that competed with EGF for receptor binding but did not require 
additional EGF for promotion of growth of cells in soft agar were called TGF- 
a  and peptides that did not compete with EGF for receptor binding but did 
require EGF for promotion of growth in soft agar were called TGF-/3. TGF-a 
and TGF-/3 have been purified to homogeneity, cloned and sequenced. They 
represent distinct families of peptides; their amino acid sequences, cell 
membrane receptors and mRNAs are unique. They share only a common 
nomenclature based on their discovery as synergistic effectors of the 
transformation of NRK fibroblasts. More recently a series of independent 
findings has shown other factors that are structurally and functionally related 
to TGF-/?. They include inhibins which are heterodimeric proteins of gonadal 
origin that act on the pituitary to suppress follicle-stimulating hormone (FSH) 
secretion; activins which are dimeric peptides also of gonadal origin and are 
potent stimulators of pituitary FSH secretion; Mullerian inhibitory substance 
which is a homodimeric testicular glycoprotein that causes regression of the 
Mullerian duct during development of the male embryo and finally the
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product of the decapentaplegic gene complex which is involved in pattern 
formation and dorsal-ventral specification during Drosophila development 
(Roberts and Spom, 1988).
Bone represents the largest reservoir of TGF/3. Platelets are the most 
concentrated source of TGF/3 with a yield of approximately 2-3mg TGF/3/kg 
wet weight of human platelets. Soft tissues such as kidneys and placenta have 
a much lower concentration of TGFjS (Roberts and Sporn, 1988).
The cDNA sequence for this group of growth factors indicate that the 
mature proteins are synthesized from the carboxyl-terminal half of larger 
precursors and that they share homologies to each other within this region. 
Common to several members of this family of polypeptides is their apparent 
involvement in developmental processes such as embryogenesis and in tissue 
repair.
There are at least 5 different isoforms of TGF/3 coded for by different 
genes on separate chromosomes. Three of the isotypes have been well 
characterised. TGFp1 is a disulphide-linked homodimer consisting of 2 
subunits, TGF/32 is a disulphide-linked homodimer consisting of 2 /32 subunits, 
TGF/3U is a disulphide-linked heterodimer consisting of one jSj and one jS2 
subunit. The and jS2 subunits are closely related and share 70% aminoacid 
sequence homology in their N terminal halves. TGFjSj aminoacid sequences 
are highly conserved and are identical in man, monkeys, cows, pigs and 
chickens (Spom and Roberts, 1989).
The cDNA encoding TGF/^ was isolated from a library derived from
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human placenta (Derynck et al, 1985). The gene was subsequently localised 
to the long arm of human chromosome 19 and to murine chromosome 7 (Fujii 
et al, 1986). The human TGF/^ cDNA encodes a precursor polypeptide of 391 
amino acids (Derynck et al, 1985). A  monomer of 112 amino acids is cleaved 
from the C-terminal end of the parent molecule. The TGF/3j precursor 
contains 3 potential N-glycosylation sites, none of which are located in the 
TGFjSj polypeptide. The 112 amino acid sequence contains 9 cysteine residues 
and forms a 25 kD dimer, which under reducing conditions yields a single 12.5 
kD band.
However TGF/3 receptors have been found in virtually all tissues and 
cell types examined. The number of receptors per cell ranges from 600 on 
human tonsillar T-lymphocytes to about 80,000 in Swiss 3T3 cells (Roberts and 
Sporn, 1988). Three TGF/3 receptors have been described, Class I, II and III 
with molecular weights of 53-65,73-95 and 250-350 kD respectively. The Class 
III receptor is also known as TGF/3-binding proteoglygan betaglygan. Both the 
Class I and II receptor glycoproteins display a 10-fold higher affinity for 
TGFjSj, than for TGF/32. The function of these 2 receptors nevertheless 
remains unknown. The human Class II receptor has recently been cloned 
(Massague, 1992). The third receptor, the 280 kD glycoprotein exists as part 
of a larger receptor complex. This receptor does not appear to discriminate 
between TGF/^ and TGF/32 and it has been implicated in the mediation of 
certain functions including inhibition of epithelial cell proliferation and 
adipogenesis and induction of fibronectin and collagen expression.
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In-vitro effects of TGFpj
TGFjSj is highly pleiotropic and has a multiple range of actions on 
almost all cell types. It can stimulate proliferation in some cells whilst being 
a potent inhibitor of proliferation in others. Its main in-vitro effects are as 
follows:-
1. Stimulates proliferation of fibroblasts and enriches secretion of extracellular 
matrix proteins.
2. Stimulates expression of type II collagen in immature precursor cells; 
inhibits type II collagen expression in mature cells; stimulates proteoglygan 
synthesis.
3. All the isoforms except for TGF/32 have an inhibitory effect on the growth 
of endothelial cells.
4. TGFjSj has a mitogenic effect on osteoblast proliferation and it also 
regulates synthesis of matrix proteins.
5. Inhibits differentiation and expression of creatinine kinase gene.
6. TGFjSj exerts a mainly inhibitory effect on the growth of both normal B- 
and T- lymphocytes. In B lymphocytes it inhibits secretion of IgG and IgM 
from B lymphocytes and enhances secretion of IgA.
7. TGFjSj has a chemotactic effect on both neutrophils and monocytes. In 
addition it causes monocytes to secrete TNF, TGF-a, fibroblast growth factor, 
IL-1 and TGFft itself.
8. TGFjSj inhibits growth of normal bone marrow cells stimulated by IL-3 and 
GM-CSF. In addition it has an anti-proliferative effect on megakaryocytes.
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9. Inhibits growth of hepatocytes and keratinocytes.
10. Inhibits differentiation of adipocytes.
11. Inhibits steroid formation in adrenocortical cells and Leydig cells and 
enhances FSH activity in granulosa cells (see Roberts and Sporn, 1992).
In-vivo biological effects of TGFfi1
The action TGF/3j on a target tissue depends on many parameters 
including the state of differentiation and the presence of other peptide 
regulators. The plasma half-life of active TGFjSj is 2-3 minutes (Roberts and 
Sporn, 1992). It is degraded by the liver, kidney, lungs and spleen. By contrast 
the plasma half-life of latent TGF/^ (the form secreted by most cells and 
released by platelets) is >100 minutes (Wakefield et al, 1990). TGF/^ has a 
role in the following physiological and pathological processes (from Robert 
and Sporn, 1992; Sporn and Roberts, 1989).
1. Embryogenesis: Immunocytochemistry studies have shown that TGFjSj has 
an important role in mammalian embryogenesis particularly during the 
remodelling that occurs during the formation of vertebrae, limb buds, teeth, 
facial bones and the cardiac valves. High levels of TGF/^ have been found in 
potential sites of malformation such as the palate and inter-ventricular septum 
of the heart and it is therefore likely that TGFft is an important modulator 
during normal human embryogenesis.
2. Inflammatory response and wound healing: There is now considerable 
information on the role of TGF/^ in inflammation and wound healing.
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Platelets are the most concentrated source of TGFjS and it is stored in platelet 
a-granules. The process of platelet degranulation releases TGFjS at the site of 
a wound. TGFjSj attracts monocytes, macrophages and fibroblasts by 
chemotaxis to the site of the wound. Sub-cutaneous injections of TGFjS can 
stimulate formation of granulation tissue and enhance wound healing (Roberts 
et al, 1986; Mustoe et al, 1986). TGFjS plays an important role in bone 
formation and fracture healing, by stimulating the synthesis and secretion of 
matrix proteins, and chondrogenesis.
3. Immune function: TGFjS is a potent suppressor of lymphocyte proliferation 
and function. It is 10,000 to 100,000 times more potent than cyclosporin 
(Sporn and Roberts, 1989). TGFjS inhibits proliferation of T-lymphocytes 
stimulated by II^l or IL-2, proliferation and antibody production by B- 
lymphocytes and cytotoxic T-lymphocyte and lymphocyte-activated killer cell 
activity. It also depresses cytolytic activity of natural killer cells.
In vivo effects of TGFfi1 on haemopoiesis
Direct intravenous injection of TGFjSj into the femoral artery of a 
mouse (to avoid first pass metabolism) inhibited constitutive and IL-3-driven 
bone marrow growth. The inhibition was selective in that 100% of CFU- 
GEMM was inhibited while only 50% of the more mature committed colony- 
forming cells were affected (Goey et al, 1989). This inhibition was time and 
dose-dependent with the maximum effect observed at 24 hours and at a dose 
of 5pg/mouse. Carlino et al, 1990 studied the effects of daily sub-cutaneous 
TGFjS on a variety of murine haematological parameters. After 14 days there
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was a decrease in mature erythroid and platelet numbers, together with an 
increase in the white cell count in the peripheral blood. Increased 
granulopoiesis was observed in the spleen and the bone marrow while there 
was no change in the circulating neutrophil counts. The fact that the 
neutrophil count remains normal throughout TGF/3 treatment despite a strong 
inhibitory effect on primitive stem cell proliferation suggests that TGF^S is able 
to stimulate neutrophil production.
Macrophage inflammatory protein-la
MIP-la, an 8 Kd glycoprotein is another negative regulatory protein of 
haemopoiesis. The expression of MIP-la appears to be limited to cells of the 
mononuclear phagocyte system, mast cells and lymphocytes. Broxmeyer et al, 
in 1990 showed that MIP-la has a direct suppressive activity on immature 
progenitor cells but a myelopoietic enhancing activity for more mature 
progenitors. It is inhibitory to CFU-A and CFU-S (Wright and Pragnell, 1992). 
The CFU-A assay detects the human counterpart of the murine colony- 
forming unit. These cells form large mixed lineage colonies in agar culture. 
They have a low replating capacity for macroscopic colony formation but a 
high replating efficiency for producing small colonies of neutrophils and 
macrophages. They appear to occupy a position in the haemopoietic hierarchy 
that is intermediate between the CFU-GEMM and CFU-GM (Gordon, 1993). 
M IP-la can block the recruitment of CFU-S into cycle and this effect can be 
exploited to protect the stem cell compartment during the administration of
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chemotherapy (Lord et al, 1992; Dunlop et al, 1992). MIP-la enhances the 
proliferation of more committed progenitor granulocyte macrophage-colony 
forming cells in response to GM-CSF (Clements et al, 1992)
Regulation of haemopoiesis
Haemopoiesis involves a series of complex cellular events in which a 
small number of stem cells continuously need to generate a large population 
of more mature cells. This is achieved by the use of regulatory molecules that 
can be humoral or cell-associated. At least 40 such regulators which have a 
effect on haemopoiesis have been identified, in addition there are a variety of 
factors in the early stages of characterisation. A  current estimate of possible 
combinations is 2.217887748 (Quesenberry et al, 1993). It is important to note 
that no two haemopoietic growth factors stimulate exactly the same type of 
colony formation as judged by colony number or by the lineage and 
maturation of the cells making up the colony (Metcalf, 1993). There may 
however be a great deal of similarity, for example G-CSF, IL-3, GM-CSF, 
SCF, MCF and IL-6 all stimulate neutrophil granulocyte colony-formation. 
Hence there is, a degree of overlap between the actions of the different 
growth factors. Whilst self-renewal and differentiation of stem cells and 
progenitors appear to be a stochastic (that is random) process, survival and 
proliferation of the cells is regulated by cytokines. The growth factors may be 
divided into 3 categories:- (Ogawa, 1993)
(1) Late-acting lineage specific factors such as erythropoietin, M-CSF and
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IL-5.
(2) Intermediate-acting lineage-nonspecific factors such as IL-3, IL-4, GM- 
CSF. IL-4 has both stimulatory and inhibitory effects on haemopoiesis 
(Peschel et al, 1987; Broxmeyer et al, 1988).
(3) Factors affecting kinetics of cell cycle dormant primitive progenitors. Leary 
et al, (1990 and 1992) found that 11^6, G-CSF, IL-11, SCF and IL-12 act 
synergistically with IL-3. In addition to these factors leukaemia inhibitory 
factor was found to augment proliferation of human progenitor cells. It has 
been proposed that part of the synergistic effect of these factors is to shorten 
duration of G0 of the primitive progenitors (Ogawa, 1993). More recent 
studies have provided biochemical explanations, IL-6 and G-CSF share 
structural homology (Hirano et al, 1986), receptors for IL-6, LIF and IL-11 
share signal transducing protein IL-6 gp 130 (Gearing et al, 1992; Yin et al,
1992). IL-12 is a heterodimer consisting of 35Kd and 40Kd proteins, each 
sharing homology with IL-6 and its receptor respectively (Merberg et al, 1992). 
Thus there may be a biochemical reason for the functional duplication of the 
synergistic growth factors.
The action of individual growth factors is not restricted to cells of a 
single lineage, and for example erythropoietin which has an effect on mature 
erythroid cells probably acts on megakaryocyte precursors (Spivak, 1986). A  
further important feature of the haemopoietic growth factors is that in 
combination their response can be enhanced. When two or more growth 
factors act on the same progenitor cell and induce increased colony size this
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process is called "synergy". In the second process known as "recruitment" the 
combined actions of two or more growth factors allow increased numbers of 
progenitor cells to proliferate either because distinct subsets of progenitor cells 
exist that respond exclusively to one factor or because some progenitors 
require simultaneous stimulation by two or more factors before being able to 
respond (Metcalf, 1993).
Stem cell factor when acting alone maintains the survival of the stem 
cells but does not induce cell division (Li et al, 1992). Not all combinations of 
growth factors leads to an enhancement of response, GM-CSF with M-CSF 
acting on murine cells leads to a decrease in the formation of macrophages 
than that obtained with M-CSF alone (Gliniak et al, 1990).
Some of these combinations of growth factors have successfully been 
used in the mobilisation of peripheral blood progenitor cells, GM-CSF and IL- 
3 (Ganser et al, 1992, Brugger et al, 1992).
To randomly ascertain whether a particular combination of growth 
factors is effective would strain the financial resources of most research units, 
hence more in vitro data is needed if unexpected favourable combinations are 
not to be overlooked.
Clinical uses of growth factors
Clinical studies with G-CSF and GM-CSF commenced in 1986 and 
their potential clinical uses are listed below:
1. reduction of the period of neutropenia following chemotherapy
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2. prophylaxis against infection
3. treatment of neutropenia due to other causes e.g. cyclical neutropenia, 
glycogen storage diseases, immune neutropenia
4. following autologous bone marrow rescue or allogenic bone marrow 
transplantation
5. peripheral stem cell mobilisation
6. as an adjunct to antibiotic therapy
7. in conjunction with anti-retroviral drugs in the acquired immunodeficiency 
syndrome (AIDS)
8. in the treatment of aplastic anaemia and the myelodysplastic syndromes
9. in combination with other cytokines and growth factors
11^3 has been used with limited success in the treatment of MDS and 
aplastic anaemia and Diamond-Blackfan syndrome (Davis and Morstyn, 1992). 
IL-3 in addition to improving erythropoiesis, and increasing the neutrophil 
count also has a beneficial effect on thrombopoiesis in some patients. Toxicity 
due to IL-3 include fever, nausea and fatigue. The concerns regarding its 
clinical use relate to the possible stimulation of leukaemic blasts and side 
effects secondary to the stimulation of mast cells, although the latter has not 
been noted in clinical trials to date.
In vivo animal studies using G-CSF
Studies in mice (Shimamura et al, 1987) and monkeys (Welte et al,
70
1987) have demonstrated that G-CSF can induce a neutrophilia in normal 
animals and accelerate neutrophil recovery after 5-flurouracil, 
cyclophosphamide or total body irradiation (TBI). Lord et al (1989 and 1991) 
have shown by tritiated thymidine labelling studies that granulopoiesis induced 
by G-CSF affects all stages of neutrophil maturation but particularly the 
myeloblast stage. There was no change observed in the half life of the 
circulating neutrophils, nor was any organ sequestration noted.
Clinical studies using G-CSF
In 1965 Bodey et al reported that the percentage of days spent with 
infection in patients with acute leukaemia treated by chemotherapy increased 
when the absolute neutrophil count fell to below 1.0 x 109/1. The duration of 
neutropenia was the most important factor in predicting risk of infection and 
patients in whom the neutropenic period had exceeded 3 weeks had a 60% 
chance of developing a severe infection.
Towards the end of the last decade an important landmark in treating 
febrile neutropenic patients was the introduction of the in vivo use of G-CSF 
and GM-CSF. An underlying concern in the use of these agents in treating 
chemotherapy related neutropenia of leukaemia was the possibility that they 
could stimulate/re-activate the leukaemic clone. Negrin et al, in 1990, treated 
18 patients with MDS with G-CSF. Three of the patients developed AML 
whilst on therapy. Thus the role of G-CSF in MDS is not well defined. Ohno 
et al, 1990, carried out a prospective randomised study to determine the safety
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and efficacy of recombinant G-CSF after intensive chemotherapy in 108 
patients with relapsed or refractory acute leukaemia (67 with AML, 30 with 
ALL, 9 with CML in BT and 2 with transformation of MDS). I.V. G-CSF (at 
a dose of 200pG/square metre of body-surface area per day was begun 2 days 
after the chemotherapy and continued until the neutrophil count rose above 
1500/cubic mm. Treatment with G-CSF significantly accelerated neutrophil 
recovery (p<  0.001) and furthermore the rate of relapse was similar in both 
groups. To date, there are no reports citing a definite link between the use of 
G-CSF and leukaemic relapse or disease transformation.
Phase I studies have shown that G-CSF is effective in increasing the 
neutrophil count in a dose dependent fashion, whether given by continuous 
intravenous infusion, short intravenous infusion or sub-cutaneous infusion 
(Bronchud et al, 1987). G-CSF has few side effects. The main adverse effects 
are bone pain in 20% of patients, elevation of alkaline phosphatase and lactic 
dehydrogenase, elevation of serum urate and splenic enlargement in children 
with chronic neutropenia (Davis and Morstyn, 1992).
Peripheral stem cell mobilisation using G-CSF
Sheridan et al, 1990, demonstrated that G-CSF is effective at mobilising 
progenitor cells into the peripheral blood where they may be collected using 
leukapheresis. When infused together with autologous bone marrow cells 
following high dose chemo-radiotherapy neutrophil recovery follows similar 
kinetics to that of autologous bone marrow rescue plus G-CSF, although
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recovery may be slightly accelerated. The platelet recovery however is greatly 
accelerated with patients achieving platelet counts of >20 x 109/1 at a median 
of 9 days, and >50 x 109/1 at a median of 14 days. The mechanism of G-CSF 
action in releasing early progenitors into the circulation is not clear and these 
"stem cells" have not been well characterised. The circulating cells mobilised 
by G-CSF are similar to normal bone marrow in their capacity to generate 
CFU-GM in culture and these cells may therefore be an alternative to bone 
marrow cells after marrow ablation for allogeneic transplantation.
In vivo animal studies using GM-CSF
In mice GM-CSF given intra-peritoneally has the effect of increasing 
granulopoiesis and the accumulation of mature neutrophils and monocytes has 
been observed in the liver and spleen (Metcalf et al, 1987). Human GM-CSF 
given to non-human primates causes a marked leucocytosis which is 
maintained for up to 28 days, with increases in neutrophils, eosinophils 
monocytes and lymphocytes (Donahue et al, 1986). In mice given recombinant 
murine GM-CSF following melphalan, the period of neutropenia was 
shortened and there was a reduction in mortality during neutropenia (Douer 
et al, 1987).
Clinical studies using GM-CSF
Early studies with GM-CSF were hampered by the species specificity of 
this growth factor. Phase I studies have confirmed that GM-CSF administered
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by various routes results in leucocytosis which is predominantly comprised of 
neutrophils as well as eosinophils and monocytes (Antman et al, 1988; 
Lieschke et al, 1990). Sub-cutaneous or continuous i.v. infusions of GM-CSF 
are more potent and preferable to short i.v. infusions of GM-CSF (lieschke  
et al, 1990). A  "first dose" effect was recognised with intravenous GM-CSF 
(Lieschke et al, 1989). Within 20 minutes of the first dose many patients 
develop symptoms of flushing, sweating, nausea, vomiting, back pain, 
involuntary leg spasms and dyspnoea, with hypotension, tachycardia and 
hypoxia being observed. These reactions were seen more often in patients 
receiving short infusions. These responses were not seen in subsequent doses 
in the same course of GM-CSF but were seen at the start of following courses. 
Other side effects observed at high doses in phase I studies include 
thromboses, pleural and pericardial effusions, inflammation and oedema. At 
lower doses skin rashes, arthralgia, myalgia, lethargy, anorexia, malaise and 
nausea (Lieschke et al, 1989; Davies and Morstyn, 1992). Intravenous dosage 
is associated with a higher incidence of first dose reactions than the equivalent 
sub-cutaneous dose (Lieschke et al, 1989).
All clinical studies using GM-CSF in the setting of myelotoxic 
chemotherapy have shown that it shortens the duration of the neutropenic 
period. Some studies have shown clinical benefit, being fewer days with fever 
or on antibiotics (Herrmann et al, 1990). The use of GM-CSF in aplastic 
anaemia, MDS and AML are not well defined. After ABMR and ABMT, GM- 
CSF reduces the period of neutropenia (Gianni et al, 1989; Powles et al, 1990)
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but there have been no significant reductions in infection related mortalities.
Peripheral stem cell mobilisation using GM-CSF
During phase I studies it was noticed that GM-CSF administration 
increases circulating haemopoietic progenitor cells in the peripheral blood 
(Siena et al, 1989; Villeval et al, 1990). These cells are capable of restoring 
haemopoiesis after high dose chemotherapy (Haas et al, 1990) and lead to 
early platelet, as well as myeloid, engraftment (Nemunaitis et al, 1988; Gianni 
et al, 1989). When ABMR is combined with peripheral stem cell stimulated 
by GM-CSF, engraftment is more rapid and platelet recovery is also 
accelerated (Gianni et al, 1989). Seven patients with large granular cell 
lymphoma were treated with cyclophosphamide followed by TBI and 
melphalan. Neutrophil counts of 1 x 109/1 or more were achieved at a mean of 
9.9 days (range 8-13) and platelet counts of more than 1 x 109/1 were reached 
at a mean of 13.6 days (range 13-21). The method of stimulating peripheral 
stem cells is important. The objective is to obtain as many progenitor cells as 
possible from the peripheral blood and the optimal conditions for achieving 
this are not yet determined. It is probably important to have minimally 
pretreated patients who are more likely to have good marrow reserve. Some 
of these studies use cyclophosphamide which is known to stimulate the 
mobilisation of peripheral stem cells (To et al, 1990) and to have a relatively 
sparing cytotoxic effect on stem cells (Smith et al, 1983). The mean CFU-GM  
was 43.88 x 104 versus 6.16 x 104 per kg body weight per leukapheresis in the
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cyclophosphamide only group.
Circulating levels of haemopoietic growth factors in serum
Amount of colony stimulating activity (CSA) in the serum increases 
substantially after high dose chemoradiotherapy (Millar et al, 1992). They 
studied 62 patients after intensive treatment for haematological malignancies. 
In 44/62 patients maximum CSA occurred at 7 days. Despite this early peak 
in CSA there was no correlation between the time at which CSA activity was 
maximum and the return of the neutrophil count to 0.5 x 109/1. In a previous 
study, (Millar et al, 1990), showed that CSA activity in serum of patients 
treated with high dose chemoradiotherapy for multiple myeloma could be 
neutralised with anti-bodies to GM-CSF. Other workers have shown that G- 
CSF, GM-CSF (Watari et al, 1989) and megakaryocyte CSA (Fauser et al,
1988) are present in serum post transplantation.
Watari et al using an enzyme immunoassay specific for human G-CSF 
(which estimates serum G-CSF concentrations greater than 30pg/ml) showed 
that 49/56 (83%) of normal donors had serum G-CSF levels below the 
sensitivity of the assay. Conversely 82% of patients with aplastic anaemia, 50% 
of patients with MDS, 42% of patients with AML and 33% of patients with 
CML had serum G-CSF levels ranging from 46pg/ml to >2000pg/ml. The 
serum G-CSF level rose after chemotherapy or BMT in 3 patients with 
leukaemia.
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Aims of the thesis 
Haemopoiesis is controlled by appropriate combinations of positive and 
negative regulators. Although much information has been accumulated 
concerning positive regulators such as colony-stimulating factors, the role of 
negative regulators remains controversial. Molecules which have been 
identified as potential negative regulators include tumour necrosis factor 
(TNF), TGF-/3, MIP-la: and the interferons.
The production of TGFBj by haemopoietic cells suggests that it may 
play an important role in regulating haemopoiesis. In murine bone marrow 
cells TGFBj inhibits colony formation induced by IL-3 but not by GM-CSF 
(Keller et al, 1988). In human haemopoiesis TGFBj inhibits CFU-GM 
production by IL-3 and GM-CSF and megakaryocyte development by IL-3 but 
has no effect on G-CSF-induced cell proliferation from normal bone marrow 
cells in vitro (Sing et al, 1988; Han et al, 1992).
In this study the effects of TGFBj on the G-CSF-induced proliferation 
of normal, CML and AML cells were studied alone or in combination with ILr 
4 which is known to enhance the number and size of colonies induced by G- 
CSF (Broxmeyer et al, 1988). The purpose being to ascertain if the effects of 
TGFBi on normal and myeloid leukaemic cells were different and to 
determine if this differential effect could be exploited in future treatment 
strategies of CML. In-situ hybridisation studies were done to determine if the 
effects of TGFBj on normal and myeloid leukaemic cells were mediated via 
receptor expression
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CD34+ is a heavily glycosylated surface antigen which is preferentially 
expressed on haemopoietic stem/progenitor cells and is progressively lost as 
cells differentiate. The expression of CD34+ on early haemopoietic cells has 
been used in transplantation studies and these cells may be the target of gene 
therapy protocols. Immunophenotypic studies were done to characterise 
surface antigen markers on CML and AML cells, to determine whether an 
increased CD34 positivity (signifying a greater number of early progenitors) 
correlates with increased CFU-C in vitro. The effects of G-CSF, IL-4 and 
TGFjSj on CD34+ enriched cells were compared to their effects on 
unmanipulated normal, AML and CML mononuclear cells, to determine if 
these cytokines have a similar effect on more primitive progenitor cells.
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CHAPTER 2 
MATERIALS AND METHODS
Patient samples
Bone marrow: Samples were collected with the consent of the patients 
either at their out-patient visit or during their bone marrow harvest. Samples 
were aspirated from one or other of the iliac crests. When samples were 
unobtainable from the iliac crest they were aspirated from the sternum. Five 
to ten ml of lignocaine ( Iignocaine 2%, Antigen Ltd, U.K) was injected into 
the skin, and the subcutaneous tissue and periosteum infiltrated with the local 
anaesthetic. A  Salah bone marrow aspirate needle was introduced into the 
marrow cavity. Two to five ml of marrow was aspirated into a sterile plastic 
syringe (Gillette, U.K.) and then transferred into a sterile universal container 
(Sterilin Ltd, U .K ) containing 0.1ml preservative free heparin (PFH), (1000 
units/ml Monoparin, CP Pharmaceutical Ltd, Wrexham, U.K).
Peripheral blood samples: Samples were collected with the consent of 
the patient either during their visit to the out-patient clinic or when they were 
undergoing leukapheresis. During leukapheresis white cells were separated 
from red cells and platelets using a continuous-flow blood cell separator (Cobe 
Spectra, U.S. A). Ten to twenty ml of venous blood was collected into universal 
containers containing PFH.
Details of patients including age, sex, disease and previous treatment 
are given in the appendix (Tables I and II).
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Normal donor samples
Samples of blood and bone marrow from volunteers and normal donors 
for allogeneic bone marrow transplantation were collected with their consent 
using the method detailed above.
Cell lines
HL60: This cell line was derived from the peripheral blood of a patient 
with acute promyelocytic leukaemia (Collins et al, 1977). Suspension cultures 
of HL60 cells were maintained in exponential growth in RPMI 1640 medium 
(Flow Laboratories, Irvine, Scotland) supplemented with 7.5% foetal calf 
serum (FCS- Row Laboratories), penicillin lOOOu/ml and streptomycin 
100|ig/ml (Penicillin-streptomycin solution, Gibco, Scotland), 20mM Hepes 
buffer (Gibco), 2mM glutamine (Gibco) and 0.1% NaH C03 (7.5% solution, 
Gibco). Cells were seeded at 2 x lO^ml in 40ml of the supplemented RPMI 
1640 medium in 80cm2 tissue culture flasks (Nunc, Denmark), incubated at 
37°C and passaged every 3-4 days. At each passage a cell count and viability 
were determined using a haemocytometer (Improved Neubauer, Weber 
Scientific International, U.K). Cell viability was estimated using trypan blue 
exclusion. 0.1ml of the cell suspension was mixed with an equal volume of a 
0.25% solution of trypan blue dye (Gibco Ltd, U.K). The mixture was placed 
in the counting chamber of a haemocytometer under 20Qx magnification. 
Viable cells exclude the dye, whereas dead cells are stained blue. Viability was 
estimated by counting the number of cells which excluded the dye in a total
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of 200 cells.
Culture media
Alpha-modification of Eagles minimal essential medium (a-medium): The 
alpha-modification of Eagles medium (Flow Laboratories, U.K) was used in 
all clonogenic assays. It was supplied as a powder and reconstituted in distilled 
water with the addition of extra vitamins (100ml Eagles minimal essential 
medium) to produce a concentrated stock solution (6.25x concentrated a- 
stock) which was sterilised by passage through a 0.2pl filter and from which 
further modified culture medium was prepared. In order to dilute a-medium 
with agar solutions but retain the correct final concentrations of its 
constituents and osmolality a-medium was made up at double concentration 
(2xa). 100ml aliquots of 2xa were prepared in sterile glass measuring cylinders 
by mixing the following sterile stock solutions to 32ml of a-stock and
completing the volume with sterile distilled water;
Foetal calf serum (FCS) (Flow Laboratories) 10ml
Sodium bicarbonate (7.5%- Gibco) 6ml
10% bovine serum albumin (BSA) (Sigma) 20ml
Transferrin lOmg/ml (Sigma) 1ml
L-ascorbic acid 1ml of 100mg/20ml
(BDH, Poole, U.K) 1ml
Gentamycin 80mg/2ml (Cidomycin, Roussel, U.K) 0.1ml 
Uglutamine 200mM (Gibco, U.K) 5ml
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2xa-medium was poured into sterile screw top bottles and stored at 4°C.
The constituents of alpha medium and RPMI 1640 are given in the appendix 
(Table III and IV).
5637 conditioned medium
The 5637 cell line was kindly supplied by Dr R.E Stanley at the Albert 
Einstein College of Medicine, U.S.A. Serum-free 5637 CM was prepared by 
growing 5637 cells in RPMI 1640 medium supplemented with 2.4mM E- 
glutamine, lOOunits/ml penicillin, 100pg/ml streptomycin, 3.63 ng/ml 
hydrocortisone, 5pg/ml insulin, lOOpg/ml transferrin, 2.72ng/ml /3-oestradiol 
and 10.4ng/ml sodium selenite (all supplied by Sigma). 5637 CM contains a 
variety of growth factors which include haemopoietin-1, G-CSF, IU6, IL-1, 
GM-CSF and stem cell factor.
Recombinant human growth factors and lymphokines
Recombinant human granulocyte colony-stimulating factor (rhG-CSF): 
rhG-CSF manufactured by Chugai was a gift from Chugai Pharmaceutical Co. 
Ltd, Japan. The Chugai product is expressed in Chinese hamster ovary cells 
from cDNA derived from a human squamous cell carcinoma cell line (CHU-2) 
that produces G-CSF in culture. rhG-CSF was supplied as a sterile lyophilised 
powder, free of pyrogens in vials of lOOpg. It was reconstituted in 2ml of 
sterile water to produce a clear solution of Ph 6.5-8.0. Aliquots were diluted 
in phosphate buffered saline A  (PBSA) containing 0.1% bovine serum albumin
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in sterile plastic Bijou bottles and stored at -20°C until required.
Recombinant human granulocyte macrophage colony-stimulating factor 
(rhGM-CSF): rhGM-CSF was supplied by Sandoz, U.K. It was derived from 
Chinese hamster ovary cells. The product is 95% pure and is species specific. 
It was supplied as a lyophilised powder at a concentration of 216 pg/vial. It 
was diluted in 108ml of PBS A and 0.1%BSA, to give a final concentration of 
2pg/ml. Aliquots of the stock solution were frozen at -20°C until used.
Recombinant human interleuldn-3 (rhIL-3): rhIL-3 was supplied by 
Sandoz, Leeds, U .K  It was expressed in yeast from cDNA cloned from 
activated human lymphocytes. It differs from natural human IL-3 by an 
intentional substitution of aspartic acid for asparagine at positions 15 and 70 
to reduce N-linked glycosylation. The molecular weight was 15kD and the 
stated activity was 1.5 x 106 i.u./mg. It was supplied as a frozen solution 
containing 4|ig/ml. The stock solution was diluted in aliquots of lpg/ml and 
stored frozen at -20°C for later use.
Recombinant human interleukin-4 (rhIL-4): rhIL-4 was supplied by 
British Bio-technology Ltd, Abingdon, U.K It was expressed in E.Coli from a 
designer gene (BBG 15). The sequence differed from that of natural human 
IL-4 by the presence of a N-terminal methionine. Activity measured by 3H- 
thymidine incorporation into T-lymphocytes was 1-3 x 106units/mg. It was 
supplied in vials containing 5jig as a lyophilised powder and reconstituted and 
stored as above.
Transforming growth factor fi1 (TGFpj): TGF/32 was a gift from Professor
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M Dexter, The Paterson Institute, Manchester, U.K. It had a purity of 95% 
and specific activity of lx l0 6 units/mg. It was supplied in vials of 20|ig/ml.
It was diluted down to 1 pg/ml and stored frozen at -20°C for later use.
Monoclonal and polyclonal anti-bodies
Monoclonal mouse anti-human progenitor cell antigen (Anti-HPCA), (anti- 
CD34): The purified antibody was obtained from Beckton Dickinson, Oxford, 
U .K  CD34 is a human progenitor cell associated antigen with a molecular 
weight of 115kD. The CD34-positive compartment of normal human bone 
marrow (approximately 1% of nucleated cells) is comprised of unipotent and 
multipotent progenitor cells (CFU-E, BFU-E, CFU-GEMM, CFU-GM, CFU- 
blasts) as well as all terminal deoxynucletidyl transferase (TdT) positive cells. 
It is not found on normal peripheral blood lymphocytes, monocytes, 
granulocytes or platelets.
Monoclonal mouse anti-human Leu-17 (anti-CD38): The purified 
antibody was obtained from Beckton Dickinson, Oxford, U .K  CD38 is a 
human lymphocyte antigen of molecular weight 45kD. It is present in low 
density on most normal human natural killer (NK) cells, most B-cells, subsets 
of CD8+ and CD4+ T cells and monocytes. CD38 is found in high density on 
plasma cells, mitogen-activated T cells and several B and T cell lines. 
Approximately 40% of bone marrow cells (including myeloblasts and 
promyelocytes are positive.
Monoclonal mouse anti-human CD33: The purified antibody was
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obtained from Serotec, U.K. The CD33 antigen has a molecular weight of 
70kD. The antibody is restricted to cells of the myeloid lineage. It binds 
strongly to monocytes and to the majority of acute myeloid leukaemia 
progenitor cells. Approximately 25% of normal bone marrow MNC are CD33 
positive.
Polyclonal rabbit anti-human IL-4 antibody: The purified antibody was 
supplied by Genzyme, Herts, U .K  The antigen used to generate the antibody 
was recombinant human interleukin-4. The antibody was aliquoted and stored 
at -20°C.
Oligonucleotide probes
The DNA probes for the G-CSF receptor and IL-4 receptor were 
supplied from British Bio-technology, Oxford, U.K. The probes were single 
stranded oligonucleotides which were chemically synthesised and based on the 
anti-sense sequence. They were designed to detect the 5’, central and 3’ region 
of the receptor. The 5’ end of each oligomer was labelled with digoxigenin. 
The sequences of the probes are given below:
G-CSF receptor
Top of receptor 5’- 5GT TGT GAG GTT CAT GAG GCA GGA GA -3’ 
Middle of receptor 5’- 5CT CCA GGT CTT GTT GCT ATT GCT CG -3’ 
End of receptor 5’- 5GA GTG GAG TCA CAG CGG AGA TAG - 3’
IL-4 receptor
Top of receptor 5’- 5CC AGG TGG TGT TAT AGC ACT GAG CC -3’
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Middle of receptor 5’- 5GC GTC TCT GTG CAA GTC AGG TTG TC -3’ 
End of receptor 5’- 5AT GAG CAC CTC TAG GCA ATG ACC AC -3’
In addition, a cocktail of 3, 25 mer sense probes to the IL-4R was used 
as a negative control. The mRNA sequence for the G-CSF and IL-4 receptors 
are shown in the appendix (Figure 2 and 3)
Laboratory methods 
Cell culture: The work was carried out in a class II microbiological safety 
cabinet (Envair, U.K Ltd).
Separation of blood and bone marrow mononuclear cells: The volume of
blood/bone marrow was measured and then diluted with an equal quantity of 
PBSA. Aliquots (4-5ml) of the diluted blood/bone marrow were layered onto 
10ml of Ficoll-Hypaque (Lymphoprep, density 1.077; Nycomed, Norway) and 
separated at 128gby centrifugation (IEC-CENTRA 7-Intemational Equipment 
Company, U.S.A) for 20 minutes. Using this technique most red cells and 
mature granulocytes are forced to the bottom of the tube, leaving 
mononuclear cells (including blast cells) at the interphase (Boyum, 1968). The 
leucocytes lighter than 1.077g/ml were collected from the interphase and 
diluted with 15ml of PBSA. The cells were washed by further centrifugation 
at 450g for 10 minutes. The supernatant was discarded and the mononuclear 
cells resuspended in single strength a-medium. 40pi of this cell suspension was 
diluted in 20ml Isoton solution (Coulter Electronics, Luton, U.K). The 
residual red cells were lysed with 6 drops of Zapo-globin (Coulter
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Electronics), and the white cells counted using a Coulter counter (Coulter 
Electronics).
Cryopreserved samples: Blood and bone marrow samples from patients 
with AML and CML were collected into PFH as previously detailed. The 
samples were either taken at leukapheresis prior to treatment or were the 
initial diagnostic samples. The cell suspension was diluted with TC199 growth 
medium (Wellcome, U.K) containing 5% dimethylsulphoxide (DMSO, Fisons 
pic, U.K) and was then dispensed into 2ml sterile glass ampoules. These were 
heat-sealed and then immediately cooled using a liquid nitrogen gas-phased 
programmed freezer (Planar Ltd, Model R201) to a temperature of -130°C. 
All the ampoules were finally stored in the gas phase of liquid nitrogen at 
below -150°C. When required an ampoule of frozen cells was thawed, and its 
contents transferred into a universal container. The suspension was diluted in 
RPMI 1640 and centrifuged 128g for 10 minutes. After centrifugation the cell 
pellet was resuspended in medium and the mononuclear cells counted as 
above.
Assay of CFU-GM, CFU-CML and CFU-AML from peripheral blood 
and bone marrow mononuclear cells: A  modification of the two-layer soft 
agar technique developed by Bradley and Metcalf in 1966 was used (Bradley 
and Metcalf, 1966). Each assay was carried out in triplicate in 35mm sterile 
Petri dishes (Nunc, Denmark) to which aliquots of cytokines were added. The 
first agar layer was prepared using a concentration of 1% agar (Agar noble, 
Difco, U.S.A) in distilled water. The agar was sterilised by heating in an
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autoclave (Ensign-Rodwell, U.K) at 120°C for 15 minutes. The agar was 
melted using a microwave oven (Finess 500) and was maintained at 56-60°C 
on a hot plate. This temperature range was sufficient to maintain the fluidity 
of the agar without damaging the components of the medium or killing the 
cells. Volumes of cytokines no greater than lOOpl were added, and then a 1ml, 
1:1 mixture of the 1% agar and 2xa-medium was dispensed into the Petri 
dishes, and the underlayers allowed to cool and solidify at room temperature. 
The overlay contained the normal donor or leukaemic mononuclear cells in 
a 0.5ml of a 1:1 mixture of 0.66% agar (prepared as above) and 2xa-medium. 
The number of peripheral blood mononuclear cells incorporated in the overlay 
was between 104 and 5 x 105/plate and the concentration of bone marrow 
mononuclear cells was between 105 and 5 x lO^plate. Petri dishes were placed 
in plastic boxes, gassed with a combination of 5% C02, 10%O2 and 85%N2, 
sealed and incubated for 12-14 days at 37°C. Distilled water (5ml) was added 
to each box for humidification (to prevent drying of the agar).
Colony morphology and numbers: Colonies were counted using an inverted 
microscope (Nikon, Japan). A  colony was defined as more than 50 cells and 
a cluster as between 10-50 cells. Individual colonies were removed from the 
agar overlay using a fine pasteur pipette. The cells were diluted in a few drops 
of PBSA and cytocentrifuged (Shandon, U.K) at 500rpm for 5 minutes. The 
slides were air dried, fixed in 99.8% methanol (BDH) and stained with May-
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Grunwald-Giemsa (Gurr, BDH). The cells were examined under a light 
microscope (Axioscope, Zeiss, W.Germany).
Chromosome analysis: Chromosome analysis was carried out by Mr J. 
Swansbury (Dept, of Cytogenetics, The Royal Marsden Hospital, Sutton, 
U.K.). Briefly the technique used was as follows; the mitotic divisions were 
arrested in metaphase by destroying the spindle with colcemid (lpg/ml; Gibco, 
U.K) overnight. The cells were treated with a hypotonic solution of potassium 
chloride (0.075M) to help spreading of the chromosomes. The fixed cells were 
spread on slides and air-dried. To induce banding patterns the slides were 
immersed in salt solution [2xSSC; NaCl (17.53g) and sodium citrate (8.82g) 
made up to 1 litre of aqueous solution] at 60°C followed by a brief exposure 
to trypsin (2.5% diluted 1:50 PBS), (Williams et al,1984). The slides were 
stained and analysed on a Cytoscan automated analysis system (Applied 
Imaging, U .K).
Detection of CD33, 34 and CD38 antigens: The proportion of the cells
carrying these antigens was estimated by incubating 106 MNC with lOpl of 
each antibody at 4°C for 20 minutes. The cells were washed in PBSA 
containing 1% bovine serum albumin (PBSA/0.1%BSA) and then exposed to 
5|il fluorescein-conjugated rabbit anti-mouse immunoglobulins (Dako Ltd, 
U.K) for a further 20 minutes at 4°C. The cells were washed as above and
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examined by fluorescence microscopy.
Detection of IL-4 receptor: Ten pi of the rabbit anti-human IL-4 polyclonal 
antibody, (Genzyme, Herts, U.K) was added to 106 mononuclear cells and the 
cells incubated at 4°C for 20 minutes. The cells were washed in PBS- 
A/0.1%BSA and then exposed to 50pl of biotinylated sheep anti-rabbit IgG 
(Serotec, U.K), and incubated at 4°C for 20 minutes. The cells were washed 
in PBSA/0.1%BSA and exposed subsequently to 10 pi of Streptavidin bound 
R-phycoerythrin (Serotec, U.K). After further incubation for 20 minutes at 
4°C, the cells were washed with PBSA/0.1%BSA and examined under 
fluorescence microscopy.
Enrichment of CD34+ cells: CD34+ cells were prepared from peripheral 
blood and bone marrow mononuclear cells by exposing them to 100pi anti- 
CD34/2 x 107 MNC at 4°C for 20 minutes. After washing with PBSA they were 
exposed to magnetic beads coated with sheep anti-mouse IgG (Dynal, Oslo, 
Norway) at 4°C for a further 20 minutes. The beadicell ratio was 
approximately 3:1. The cells were washed with PBSA and the beads removed 
by magnet. The cells attached to the magnetic beads were incubated overnight 
in single strength a-medium which contained normal human serum (l:lv/v) 
and 5% 5637-CM. The overnight incubation allowed the cells to detach from 
the beads because of regeneration of the cell membrane. The beads were 
removed by magnet and an aliquot of the cell suspension was diluted 1:1 with 
trypan blue (0.25% final concentration). A  viable cell count was performed
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using a haemocytometer. A  second aliquot of cells was re-examined for CD34 
positivity as detailed above. Using this method 60-65% of the CD34+ cells 
were recovered. Of the recovered cells 90-95% were CD34 positive. The yield 
of CD34+ cells from marrow samples was 1-2% of the population of MNC. 
Cultures were plated in triplicate as described above. The concentration of 
cells plated per dish varied from 5 x 103 to 5 x 104/dish.
In-situ hybridisation
In-situ hybridisation was first described in 1969 (John et al, 1969; Gall 
and Pardue, 1969) for the detection of multiple copy ribosomal RNA genes. 
Since then the technique has become well established for the detection and 
isolation of both DNA and mRNA within cells and tissue sections (Warford, 
1988). Two developments in particular have contributed to the accessibility of 
this technique. Firstly the availability of synthetic oligonucleotide probes and 
secondly the use of non-radioactive detection methods (Guitteny et al, 1988; 
Hankin and Lloyd, 1989; Larsson, 1989; Pringle et al, 1990).
The following methods were employed to reduce contamination of 
tissue sections, solutions and equipment with ribonuclease (RNAse). RNAse 
is ubiquitous and is not destroyed by autoclaving, therefore special precautions 
must be taken to exclude it from experimental procedures.
a. Disposable gloves were worn at all times when preparing solutions
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and handling materials and apparatus.
b. Whenever possible sterile disposable plasticware which is essentially 
RNAse-free was used.
c. All glassware was baked at 180°C overnight and was designated for 
in-situ hybridisation only.
d. Slides, cytocentrifuge tubes and holders were rinsed in water treated 
with diethyl pyrocarbonate (DEPC) which was prepared as detailed below.
e. All prepared equipment was covered and stored away from dust.
Preparation of hybridisation chamber: The plastic lid of a sandwich box 
measuring 17cm x 11.5cm and 2 x 5ml plastic pipettes were used. The pipettes 
were snapped in two and fitted snugly into the plastic lid and glued using 
chloroform. Filter paper (fibre-free Postlip paper, Hollingsworth, U.K) was 
layered onto the bottom of the lid. The filter paper was moistened with 
DEPC-treated water and the chamber sealed with plastic tape whenever used.
Preparation of solutions:-
DEPC-treated water: DEPC is a suspected carcinogen and was handled 
wearing gloves in a fume hood. A  10%(v/v) solution of DEPC (Sigma, U.S.A) 
in absolute ethanol (BDH, U.K) was prepared in a glass bottle. Fifteen ml of 
this solution was added to 1485ml of distilled water in a 2 litre screw top
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bottle. The final concentration of the DEPC was 0.1%. The bottle was shaken 
and left to stand overnight in a fume cupboard. It was autoclaved the 
following morning at 120°C for 15 minutes. The autoclaving destroys any 
residual DEPC.
0.2% para-formaldehdye fixative solution: 0.2g of para-formaldehyde 
(BDH,U.K) was added to 100ml of DEPC-treated water and the solution 
dissolved by heating in a microwave (low) for 15 minutes. The bottle was 
covered in silver foil and allowed to cool by placing at 4°C for 1 hour.
20xTris-buffered saline (TBS): The following were added to 800ml of 
DEPC-treated water, 160g NaCl (Rose chemicals, U.K.) 7.6g KC1 (BDH, 
U.K.) and 60g Tris (Sigma, U.S.A.). The Ph was adjusted to 7.6 by adding 
approximately 25ml of concentrated HC1.
Modified Tris-buffered saline (TBS)/Triton: 5ml of 2QxTBS (Sigma, 
U.S.A), 2mM MgCl2 (BDH, U.K), O.lg BSA (Sigma, U.S.A) and 0.2ml Triton 
(Sigma, U.S. A) were added to 95ml of DEPC-treated water. The solution was 
aliquoted into 2 bottles.
TBS wash: To 95ml of DEPC-treated water were added 5ml of 20X1BS 
and O.lg BSA. D ie solution was aliquoted into 2 glass bottles.
0.6MNaCl in 30% formamide: 6.96g NaCl and 60ml formamide (BDH  
Laboratory supplies, U.K) were added to 140ml of DEPC-treated water. This 
solution was used for both the pre-hybridisation and hybridisation reactions 
and was stored at -20°C.
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Post-hybridisation washes: Following hybridisation non-specifically bound 
probe is washed out whilst retaining the specifically bound probe. This is 
achieved by using three 37°C washes (see below; a-c) of a fixed formamide 
concentration containing decreasing salt concentrations and therefore 
increasing stringency.
a. 4xSaline sodium citrate (SSC)/30% formamide: DEPC-treated 
water:2QxSSC (Sigma):formamide (5:2:3 by volume)
b. 2xSSC/30% formamide: DEPC-treated water:20xSSC:formamide 
(6:1:3 by volume)
c. 0.2xSSC/30%formamide: DEPC-treated water:20xSSC:formamide 
(69:1:30 by volume)
The bottles were swirled, the necks covered with foil and then placed in a 
37°C incubator for an hour to warm.
Controls for in-situ hybridisation:
No probe: The hybridisation solution was applied without the addition 
of the oligonucleotide probes. This provided an assessment of any non-specific 
binding.
RNAse pre-treatment: In order to demonstrate that the target nucleic 
acid is RNA, some of the cell sections were incubated with RNAse before 
application of the probe. All mRNA within the section will be degraded by 
this control and any resultant labelling is non-specific. Care was taken not to
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contaminate the positive controls with RNAse.
HL60 cells: Preliminary experiments showed that these cells expressed 
the mRNA for the IL-4 receptor and they were therefore used as a positive 
control.
Actinprobe: (British Bio-technology, U.K.) Actin is present in all animal 
cells and tissue and the probe was used as a positive control.
In-situ hybridisation looking at mRNA expression has not been carried out on 
bone marrow or peripheral blood MNC. Several difficulties were encountered 
which will be detailed later. In an attempt to overcome these difficulties 3 
different methods were used.
Method 1
In-situ hybridisation can be divided into 5 stages, fixation, addition of RNAse 
positive controls, pre-hybridisation, hybridisation, post-hybridisation and the 
revealing reaction. The technique was employed to study the expression of the 
mRNA for the IL-4 and G-CSF receptors in blood and bone marrow samples 
from normal donors and leukaemic patients.
Preparation of slides: Slides were prepared by cytocentrifugation as 
described previously using two drops of a cell suspension containing 106 
cells/ml for each slide. The slides used were coated with the adhesive, 3- 
aminopropyltriethoxysilane (APES; Maddox and Jenkins, 1987). The slides,
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cytocentrifuge tubes and holders were all washed in DEPC-treated water prior 
to use. When slides were stored, they were kept at -70°C. They were thawed 
at room temperature, washed in DEPC-treated water and dried in a 37°C 
incubator overnight.
Fixation: The process of fixation should crosslink the cell matrix, 
preserving the RNA intact and in its original location A thorough 
investigation of fixatives used for in-situ hybridisation has been performed by 
Singer and co-workers (Singer et al, 1986; Lawrence and Singer, 1985). Their 
work showed that good RNA retention was given by paraformaldehyde and 
glutaraldehyde but that ethanol:acetic acid and Camoy’s fixative caused 
significant loss of both RNA and cellular morphology. Their work however 
was done on tissue sections. On cytospins of cell samples the most satisfactory 
fixation was fixing for 10 minutes in a 1:1 solution of acetone and methanol. 
The slides were then transferred to a Hallendahl jar (Raymond Lamb, U.K.) 
containing the cooled 0.2% paraformaldehyde solution. Using this method, the 
cellular architecture and membranes were retained. Acetone/methanol, 
ethanol, ethanol/ 0.2%paraformaldehyde or a higher concentration of 
paraformaldehyde all caused loss of cellular architecture.
Addition of proteinase: In paraffin embedded tissue sections digestion 
with a proteolytic enzyme is necessary to expose the target mRNA in the 
section to the incoming probe. However in cell preparations used in this study 
even a small concentration of proteinase (lpl/mg) completely destroyed
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cellular architecture. It was therefore not used.
Addition of RNAse: Half the slides were placed in a Hallendahl jar 
containing 100p 1/ml of RNAse and 2xSSC with lOmM MgCl2. The remaining 
slides were placed in a Hallendahl jar containing only the 2xSSC and MgCl2. 
The slides were incubated at 37°C for 1 hour. The slides were washed with 
PBS/DEPC-treated water. The "no RNAse" slides were washed first to avoid 
contamination of the other slides with RNAse. The slides were drained onto 
postlip paper.
Pre-hybridisation reaction: Before the hybridisation it is conventional to 
block any non-specific binding sites in the cell section by pre-hybridising in the 
absence of the probe. The pre-hybridisation solution contains 0.6M NaCl, 30% 
(v/v) formamide and 150pl/ml salmon sperm DNA (Sigma, U.S.A). 300^1 of 
the pre-hybridisation solution was placed on each slide, the filter paper at the 
bottom of the hybridisation chamber was moistened with DEPC-treated 
water, the box sealed and placed in a 37°C incubator for 1 hour.
Hybridisation reaction: During hybridisation the oligonucleotide probes 
anneal by complementary base pairing with the target mRNA. The specificity 
of hybridisation is controlled by the stringency used (stringency refers to the 
degree to which reaction conditions favour the dissociation of nucleic acid 
duplexes) a low salt concentration and high temperature constitute high 
stringency and high specificity. The addition of formamide to the hybridisation
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at a given salt concentration and temperature increases the stringency still 
further. The inclusion of formamide for in-situ hybridisation maintains a high 
stringency but allows the use of lower temperatures which helps to preserve 
tissue morphology. 15pl of each probe (O.lpg/lpl) was added to the 
hybridisation solution to a final oligonucleotide concentration of 0.2pg/ml. The 
pre-hybridisation solution was drained from all the slides except the "no probe" 
controls. lOOpl of the hybridisation solution was placed on the slides (except 
onto the "no probe" controls). The slides were covered with a 18mm x 50mm 
coverslip (Chance Propper Ltd, U.K) and placed in the moistened 
hybridisation chamber. The chamber was sealed and placed in a 37°C 
incubator for 16-17 hours.
Post-hybridisation washes: Following hybridisation, non-specifically 
bound probe is washed out whilst retaining the specifically bound hybrids. This 
is achieved by using three washes at 37°C of a fixed formamide concentration 
containing decreasing concentrations of salt. The first wash containing 
4xSSC/30% formamide provides stringency almost identical to those of the 
hybridisation reaction. It would therefore wash away any excess or loosely 
bound probe. Two further washes of increasing stringency containing 
2xSS/30% formamide and 0.2xSSC/30% formamide are then used to ensure 
that any non-specific loosely bound probe is washed away. The slides were 
removed from the hybridisation chamber and placed for 5 minutes, at 37°C in 
a pre-warmed Hallendahl jar containing the 4xSSC/30% formamide. At the
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end of the 5 minutes the wash solution was discarded and a fresh 50ml of the 
pre-warmed 4xSSC/30% formamide poured into the Hallendahl jar and the 
slides incubated for a further 5 minutes at 37°C. This process was repeated 
using the 2xSSC/30% formamide and the 0.2xSSC/30% formamide. When the 
post-hybridisation solutions were not being used they were kept in the 
incubator at 37°C and not allowed to cool. After the final wash the slides were 
transferred to a Hallendahl jar containing modified TBS/Triton. They were 
rinsed in this solution at room temperature for 15 minutes. The slides were 
drained onto postlip paper and allowed to dry.
Revealing reaction: The purpose of the revealing reaction is to detect the 
target/probe complex. The method is a sandwich technique, the biotinylated 
antibody binds to digoxigenin on the probe. Streptavidin bound horseradish 
peroxidase is then added which binds to the target/probe complex. In the 
presence of 3’3’ diaminobenzidine an insoluble brown precipitate is formed on 
the addition of H2C>2 , the reaction being catalysed by peroxidase. The details 
are given below:-
To block endogenous peroxidase the slides were placed in a jar 
containing 3%H20 2 (FSA Laboratory supplies, U.K) for 10 minutes at room 
temperature, after which they were washed in TBS/0.1%BSA. 100pi of the 
anti-digoxigenin-POD, Fab fragments, which binds to digoxigenin labelled 
compounds (150u/ml Boehringer Mannheim Biochemica, W Germany) was 
added to 3.2ml of a solution containing Tris-HCl 100mmol/l and 150mmol/l
101
NaCl (pH 7.5) plus 0.4ml foetal calf serum. This quantity of solution was 
sufficient for 12 slides. 300pi of this solution was placed on each slide. The 
slides were placed inside the hybridisation chamber and left at room 
temperature for 30 minutes and then were drained onto postlip paper and 
washed twice in TBS/0.1%BSA for 5 minutes. The slides were then transferred 
to a jar containing 68g Imidazole (Sigma, U.S.A) in 50ml water and 4pl of 
H20 2 plus 50mg 3,3’-diaminobenzidine (Sigma, U.S.A) in 50ml of Tris-HCl pH 
7.6 and left at room temperature for 10 minutes. If a brown colour change was 
not observed in the positive controls they were left for a longer period of time 
(30 minutes), or more H20 2 was added. The slides were counter stained with 
Mayer’s Hemotoxylin solution (Sigma, U.S.A) for 2 minutes and mounted 
using DePeX (BDH Ltd, U.K).
Using the above method the following problems were encountered:
(1) Loss of cellular architecture due the paraformaldehyde and formamide.
(2) Non-specific positive staining with the sense probes and negative staining 
with the actin probe.
In an attempt to overcome these problems the following methods were 
adopted:
Method II
To overcome the problems encountered with Method I, the following 
changes were made to the methodology.
1. The slides were fixed in a 1:1 mixture of acetone and methanol and then
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rinsed in PBSA.
2. The composition of the prehybridisation solution was changed to - 5.0ml 
deionised formamide (Sigma, U.S.A), 2.0ml 2QxSSC (Sigma, U.S.A), 0.2ml of 
50x Denhardt’s solution (Sigma, U.S.A), 0.5ml of salmon sperm DNA  
(lOmg/ml, Sigma, U.S.A), 0.25ml of yeast tRNA (lOmg/ml) and 2.0ml of 
dextran sulphate (Sigma, U.S.A). 500 pi of the above solution was added to 
each slide. The slides were incubated in a humidified chamber for 1 hour at 
room temperature.
3. Hybridisation - the slides were rinsed in 2xSSC and 40pl of the 
prehybridisation solution containing a 1/50 dilution of the probes were placed 
on the slides. Hybridisation was allowed to occur in a humidified chamber at 
37°C overnight.
4. Post-Hybridisation - the post-hybridisation washes consisted of the following 
steps
a. The slides were incubated in 2xSSC for 1 hour at room temperature
b. lxSSC for 1 hour at room temperature
c. 0.5xSSC for 30 minutes at 37°C
d. 0.5xSSC for 30 minutes at room temperature
5. The revealing reaction was carried out as detailed in Method I.
This method (Crabbe et al, 1992) was employed to detect mRNA  
expression in chondrocytes. Peripheral blood and bone marrow MNC are 
more fragile than chondrocytes and using this method problems with non­
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specific background staining together with loss of cellular architecture, were 
encountered. A  dot blot analysis revealed that the salmon sperm bound to the 
anti-digoxigenin-POD, Fab fragment. A  further method was therefore was 
devised which omitted both the formamide and the salmon sperm.
Method III
1. Fixation - the slides were fixed in acetone/methanol.
2. Addition of RNAse - the slides were incubated in 500pg/ml RNAse in 
2xSSC and 0.1% triton for 30 minutes at 37°C. The slides were washed in PBS 
followed by DEPC treated water.
3. Hybridisation - the hybridisation solution consisted of 8|±1 of 5mM of MgCl2 
(BDH, U.K) 26pi of annealing buffer [50mM Tris (Sigma, U.S.A), 250mM 
KC1 (Aldrich Chemical Company, Inc, U.S.A) in DEPC water pH 8.3] and 2pl 
of each probe (O.lpg/pl) giving a total volume of 40pl/slide. The slides were 
incubated at 60°C for 2 minutes using a thermal cycler (Hybaid, Teddington, 
U.K)
4. Post hybridisation - the slides were washed sequentially in the following 
solutions
a. 4xSSC for 10 minutes at 37°C
b. 2xSSC for 10 minutes at 37°C
C. lxTBS/triton for 15 minutes at room temperature.
5. Revealing reaction - was carried out as detailed in Method I. In order to 
give a greater contrast in colour (peroxidase stains brown) than that obtained
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with Mayer’s Haematoxylin, light green (Raymond Lamb, U.K) counter stain 
was used.
Using this method the cellular architecture was in most instances not 
destroyed. Furthermore there was no non-specific back-ground staining. The 
addition of the RNAse whilst reducing the signal also caused deterioration in 
cellular integrity and detail. The most disturbing problem with this technique 
was that whilst the "no probe, no antibody" gave a negative result the "no 
probe, plus antibody" which should have given a negative result on some 
occasions gave a positive result (UPN 52 and 53). Neutrophils contain 
peroxidase which has an important role in its anti-microbial activity. It may be 
that in these patients high levels of endogenous peroxidase were present (after 
incubation with 3% H202) permitting non-specific deposition of chromogen 
following addition of substrate.
Statistical analysis 
Statistical analyses were performed using paired, non-parametric Sign 
Rank Wilcoxon tests from a computer programme from Epistat (Epistat 
software, U.S.A).
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CHAPTER 3
EFFECT OF CYTOKINES ON PROGENITOR CELL GROWTH 
Introduction:
Early stages of haemopoietic cell development can be quantitated and 
characterised using in vitro colony assays. Clonogenic assays are now available 
for all types of committed granulopoietic, erythroid and megakaryopoietic 
progenitor cells. Colony assays are carried out in semi-solid medium and 
individual colonies can be identified and distinguished by their size, 
morphology and cytogenetic analysis.
Growth of CML cells in vitro:
In patients with CML the abnormal leukaemic clone expands and 
usually replaces the normal haemopoietic system. This results in a marked 
increase in the number of granulocytes in the circulation. Colonies generated 
in assays of chronic phase CML peripheral blood or bone marrow specimens 
are morphologically indistinguishable from colonies generated by normal 
progenitors because the mature blood cells produced by the neoplastic clone 
are not grossly altered (Eaves, 1992). The total number of clonogenic 
progenitors is increased in CML patients with untreated disease and this has 
been correlated exponentially with the white cell count (Eaves,1992). In 
normal individuals the more primitive types of clonogenic cells in the marrow, 
and all circulating clonogenic progenitors are quiescent populations. In CML 
these populations are in continuous turnover (Eaves and Eaves,1987). At 
present it is not known how this deregulation of control is achieved in vivo.
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Otsuka et al, 1991) showed by Northern blot analysis that there was no 
evidence of increased expression of G-CSF, GM-CSF, ILl-a, IL1-/5, IL-3, IL-6 
or tumour necrosis factor-a (TNF-a) in CML blood samples compared with 
normal donor samples. Furthermore they showed there was no evidence of a 
decreased production of putative inhibitors of haemopoietic progenitor cells,
i.e. TGF/3 and macrophage inflammatory protein-la (MIP-la) by CML cells 
compared to normal cells.
In long term cultures the most primitive progenitor cells are known as 
long term culture initiating cells (LTC-IC). The LTC-IC are so named because 
of their ability to generate clonogenic cell progeny that are detectable after a 
minimum of 5 weeks incubation on competent fibroblast feeder layers. LTC-IC 
are multipotent cells and are the earliest progenitors that can be detected by 
in vitro cultures. In patients with CML both normal and Ph positive LTC-IC 
are present. Ph positive LTC-IC are present in elevated concentrations in 
blood but the number of Ph positive LTC-IC in the marrow of chronic phase 
patients is usually very low. In LTC the Ph positive LTC-IC decrease in 
number in contrast to the normal LTC-IC which are usually well maintained 
(Eaves, 1992). This is the rationale for using these cells for autografting.
Growth of AML in vitro
Haemopoiesis in AML has some features in common with that of 
normal haemopoiesis in that there is a hierarchical organisation of leukaemic 
cells with a small population of stem cells which maintain the leukaemic clone.
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The requirements of these cells for proliferation have been studied both in 
clonogenic assays in semi-solid media and liquid culture.
Clonogenic assays with AML cells have demonstrated that leukaemic 
blast progenitors proliferate in vitro in the presence of colony-stimulating 
factors (CSF) including GM-CSF, G-CSF and IL-3 (Delwel et al 1988; Hoang 
et al, 1986; Vellenga et al; 1987a, Miyauchi et al; 1987 and Delwel et al; 1987). 
GM-CSF and IL-3 have been found to have an equivalent activity in 
stimulating AML blasts which is usually greater than that seen with G-CSF 
(Kelleher et al, 1987). The response of AML blasts to these growth factors 
have shown a marked patient to patient variation which is in keeping with the 
heterogenous nature of the disease (Vellenga et al, 1987b; Kelleher et 
al,1987). This heterogeneity of in vitro growth has not been correlated with the 
morphological FAB sub-type of the disease (Russell, 1992). The effect of a 
single growth factor has frequently been sub-optimal and combinations of 
factors such as G-CSF with GM-CSF have been synergistic in stimulating 
proliferation (Vellenga et al, 1987a; Kelleher et al, 1987). Other growth factors 
implicated in the in vitro growth of AML include IL-1 and IL-6. IL-1 \ 
synergises with GM-CSF and G-CSF in stimulating the proliferation of some 
AML cells (Hoang et al, 1988a). Similarly IL-6 which augments IL-3- 
dependent proliferation of normal bone marrow mononuclear cells (Ikebuchi 
et al, 1987) synergises with GM-CSF in stimulating AML cells from some 
patients in vitro (Hoang et al, 1986).
TNF-a has both stimulatory and inhibitory effects on the growth of
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AML cells in vitro. It synergises with GM-CSF and IL-3 to stimulate 
proliferation (Hoang et al, 1989), but inhibits the stimulating effect of 
G-CSF on AML blasts (Hoang et al, 1989; Salem et al, 1990) by down- 
regulating the G-CSF receptor (Elbaz et al, 1991). The effects of TNF-a on 
AML progenitors parallels its effects on normal bone marrow mononuclear 
cells (Caux et al, 1990).
Autocrine growth of AML cells
In 1986 Young and Griffin reported 2 cases where the autonomous 
growth of AML blasts was associated with the presence of GM-CSF transcripts 
on Northern blot analysis. Since then many reports have confirmed these 
findings and have shown that transcripts for other cytokines including G-CSF, 
M-CSF, IL-1, IL-6, TNF-a as well as GM-CSF are frequently detected on 
AML blasts (Oster et al, 1989; Griffen et al, 1987; Young et al, 1988; 
Kaufman et al, 1988; van der Schoot et al, 1989). Young et al were unable to 
correlate the expression of GM-CSF transcripts with autonomous growth in 
culture (Young et al, 1987; Young et al, 1988). In contrast other workers have 
been able to correlate CSF production with partial or total autonomous 
growth (Reilly et al, 1989; Bradbury et al, 1992). This discrepancy probably 
reflects the differences in culture and assay methods used to detect CSF 
production. In some but not all AML blasts that produce GM-CSF 
autonomous growth can be inhibited with neutralising anti-bodies to GM-CSF 
(Young and Griffin, 1986; Reilly et al, 1989, Murohashi et al, 1989; 
Rodriguez-Cimadevilla et al, 1990) or with antisense oligonucleotides to GM-
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CSF (Rogers et al, 1991).
Classification of the autonomous growth of AML in vitro
Reilly et al, in 1989 have proposed a classification of AML growth 
properties based upon the presence or absence of autonomous growth 
characteristics in methylcellulose. Four major groups of AML blasts were 
identified:
Group 1 blasts - failed to grow in the presence or absence of 5637 
conditioned medium (5637 CM)
Group 2 blasts - were totally dependent on the presence of 5637 CM 
for their growth
Group 3 blasts - exhibited a variable degree of autonomous growth but 
could be further stimulated by growth factors present in 5637 CM 
Group 4 blasts - exhibited totally autonomous growth 
In a series of 25 patients that they studied autonomous growth was observed 
in 70% of cases (Reilly et al, 1989). Autonomous growth of AML is associated 
with lower remission and survival rates (Lowenberg et al, 1993). It should be 
noted that 5637 CM contains a variety of haemopoietic growth factors which 
include haemopoietin-1, G-CSF, 11^6, IL-1, GM-CSF and stem cell factor.
Interleukin-1 in AML
In normal haemopoiesis IL-1 can induce the production of a number 
of cytokines including GM-CSF, G-CSF, M-CSF, IL-6 and IL-1 from multiple
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cell types including bone marrow stromal cells (Bagby, 1989). Some AML 
blasts can proliferate in response to IL-1 alone and GM-CSF is synergistic 
with IL-1 (Hoang et al, 1988a; Delwel et al, 1989). In addition some AML 
blasts express IL-1 transcripts and secrete IL-la and IL-1/3 (Griffen et al, 
1987; Cozzolino et al, 1989; Sakai et al, 1987). There is also evidence to 
suggest that IL-1 is an autocrine growth factor in AML (Bradbury et al, 1992).
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Experiments
Effect of G-CSF, GM-CSF and IL-3 on normal, CML and AML cells 
Objective
The aim of these experiments was to determine which cytokine (G-CSF, 
GM-CSF or IL-3) was most effective at stimulating the growth of colonies 
from normal, CML or AML cells in vitro.
Results:
Preliminary experiments were done to determine the optimum 
concentration of G-CSF, GM-CSF and IL-3 necessary to yield maximum 
colony numbers. Only 4/15 normal peripheral blood and 8/12 normal bone 
marrow mononuclear cells grew in vitro. The number of cells plated varied 
from 104 to 106/plate. As autostimulation of cells can occur, higher number of 
cells were not plated. Dose response curves in these patients were not possible 
because low numbers of mononuclear cells from normal PB and BM were 
obtained. Preliminary experiments done by other workers in the laboratory 
showed that in six normal donor bone marrow mononuclear cells, 15ng G- 
CSF, 50ng GM-CSF and 50ng IL-3 gave maximum colony numbers. Increasing 
the concentrations of the cytokines did not increase colony numbers further 
(B Millar and J B G Bell, personal communication).
When leukaemic mononuclear cells were plated, the CFU-GM numbers 
obtained was variable. Low numbers of CFU-GM were obtained in all dose- 
response curves attempted (12 in total) except in the 3 illustrated in Figure 4. 
These 3 patients are not representative of the patients studied, UPN 25 was
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Ph negative; UPN 26 and 35 were in lymphoid and myeloid blast 
transformation respectively. From this limited data 50ng of GM-CSF gave a 
plateau in response in all 3 patients, 50ng of IL-3 in UPN 25 and 35, and the 
amount of G-CSF to give a plateau in response varied in the 3 patients. 
Because there was some variation in dose response of the leukaemic cells to 
growth factors (see Fig 4) the concentrations of G-CSF, GM-CSF and IL-3 
chosen were based on data from normal donor BM mononuclear cells. The 
following concentration of cytokines and cells were used in the clonogenic assays:-
Peripheral blood mononuclear cells = 5 x l0 5/plate*
Bone marrow mononuclear cells = lOVplate*
Concentration of G-CSF used = 15ng/plate 
Concentration of GM-CSF used = 50ng/plate 
Concentration of IL-3 used = 50ng/plate 
- if the CFU-C obtained were too high in the leukaemic samples 
(>  1000/plate), cells were plated at a lower concentration.
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Legend to Figure 4
The figures shows the dose response curves of the 3 colony-stimulating factors
used and the CFU-CML numbers obtained. The symbols indicating the
different cytokines are shown in figure of UPN 35. The underlying diagnosis
and number of cells plated are as follows:-
UPN 25, Ph negative CML, cells plated = 5 x l0 5/p late
UPN 26, CML in lymphoid blast transformation, cells plated = 4xl05/plate
UPN 35, CML in myeloid blast transformation, cells plated = 104/plate
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The effects of G-CSF, GM-CSF and IL-3 on normal bone marrow CFU-GM
are shown in Table V, below.
UNIQUE
PATIENT
NUMBER
G-CSF
15ng
GM-CSF
50ng
EL-3
50ng
1 5.3 7.3 5.0
2 13.3 3.3 1.7
3 2.3 0.0 0.0
6 6.6 4.3 6.6
7 4.3 2.3 3.6
10 24.7 31.3 18.7
12 19.0 68.3 59.3
13 5.7 4.7 2.0
Ilie cells were platec at lCr/plate. In each instance the mean colony numbers
(of triplicate samples) are shown. The mean number of CFU-GM per plate, 
obtained with G-CSF was 10.2 (range 2.3-24.7); with GM-CSF was 15.2 (range 
0-68.3) and with IL-3, 12.0 (range 0-59.3). Colony numbers obtained in all 
instances were extremely low.
The effects of G-CSF, GM-CSF and 11^3 on normal peripheral blood CFU- 
GM are shown in Table VI, below.
UNIQUE
PATIENT
NUMBER
G-CSF
15ng
GM-CSF
50ng
IL-3
50ng
4 6.0 5.0 14.0
5 4.6 6.3 7.7
8 1.3 1.6 1.6
18 4.0 3.7 7.3
The cells were plated at 5xl07plate. Cyto lone concentrations used are shown
in the table. Mean colony numbers (of triplicate samples) are shown.
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Of 12 normal bone marrow and 15 normal PB samples, only 8 and 4 grew in 
vitro respectively. The number of colonies obtained in all instances were small.
The effect of G-CSF, GM-CSF and IL-3 on peripheral blood CFU-CML are 
shown in Table VII, below. Cells plated were 5xlOs/plate, in each instance the 
mean colony numbers obtained (of 3 plates) are shown. The concentrations 
of cytokines used are given in the table. All samples were obtained from CML 
patients in chronic phase, * =Ph negative CML in chronic phase.
UNIQUE
PATIENT
NUMBER
G-CSF
15ng
GM-CSF
50ng
IL-3
50ng
21 8.3 3.0 2.6
22 52.7 55.3 35.7
23 23.0 6.0 4.7
24 30.0 13.0 9.0
25* 15.3 21.0 19.7
30* 45.0 42.0 32.0
31 202.0 65.0 60.0
37 90.7 67.3 43.0
38 67.0 79.0 63.0
39 0.0 0.0 0.0
54 0.0 0.0 0.0
55 73.0 25.3 19.3
56 0.0 0.0 0.0
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Table V ila below, shows the effect of G-CSF, GM-CSF and IL-3 on CML 
blast transformation MNC. UPN 26$ was in lymphoid BT, the others were in 
myeloid BT.Cells from UPN 26 and 27 were plated at 5xl05/plate, UPN 34 and 
35 were plated at 2 x l0 4/p late and UPN 54b at 2 x l0 5/plate. The concentrations 
of cytokines used were G-CSF 15ng, GM-CSF 50ng, IL-3 50ng and TGFBj 
5ng.
UNIQUE
PATIENT
NUMBER
G-CSF 15ng GM-CSF
50ng
IL-3
50ng
26$ 11.0 4.0 <1.0
27 311.0 119.0 135.0
34 310 15.3 12.0
35 278.0 342.0 55.0
54b 334.3 493.0 837.0
The mean CFU-CML obtained with CML CP samples (n= 13) using G-CSF were 
46.69(range 8.3-202); with GM-CSF 28.99 (range 3.0-79) and with IL-3 22.23 (range 
2.6-135). There was a difference between using G-CSF and IL-3 as stimulators of 
CFU-CML (p=0.05). This difference does not take into account the different 
concentrations of cytokines used.
The four patients in myeloid blast transformation had satisfactory in vitro 
growth with G-CSF, 3/4 also had good in vitro growth with GM-CSF and IL-3. As the 
cells were plated at different concentrations the only conclusion that can be deduced 
from this data is that G-CSF, GM-CSF and IL-3 induced satisfactory CFU-CML 
from CML blast transformation MNC.
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Table VIII, below shows the effect of G-CSF, GM-CSF and IL-3 on 
CFU-AML, the legend to the table is given below.
UNIQUE
PATIENT
NUMBER
FAB
SUB-TYPE
G-CSF
15ng
GM-CSF
50ng
IU3
50ng
44 M l 26.3 0.0 0.0
44b* M l 2.7 0.0 0.0
47 M2 21.0 104.0 115.0
49 M4 25.3 230.0 ND
UPN 44, 47 and 49 were peripheral blood samples. UPN 44 was plated at 
5xl05/plate and UPN 47 & 49 were plated at 5xl04/plate. UPN 44b was 
obtained from bone marrow and was plated at 105/plate. ND - not done
Of a total of 18 AML samples studied only 6 grew CFU-AML in vitro, 4/6 
were plated with G-CSF, GM-CSF and IL-3 and 2/6 grew when stimulated by 
5637 CM. Of the 4 samples, 4/4 grew when stimulated with G-CSF, 2/4 grew 
in vitro with GM-CSF and 1/3 grew in vitro with IL-3. None of the CML or 
AML grew in vitro in the absence of growth factors or 5637 CM.
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Effect of TGFp 1 on normal, CML and AML cells stimulated with either 
G-CSF, GM-CSF or IL-3
TGFjS is a highly stable peptide which has a multiple range of activities. 
It is produced by almost all cells and most normal cells have receptors for 
TGFjS (Spom and Roberts, 1989). The production of TGFjS by haemopoietic 
cells suggests that it may play an important role in regulating haemopoiesis. 
In human haemopoiesis TGFjS inhibits CFU-GM production by IL-3 and GM- 
CSF and megakaryocyte development by IL-3 (Sing et al, 1988a, Han et al, 
1992) but has no effect on G-CSF-induced cell proliferation from normal bone 
marrow cells in vitro (Sing et al, 1988a). TGFjS inhibits the G-CSF-directed 
proliferation of CML cells in vitro (Sing et al, 1988a, Aglietta et al, 1989). The 
inhibitory effects of TGFjS on human haemopoiesis are augmented by TNF-a 
and a-interferon in vitro (Sing et al, 1988b). TGFjS has also been reported as 
having an inhibitory effect on CFU-AML in vitro (Rogers et al, 1992, 
Shirakawa et al, 1992). In contrast TGFjS has no inhibitory effects on 217 AML 
cells (Shirakawa et al, 1992).
Objective
Experiments were carried out to compare the effects of TGFjSj on the 
proliferation of normal, CML and AML cells stimulated with either G-CSF, 
GM-CSF or IL-3.
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Results
The effects of TGFjSj on normal BM and PB MNC stimulated with either 
G-CSF, GM-CSF or IL-3 are shown in Table X and XI below and overleaf.
Table X shows the effect of TGFjS on G-CSF, GM-CSF and IL-3-induced 
proliferation of normal BM MNC. The concentration of G-CSF, GM-CSF and 
IL-3 were 15ng/plate, 50ng/plate and 50ng/plate respectively. The dose of 
TGFjS was 5ng/plate. Cells were plated at 105/plate. Mean, of triplicate CFU- 
GM numbers, are shown.
UPN G-CSF G-CSF
+
TGFjS
GM-CSF GM-CSF
+
TGFjS
IL-3 IL-3
+
TGFjS
1 5.3 0.0 7.3 3.0 5.0 0.0
2 13.3 14.7 3.3 0.0 1.7 0.0
3 2.3 2.3 0.0 0.0 0.0 0.0
6 6.6 6.6 4.3 3.0 6.6 <1.0
7 4.3 2.3 2.3 1.6 3.6 2.0
10 24.7 44.3 31.3 15.0 18.7 4.0
12 19.0 28.7 68.3 ND 59.3 ND
13 5.7 12.0 4.7 <1.0 2.0 <1.0
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Table XI below, shows the effect of TGF/3 on G-CSF, GM-CSF or IL-3- 
induced prohferation of normal peripheral blood MNC. Cells were plated at 
SxlC^/plate. The concentration of cytokines used was G-CSF 15ng, GM-CSF 
50ng, IL-3 50ng and TGF/^ 5ng. Mean colony numbers (of triplicate samples) 
are shown in each instance.
U P N G -C SF G -C S F +
TGF/3
G M -C SF G M -C S F +
TGF/3
IU 3 IL -3+
TGFjS
4 6 5.7 5.0 10.3 14.0 10.0
5 4.6 4.3 6.3 2.0 7.7 2.6
8 1.3 2.0 1.6 < 1 .0 1.6 < 1 .0
h-* 00 4 .0 2.0 3.7 < 1 .0 7.3 2.0
In normal BM and PB samples, TGFjSj had no consistent effect on 
CFU-GM stimulated by GM-CSF or IL-3 or G-CSF. As colony numbers were 
low it is not justifiable to do statistical analysis on this data.
The effect of TGF/^ on CML chronic phase peripheral blood MNC (Figure 
5) and CML blast transformation peripheral blood MNC (Figure 6) are shown 
overleaf. Comparison between samples containing TGF/^ and each of the 
growth factors were normalised to colony numbers obtained with single growth 
factors alone, for each patient [For example in UPN colony numbers obtained 
with G-CSF (n=30) was arbitrarily taken as 1; the colony numbers obtained 
with G-CSF and TGFBj (n=8.0) were normalized to the value obtained with 
G-CSF i.e. 0.26]. Actual colony numbers are given in Table XII and Xlla, also 
shown overleaf. In addition Table XIII shows CFU-CML numbers obtained 
with CML bone marrow MNC in 4 patients (not illustrated).
In the CML chronic phase samples TGF/^ reduced CFU-CML all 12
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samples where G-CSF-induced CFU-CML were obtained (p<  0.005). See 
Tables XII (overleaf). TGFjSi also reduced GM-CSF and IL-3-induced CFU- 
CML (mean colony numbers were reduced from 26.0 to 11.7, and 28.9 to 12.9 
respectively). Thus in the CML chronic phase samples, TGFpl had an 
inhibitory effect when either G-CSF, GM-CSF or IL-3 was used as the 
stimulus. Similarly in patients in myeloid blast transformation, TGF/^ inhibited 
G-CSF-induced CFU-CML in 4/4 samples, and GM-CSF- and 11^3-induced 
CFU-CML in 3/4 samples.
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Figure 5: Effect of TGFI3 on CML CP MNC 
stimulated by G-CSF, GM-CSF and IL-3
change in CFU-CML
10
1
0.1
0.01
IL-3+TGFBG-CSF+TGFB GM-CSF+TGFB
Figure 6: Effect of TGFI3 on CML BT MNC 
stimulated by G-CSF, GM-CSF and IL-3
10
1
0.1
0.01
G-CSF+TGFB GM-CSF+TGFB IL-3+TGFB
change in CFU-CML
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Table XII below, shows the effect of TGF/3 on CML chronic phase peripheral 
blood mononuclear cells, stimulated by G-CSF, GM-CSF and IL-3. The cells 
were plated at 5X 105/plate. * - Ph negative CML; ND-Not done. In each 
instance the mean (of triplicate samples) CFU-CML are given. The 
concentrations of cytokines used per plate were G-CSF 15ng, GM-CSF 50ng, 
IL-3 50ng, TGFft 5ng
UPN G-CSF G-CSF+
TGF/3
GM-CSF GM-CSF+
TGF/2
IU3 IU 3+
TGF/3
21 8.3 3.0 3.0 1.0 2.6 <1.0
22 52.7 22.3 55.3 8.7 35.7 <1.0
23 23.0 7.7 6.0 8.7 4.7 <1.0
24 30.0 8.0 13.0 0.0 9.0 0.0
25* 15.3 13.0 21.0 24.3 19.7 18.7
29 317.5 203.3 ND ND ND ND
30* 45.0 30.0 42.0 7.0 32.0 4.0
31 377.5 127.5 65.0 ND 60.0 ND
36 104.0 23.3 ND ND ND ND
37 90.7 33.7 67.3 47.3 43.0 32.7
38 67.0 21.7 79.0 24.7 63.0 46.7
39 0.0 0.0 0.0 0.0 0.0 0.0
54 0.0 0.0 0.0 0.0 0.0 0.0
55 73.0 24.0 25.3 18.7 19.3 13.3
56 0.0 0.0 0.0 0.0 0.0 0.0
126
Table X lla below, shows the mean colony numbers obtained when CML blast 
transformation mononuclear cells were stimulated with G-CSF, GM-CSF and 
IL-3 alone and combination with TGF6. UPN 26$ was obtained from a patient 
in lymphoid blast transformation, the others were obtained from patients in 
myeloid blast transformation. UPN 26 and 27 were plated at SxlC^/plate, UPN  
34 and 35 at 2 x l0 4/p late and UPN54b at 2xl05/plate. The concentrations of 
cytokines used were:- G-CSF 15ng, GM-CSF 50ng, IL-3 50ng and TGFB 5ng. 
ND - not done. In each instance the mean of triplicate samples is shown.
UPN G-CSF G-CSF+
TGF/3
GM-CSF GM-CSF+
TGFB
IL-3 IL-3+
TGFJ3
26$ 11.0 0.0 4.0 0.0 <1.0 0.0
27 311.0 31.0 119.0 30.0 135 30.0
34 310.0 17.5 15.3 0.0 12.0 0.0
35 278.0 53.4 342.0 ND 55.0 ND
54b 334.3 89.7 493.0 445.7 837 489.0
Table XIII below, shows the effect of TGF/3 on BM CFU-CML stimulated by 
G-CSF, GM-CSF or IL-3. Cells plated at 105/plate. ND - Not done 
Concentration of cytokines used as above, in each instance the mean of 
triplicate samples is shown
UPN G-CSF G-CSF+
TGF/3
GM-CSF GM-CSF+
TGFjS
IL-3 IL-3+
TGF/3
28 10.3 1.3 1.3 0.7 0.0 0.0
31 65.7 55.5 26.0 34.0 ND ND
32 32.8 41.3 ND ND ND ND
33 37.7 20.7 26.0 24.0 ND N
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Table XTV below, shows the effect of TGF/3 ON CFU-AML stimulated by G- 
CSF, GM-CSF or IU3. Cells were plated at 5xl05/plate except for UPN 47 & 
49 which were plated at 5 X 1 0 4/ p l a t e .  Concentration of cytokines used were G- 
CSF 15ng, GM-CSF 50ng, IL-3 50ng, TGFB 5ng. ND - not done
UPN FAB
TYPE
G-CSF G-CSF
+
TGF/3
GM-CSF GM-CSF
+
TGF/3
IL-3 IU3
+
TGF/3
44 M l 26.3 14.7 0.0 0.0 0.0 0.0
46 M4 350.0 392.5 ND ND ND ND
47 M2 21.0 26.7 104.0 30.7 115.0 0.0
48 2iy 335.0 433.3 ND ND ND ND
49 M4 25.3 10.0 230.0 ND ND ND
There was no consistent anti-proliferative effect of TGFf31 on the proliferation
of G-CSF-induced proliferation of AML samples (see Table XIV).
A summary of the effects of TGF/3j on G-CSF, GM-CSF and IU 3 induced 
proliferation of normal and CML cells are shown in Table XV, below. Mean 
colony numbers, taking into account all similar samples i.e all CML chronic 
phase samples, all normal bone marrow and all peripheral blood samples, are 
shown. AML samples are not shown as sample numbers were small.
COLONIES G-CSF G-CSF+
TGF/3
GM-CSF GM-
CSF+
TGF/3
IL-3 IL-3+
TGF/3
CFU-GMBM 10.2 13.9 15.2 3.3 12.1 <1.0
CFU-GMpB 4.0 3.5 4.2 3.2 7.7 3.7
CFU-CMLcppb 80.3 34.5 26.0 11.7 17.6 9.0
Normal bone marrow samples n=8, normal PB samples n=4, CML CP 
samples with G-CSF n=15, GM-CSF n=13, IL-3 n=13
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To summarise TGFBi reduced G-CSF, GM-CSF and IL-3-induced 
proliferation of CML cells (both chronic phase and blast transformation). 
TGFBi did not have a consistent anti-proliferative effect on normal or AML 
cells
Effect of IL-4 on G-CSF-induced proliferation in normal, CML and AML 
mononuclear cells
ID-4 is a small soluble glycoprotein that has diverse effects on 
B-lymphocytes and on other lymphoid and non-lymphoid cell types. IU 4 has 
an anti-proliferative effect on progenitor cells stimulated by GM-CSF or ILr3 
in vitro (Peschel et al, 1987, Paul et al, 1991). In contrast IL-4 augments G- 
CSF-induced cell proliferation in vitro (Broxmeyer et al, 1988).
Objective
These experiments were done to determine if IL-4 augments G-CSF- 
induced proliferation in normal, CML and AML MNC.
Results
Preliminary experiments were carried out to determine the 
concentration of IL-4 which produced maximum colony numbers in 
combination with 15ng of G-CSF. Bone marrow mononuclear cells were plated 
at 105/plate and peripheral blood MNC were plated at 5xlOs/plate, except UPN  
34 and 35 which were plated at 2xl04/plate. Dose response curves were done 
on 13 normal samples, (UPN 10 is illustrated in Fig 7), 10 CML PB samples 
(UPN 32 and 34, chronic phase and blast transformation respectively are
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illustrated in Fig 8a and 8b respectively), and 3 AML samples (UPN 48 is 
illustrated in Fig 9). From the dose response curves and in the dose ranges 
used, 5ng of IL-4 gave a maximum response in UPN 10; lng of IL-4 gave a 
maximum response upn 32; IL-4 had an inhibitory effect on G-CSF-induced 
CFU-CML, in UPN 34, 15ng of IL-4 gave maximal response in UPN 48. An 
intermediate dose of 5ng was therefore chosen for subsequent experiments.
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Figure 7
G-CSF
G-CSF + 1ng IL-4
G-CSF + 5ng IL-4
G-CSF + 10ng IL-4
G-CSF + 15ng IL-4
G-CSF 15ng
0 20 40 5 60 80 100
CFU-GM/10 BM MNC
Figure 7
The figure illustrates the effect of concentrations of IL-4 (lng, 5ng, lOng and 
15ng) on G-CSF-induced CFU-GM in a normal donor BM MNC (UPN 10).
The addition of IL-4 augmented G-CSF-induced CFU-GM and a plateau in 
response was reached with 15ng of IL-4.
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Figure 8a
G-CSF 
G-CSF + 1nglL-4 
G-CSF + 5nglL-4 
G-CSF + 10nglL-4
G-CSF + 15nglL-4
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CFU-CML/5X10 PB MNC
G-CSF 15ng 
Figure 8a
The figure illustrate the effect of concentrations of IL-4 (lng, 5ng, lOng and 
15ng) on G-CSF-induced CFU-CML in a patient with CML CP (UPN 32).
Similar to its effects on normal MNC, IL-4 augmented G-CSF-induced 
CFU-CML and a plateau in response was seen with lng IL-4.
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Figure 8b
G-CSF 
G-CSF + 1nglL-4 
G-CSF + 5nglL-4 
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G-CSF + 15nglL-4
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Figure 8b shows the effect of concentrations of IL-4 (lng, 5ng, lOng and 15ng) 
on G-CSF-induced stimulation of CML blast transformation MNC (UPN 34). 
The cells were plated at 2xl04/plate; concentration of G-CSF used was 15ng. 
In contrast to its effects on normal and CML CP MNC, IL-4 inhibited G-CSF- 
induced colony formation and a maximum inhibitory effect was seen with 15ng 
of IL-4.
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Figure 9
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Figure 9 shows the effect of concentrations of IL-4 (lng, 5ng, lOng and 15ng) 
on G-CSF-induced stimulation of CFU-AML (UPN 48).
The in vitro response to G-CSF and IL-4 to MNC from patients with AML 
was similar to that of MNC from normal donors and patients with CML in 
chronic phase. IL-4 augmented G-CSF-induced CFU-AML and a maximum 
response was seen with 15ng of IL-4.
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The effect of IL-4 on, all CML and all AML (Fig 10) cells stimulated with G- 
CSF are shown overleaf, in each instance the mean number of colonies for 
each group were used. Comparisons between samples containing G-CSF and 
IL-4 were normalised to colony numbers obtained with G-CSF alone. Actual 
colony numbers obtained and MNC plated are also shown below and overleaf 
in Tables XVI (normal bone marrow), XVII (normal peripheral blood), XVIII 
and XVIIIa (CML chronic phase and blast transformation peripheral blood 
MNC respectively) XIX (CML bone marrow MNC) and XX (AML 
mononuclear cells).
Table XVI below, shows the effect of IL-4 on G-CSF-induced proliferation on 
normal bone marrow MNC. Cells were plated at 105/plate. Concentrations of 
cytokines used are given in the table. Mean CFU-GM of triplicate samples are 
shown.
UPN 15ng G-CSF 15ng G-CSF+5ng IL-4
1 5.3 13.0
2 13.3 39.3
3 2.3 9.6
6 6.6 6.6
7 4.3 3.0
9 4.3 12.3
10 24.7 70.0
11 11.3 56.7
12 19.0 32.7
13 5.7 11.7
20 30.0 65.0
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Fig 10: Effect of G-CSF and IL-4 on 
CFU-CML and CFU-AML
ch an g e  in co lony  no
100
10
1
1 CML CP PB CML CP BM CML BT PB AML PB
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Table XVII below, shows the effect of G-CSF and IL-4 on normal PB MNC. 
Cells were plated at 5xl05/plate. Concentrations of cytokines used are given 
in the table. In each instance mean colony numbers of triplicate samples are 
shown.
UPN 15ng G-CSF 15ng G-CSF+5ng IL-4
4 6.0 10.0
5 4.6 5.0
8 1.3 1.6
14 7.6 25.0
15 17.0 20.6
16 <1.0 1.7
18 4.0 8.7
Table XVIII below, shows the effect of G-CSF and IL-4 on CML chronic 
phase peripheral blood MNC. Cells were plated at 5 X 1 0 5/ p l a t e .  Concentrations 
of cytokines used are given in the table. * Ph negative. Mean colony numbers 
(of triplicate samples) are shown.
UPN G-CSF 15ng 15ng G-CSF+ 5ng IL-4
21 8.3 13.6
22 52.7 71.7
23 23.0 55.0
24 30.0 41.7
25* 15.3 16.7
29 317.5 332.5
30* 45.0 70.0
31 377.5 450.0
36 104.0 312.5
37 90.7 84.0
38 67.0 75.0
51 517.0 91.7
55 73.0 81.3
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Table XVIIIa below, shows the effect of G-CSF and IL-4 on CML blast 
transformation peripheral blood mononuclear cells. UPN 26 was in lymphoid 
blast transformation, the remainder were in myeloid blast transformation. 
UPN 26 and 27 were plated at 5 x l0 5/plate, UPN 34 and 35 at 2 x l0 4/p late and 
UPN 54b at 2xl05/plate. The concentrations of cytokines used are given in the 
table. Mean colony numbers (of triplicate samples) are shown.
UPN 15ng G-CSF 15ng G-CSF+ 5ng IU4
26$ 11.0 7.1
27 311.0 680.0
34 310.0 210.0
35 278 130.6
54b 334.3 317.0
Table XIX below, shows the effect of G-CSF and IL-4 on CML bone marrow 
MNC. Cells were plated at 105/plate. Concentrations of cytokines used are 
given in the table. Mean colony numbers (of triplicate samples) are shown.
UPN 15ng G-CSF 15ng G-CSF+5ng IL-4
28 10.3 19.6
31b 65.7 180.0
32 32.8 49.1
33 37.7 39.3
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Table XX below, shows the effect of G-CSF and IL-4 on AML MNC. The cell 
type (i.e peripheral blood - PB- or bone marrow-BM-) cell number plated and 
concentrations of cytokines are given in the table.
UPN CELL TYPE CELL NO FAB TYPE G-CSF
15ng
G-CSF+IL-4 
15ng +5ng
44 PB
inOX
AML Ml 26.3 52.6
46 PB 5X105 AM LM4 4.5 15.0
46b BM 105 AM LM4 350.0 776.7
47 PB 5X104 AML M2 25.3 38.3
48 PB 2X105 2^ AML 325.0 1153.0
49 PB 5X104 AMLM4 21.7 329.3
11^4 in combination with G-CSF had no appreciable effect on CFU-GM 
formation from normal bone marrow or peripheral blood MNC. The mean 
CFU-GM using PB MNC obtained with G-CSF was 5.9 (range <1.0-17) and 
this increased to 9.74 (range 1.7-25) on the addition of 11^4. In normal BM 
MNC, the mean CFU-GM obtained with G-CSF was 11.5(range 4.3-30) and 
this number increased to 26.3(range 3-70) when IL-4 was added to the 
cultures. Although IL-4 increased G-CSF-induced CFU-GM in normal 
peripheral blood and bone marrow samples, as the total colony numbers 
obtained was low, statistical analysis was not done.
11^4 augmented G-CSF-induced colony formation in 11/13 CML CP 
peripheral blood MNC (p < 0.005). The mean CFU-CML obtained when 
cultures were stimulated with G-CSF and G-CSF in combination with IL-4 
were 132.5 (range 8.3-377.5) and 158 (range 13.6-450) respectively (see Table
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XVIII). IU 4 augmented G-CSF-induced CFU-CML in 3/4 CML chronic phase 
BM MNC samples, the mean CFU-CML were increased from 36.6 (range 
10.3-65.7) to 72 (range 19.6-180; see Table XIX). EU4 also augmented G-CSF- 
induced CFU-AML in 5/5 AML samples.
In contrast to its effects on normal, CML chronic phase and AML cells 
IL-4 reduced G-CSF-induced colony formation in 2/4 samples from patients 
with CML myeloid blast transformation. IL-4 had no effect on G-CSF-induced 
stimulation of CFU-CML in the only patient with CML in lymphoid blast 
transformation.
In summary, IL-4 augmented G-CSF-induced colony formation in CML 
chronic phase and AML mononuclear cells. The effects of IL-4 on G-CSF- 
induced proliferation of normal and CML blast transformation cells was not 
consistent.
Effect of TGFjSi on combined stimulation with G-CSF and IL-4 on normal,
CML and AML MNC
Objective
The aim of these experiments was to determine whether TGFjSj could 
inhibit potentiation of G-CSF and IL-4-induced colony formation in cultures 
of normal, CML and AML cells.
Results
Figures 12, 13a, 13b and 14 show the effect of TGFft on G-CSF- and G-CSF 
and IU4-induced proliferation in normal (UPN 10), CML chronic phase 
(UPN32) CML blast transformation (UPN34) and AML MNC (UPN48).
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Figure 11
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Figure 11
The effects of G-CSF, IL-4 and TGF/^ on CFU-GM in a normal BM sample 
(UPN 10) are shown.
TGFjSj and IL-4 when used separately augmented G-CSF-induced colony 
formation. TGFjSj in combination with G-CSF and IL-4 (lng, 5ng and lOng) 
had no effect on CFU-GM, compared to CFU-GM numbers obtained in 
cultures stimulated by G-CSF and IL-4 (lng, 5ng and lOng). However 15ng of 
IL-4 together with G-CSF and TGFp1 augmented CFU-GM-formation 
compared to G-CSF and IL-4 (100.7 and 60.3 CFU-GM respectively).
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Figure 12a
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Figure 12a
The figure illustrates the effect of G-CSF, IL-4 and TGF/^ on CML chronic 
phase peripheral blood mononuclear cells.
TGFjSj inhibited CFU-CML formation in cultures stimulated with G-CSF 
(mean colony numbers were reduced from 164 to 38.2). IL-4 augmented G- 
CSF-induced colony formation and a maximum response was seen with lng 
of IL-4. The addition of TGF/^ to cultures containing G-CSF and IL-4 
inhibited CFU-CML formation.
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Figure 12b
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Figure 12b
The figure illustrates the effect of G-CSF, IL-4 and TGFpt on CML blast 
transformation MNC (UPN 34).
IL-4 reduced G-CSF-induced CFU-CML and this inhibitory effect was further 
enhanced by the addition of TGF/3 ^
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Figure 13
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Figure 13
The figure illustrates the effect of G-CSF, IL-4 and TGFfi1 on AML 
peripheral blood MNC.
IL-4 augmented G-CSF-induced CFU-AML and a maximum response was 
seen with 15ng of IL-4. TGF/3j augmented G-CSF-induced colony formation 
but inhibited CFU-AML stimulated by G-CSF and IL-4 in combination.
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Table XXI below, shows the effect of G-CSF, IL-4 and TGF/31 on normal PB 
MNC. Cells were plated at 5X 105/plate. Concentration of cytokines used was 
G-CSF 15ng; IL-4 5ng; TGF/3j 5ng. In each instance the mean of triplicate 
samples is shown
UPN G-CSF G-CSF+IL-4 G-CSF+ TGF/3 G-CSF+ IL-4+ TGF/3
4 6.0 10.0 5.7 16.0
5 4.6 3.6 4.3 2.3
8 1.3 1.6 2.6 1.6
14 7.6 22.0 6.6 42.6
15 17.0 20.6 8.6 14.3
16 <1.0 1.7 1.3 2.0
18 4.0 8.7 2.0 3.0
Table XXII below, shows the effect of G-CSF, IL-4 and TGF/3} on normal BM 
MNC. Cells were plated at K^/plate. Concentration of cytokines used, as 
above. Mean (of triplicate samples are shown).
UPN G-CSF G-CSF+IL-4 G-CSF+TGF/3 G-CSF+ I U 4 + TGF/3
1 5.3 13.0 0.0 11.7
2 13.3 39.3 14.7 40.0
3 2.3 9.67 2.3 4.0
6 6.6 6.6 6.6 10.3
7 4.3 3.0 2.3 3.0
9 4.3 12.3 4.0 5.3
10 24.7 70.0 44.3 94.3
12 19.0 32.7 28.7 56.7
13 5.7 11.7 12.0 20.3
20 30.0 65.0 30.0 83.0
TGFjSj had no effect on normal peripheral blood MNC stimulated by 
a combination of G-CSF and IL-4. In the peripheral blood samples the mean
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number of CFU-GM obtained with G-CSF was 5.8 (range 4-17; see Table 
XXI) and this increased to 11.7 (range 3-42.6; see Table XXI) when TGFjSj 
was added to cultures. In 2/7 normal PB samples (UPN 4 and 14) TGFjSj 
increased the G-CSF and IU4-induced proliferation and in 5/7 samples CFU- 
GM were reduced or unaltered.
The mean number of normal BM CFU-GM obtained from cultures 
stimulated with G-CSF was 11.6 (range 2.3-30; see Table XXII) and this 
increased to 32.9 (range 3-83) when cultures were stimulated with G-CSF, IL-4 
and TGFjSj. In 4/10 normal BM mononuclear cells stimulated with G-CSF plus 
IL-4, the addition of TGFBj increased colony numbers further.
A  summary of the effects of G-CSF, IL-4 and TGFfi1 on all CML 
chronic phase peripheral blood and bone marrow, CML blast transformation 
and AML MNC are shown in Figures 14a, 14b (overleaf) 15 and 16 (page 151 
and 152 respectively). The mean number of colonies obtained with the other 
samples was normalised to that obtained with G-CSF. Actual colony numbers 
obtained with the different cytokines are given in Table XXIII, XXIIIa, XXIV, 
XXIVa and XXV also overleaf.
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Figure 14a: Effect of G-CSF, IL-4 
and TGFI3 on CML CP PB.
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Figure 14b: Effect of G-CSF, IL-4 
and TGFI3 on CML CP BM.
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Table XXIII below shows the effect of G-CSF, IL-4 and TGFft on CML 
chronic phase peripheral blood MNC. Cells were plated at SXlOVplate. 
Concentrations of cytokines used were G-CSF 15ng, IL-4 5ng, TGFjSj 5ng. * 
Ph negative. In each instance the mean (of triplicate samples) is shown.
UPN G-CSF G-CSF+IL-4 G-CSF+TGF/3 G-CSF+ IL-4+ TGF/3
21 8.3 13.6 3.0 8.0
22 52.7 71.7 22.3 93.7
23 23.0 55.0 8.0 16.0
24 30.0 41.7 8.0 26.7
25 15.3 16.7 13.0 14.0
29 317.5 332.5 203.3 133.3
30 45.0 70.0 30.0 25.0
31 377.5 450.0 127.5 282.5
36 104.0 169.0 23.3 76.7
37 90.7 84.0 33.7 50.0
38 67.0 75.0 21.7 35.0
51 518.0 593.0 91.7 72.7
55 73.0 81.3 24.0 43.7
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Table XXIIIa below, shows the effect of G-CSF, IL-4 and TGFB on CML blast 
transformation cells. UPN 26 was in lymphoid BT, the others were in myeloid 
BT. UPN 26 and 27 were plated at 5X105/ plate, UPN 34 and 35 at 2xl04/plate 
and UPN 54b at 2xl05/plate. Concentration of cytokines as previously used. In 
each instance mean (of triplicate samples) is shown.
UPN G-CSF G-CSF+IL-4 G-CSF+TGFB G-CSF+IL-
4+TGFB
26$ 11 7.1 0.0 2.8
27 311 680 31 81.7
34 310 210 17.5 3.5
35 278 130.6 342 44.0
54b 334.3 317 89.7 182.3
Table XXTV below, shows the effect of G-CSF, IL-4 and TGFjSj on CML BM 
MNC. All patients were in chronic phase. Cells plated were lO^plate, the 
concentrations of cytokines as previously used.
UPN G-CSF G-CSF+IL-4 G-CSF+TGF/3 G-CSF+IL-4+ TGF/3
28 10.3 19.6 1.3 7.3
31 65.7 180.0 55.5 113.0
32 32.8 49.1 41.3 41.3
33 37.7 39.3 20.7 18.6
TGFjSj reduced CFU-CML (chronic phase) in cultures exposed to G- 
CSF and IL-4 (p < 0.05). The mean CFU-CML was reduced from 158.6 (range 
13.6-593) to 67.4 (range 8-282.5; see Table XXIII). Furthermore in 8/13 CML 
chronic phase samples the number of CFU-CML in cultures containing G- 
CSF, IL-4 and TGF/^ was lower than in cultures exposed to G-CSF alone 
(/?<0.05). The results suggest that in CML chronic phase mononuclear cells
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TGFBi inhibits G-CSF and G-CSF plus IL-4-induced colony formation. The 
addition of IU 4 to these cultures partially reverses this effect.
Mean CFU-CML obtained with CML chronic phase PB and BM samples are 
shown in Table XXIVa below.
G-CSF G-CSF+
IL-4
G-CSF
+TGF&
G-CSF+
IL-4+
TGFft
CFU-CMLcppb 
(n= 13)
132.5
(8.3-518)
158.6
(13.6-593)
46.9
(3-203.3)
67.4
(2-282.5)
CFU-CMLcpbm
(n=4)
36.6
(10.3-65.7)
72.0
(19.6-180)
29.7
(1.3-55.5)
45.0
(7.3-113)
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Figure 15: Effect of G-CSF, IL-4  
and TGF6 on CML myeloid BT MNC.
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Figure 15
The effects of G-CSF, IL-4 and TGFjSj on CML myeloid blast transformation 
MNC are shown in Figure 15. The mean colony numbers in cultures exposed 
to mixtures of cytokines was normalised to the value for colony numbers in 
cultures exposed to G-CSF alone. In 3/4 patients in myeloid blast 
transformation, TGFjSj reduced G-CSF-induced CFU-CML. The actual colony 
numbers obtained with the different cytokines are given in Table XXIII.
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Figure 16: Effect of G-CSF, IL-4  
and TGFB on AML PB MNC.
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Figure 16
The effects of G-CSF, IL-4 and TGF/31 on AML PB MNC are shown above. 
The mean colony numbers in cultures exposed to mixtures of cytokines was 
normalised to the value for colony numbers obtained in cultures exposed to 
G-CSF alone. The effects of TGFBj on G-CSF and G-CSF plus IU4-induced 
proliferation was variable. In 2/6 samples there was an increase (UPN 46b and 
47), in 3/6 there was a decrease (UPN 44, 48 and 49), and in the remaining 
sample (UPN 46) there was no change. The actual CFU-AML numbers are 
given in the Table XXV, overleaf.
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Table XXV below shows the effect of G-CSF, IL-4 and TGFp1 on AML MNC.
UPN G-CSF G-CSF+IL-4 G-CSF+TGF/3 G-CSF+ IL-4+ TGF/3
44 26.3 52.6 14.6 19.0
46 4.5 15.0 11.5 13.0
46b 350.0 776.7 392.5 1119
47 25.3 38.3 26.7 97.6
48 335.0 1155 433.0 475.0
49 21.7 329.3 ND 241.5
Cells were plated at 5X105/plate except for UPN 47 and 49 which were plated 
at 5X 104/p late and UPN 46b which was plated at 105/plate. The samples were 
from peripheral blood except UPN 46b which was from bone marrow. 
Concentrations of cytokines used were G-CSF 15ng, IL-4 5ng, TGFB 5ng.
To summarise, TGFB! reduced CFU-CML formation by G-CSF and G- 
CSF plus IL-4 when CML chronic phase cells were used. There was a partial 
reversal of this inhibitory effect of TGFBX when IL-4 was added to cultures 
stimulated by G-CSF. The effects of TGFBX on G-CSF plus IL-4-induced 
proliferation of normal, AML and CML blast transformation MNC was more 
heterogeneous. However as sample and/or colony numbers were small this 
data may not be representative.
Morphological analysis
The morphology of colonies was assessed as described in Chapter 2. A  
typical CFU-CML from UPN 31 is shown in Platel. Colonies from patients 
with CML in chronic phase showed myeloid progenitors in a distribution
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similar to that seen in the original cytospin samples (see Plate 2), whereas 
colonies from patients in blast transformation revealed predominantly 
immature blasts.
Cytogenetic analysis
Satisfactory cytogenetic analyses were obtained from colonies from 5/8 
CML samples (UPN 27, 29, 34, 36 and 47). In all 5 patients the chromosomal 
abnormality detected at diagnosis was described and they are detailed below: 
UPN 27 - 46,XX,t(9;22),inv(16)(pl3ql2orl3),iso(17q)
UPN 29 - 46,XY,t(9;22) with random loss
UPN 34 - 46,XY,t(3;21),t(9;22) and one cell with iso(17q)
UPN 36 - 46,XX,22q-
UPN 4 7 - 9  cells of normal female karyotype, 1 cell 45, XX,-5,?t(2;18)(p2;q2).
Plate 3 illustrates the chromosomal analysis performed on day 14 CFU-CML 
from UPN 27. The chromosomal karyotype is: 46, XY, t(9;22)(q34;qll), 
inv(16)(p!3ql2), i(17)(q!0)
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Discussion
The number of CFU-GM obtained with normal donor peripheral blood 
or bone marrow MNC was consistently lower than the number of CFU-CML 
or CFU-AML obtained when G-CSF, GM-CSF or IL-3 were used as the 
proliferative stimulus. In both CML and AML there are more committed 
progenitors at an arrested state of differentiation when compared with normal 
donor MNC and it is likely that these progenitors are more susceptible to the 
proliferative stimulus provided by G-CSF, GM-CSF or IL-3. Some AML blasts 
express high affinity receptors for the colony-stimulating factors and are 
therefore more likely to proliferate in vitro (Budel, et al, 1990). Similarly 
unlike in normal haemopoiesis autocrine haemopoietic growth may play an 
important role in myeloid leukaemogenesis (Lowenberg and Touw, 1992),
In the normal donor samples a greater number of colonies was obtained 
with the bone marrow MNC compared to the peripheral blood MNC (see 
Table V  and VI). This was independent of whether G-CSF, GM-CSF or IL-3 
was used to stimulate the cultures, reflecting the fact that in the normal state 
there are more progenitors in marrow than peripheral blood.
The low CFU-GM that were consistently obtained, from normal donors 
was disappointing. This may be due to technical reasons, or to the fact that as 
laboratory samples were frequently obtained at the end of the bone marrow 
harvest there may have been heavy contamination with peripheral blood. The 
number of CFU-GM obtained with normal samples were not increased by 
increasing the number of cells plated or by increasing the concentration of 
cytokines.
G-CSF unlike both GM-CSF and IL-3 acts on more mature myeloid 
progenitors (Demetri et al, 1991) and the number of G-CSFR increases with 
myeloid maturation. In CML there is an excess of myeloid activity resulting 
in an expanded myeloid compartment, with a left-shift in myeloid maturation. 
The data suggests that in CML there is an increase in committed progenitors 
that are more likely to respond to G-CSF than GM-CSF or IL-3. The mean 
number of CFU-CML obtained with G-CSF was more than that obtained with 
GM-CSF or IL-3. Alternatively the autocrine production of G-CSF in CML 
may be greater than either GM-CSF or IL-3. As may be expected the patient 
in lymphoid blast transformation (UPN 26) gave poor colony numbers with 
colony-stimulating factors which have an effect on mainly myeloid progenitors.
The increase in clonogenicity in response to G-CSF is also seen myeloid 
blast transformation. The data suggests that there is some expansion of 
selective progenitor cells that are more likely to respond to G-CSF. Table IX, 
overleaf summarises the mean and median number (taking into account all 
samples studied) of colonies/plate obtained with G-CSF, GM-CSF and IL-3 
using normal and CML samples.
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Table IX
COLONY
TYPE
G-CSF 15ng GM-CSF 50ng IL-3 50ng
MEAN MEDIAN MEAN MEDIAN MEAN MEDIAN
CFU-GMpB
(n=4)
4.0 4.3 4.2 4.35 7.7 7.5
CFU-GMbm
(n=8)
10.2 6.2 15.2 4.50 12.0 4.3
CFU-CMLcppb 46.7
n=15
30.0 29.0
n=13
21.00
II 
to 19.3
CFU - CMLbtpb 
(n=4)
308.3 310.5 242.3 230.50 259.8 95.0
PB - peripheral blood CP - chronic phase
BM - bone marrow BT - myeloid blast transformation
PB - MNC were plated at 5xlOs/plate, except for CML BT MNC which were
plated at 2xl04/plate
BM - MNC were plated at lO^plate.
The colony data from AML samples are not included in the summary table as 
the total number of samples were small.
In AML lack of differentiation occurs early on in myeloid maturation 
resulting in an excess number of leukaemic blasts with very few mature 
myeloid progenitors present in the peripheral circulation. Of the AML samples 
that grew in vitro, G-CSF stimulated colony formation in all samples and GM- 
CSF and 11^3 in 2/4 and 1/3 samples respectively. This is different to the 
findings of Kelleher et al (Kelleher et al, 1987) who reported that GM-CSF 
and IL-3 had an equivalent activity in stimulating AML which was greater than 
G-CSF, this suggests that the proportion of cells capable of responding to G- 
CSF is less than that which can respond to GM-CSF or IL-3. The limited data 
obtained in this study suggests that the distribution of progenitor types at 
different stages of differentiation is different in CML compared to AML.
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None of the AML or CML mononuclear cells grew autonomously in vitro, 
which is in contrast to the study by Reilly (Reilly et al, 1989) where all 70 
AML samples tested grew autonomously. The different culture techniques 
used by Reilly et al is unlikely to account for this difference. In their study 
MNC were plated at 105/ml on Iscoves modified Dulbecco’s medium 
containing 10% FCS and 0.8% methylcellulose. All AML samples in this study 
were obtained from cryopreserved samples. Cryopreservation of normal MNC 
is associated with reduced viability (Gorin, 1986) and a similar phenomenon 
may have occurred with the AML samples. Furthermore in this study the 
number of AML samples studied (18) was much smaller than the number 
studied by Reilly et al (70).
TGF^Sj increased G-CSF directed CFU-AML in 2 samples (UPN 46, de 
novo AML; and UPN 48 2ry AML) whereas in the three remaining samples 
there was no discernible effect (see Table XIV). TGFB: reduced GM-CSF and 
IL-3-induced proliferation but had no effect on G-CSF-induced proliferation 
in UPN 47, the only sample where sufficient number of MNC were obtained 
to test all three cytokines. The sample numbers are too low for the results to 
be representative.
In this small study AML cells had a variable response to TGFBi. Other 
workers have shown that the response of AML cells to TGFjSj is 
heterogeneous (Taetle et al, 1993) with both inhibitory and stimulatory effects 
documented. Morphology and agarose gel analysis of DNA showed that some 
AML cells underwent apoptosis when grown with GM-CSF and TGF/^ but 
not with M-CSF and TGF/^. Some of the effects of TGF/^ on AML may
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therefore occur through programmed cell death.
TGFjSi failed to inhibit G-CSF-induced proliferation in MNC from one 
case of 2ry AML. This may have been due to a reduction in the numbers of 
high affinity binding sites for the cytokine (Masuya et al, 1993), compared with 
the numbers seen in de novo AML.
TGFjSj decreases IL-6 production by stromal cells (Lagneaux et al,
1993). Since IL-6 is a co-factor for myelopoiesis (Montes Borinaga et al, 1990) 
the inhibitory effects of TGFB: may be mediated by reducing IL-6 production.
Serum from patients with thrombotic thrombocytopenic purpura inhibits 
the proliferation of immature haemopoietic progenitors. When an antibody to 
TGFjSj was added this inhibitory effect was partially reversed (Zauli et al,
1993). It is possible that the sera of leukaemic patients may also contain 
inhibitory factors that suppress normal haemopoiesis.
In normal MNC TGF/^ had no effect on CFU-GM stimulated by GM- 
CSF, IL-3 or G-CSF. In contrast TGF/^ significantly reduced G-CSF-induced 
colony formation by CML CP cell (p<  0.005) and CML myeloid blast 
transformation cells. These results support the findings of other workers (Sing 
et al, 1988a; Aglietta et al, 1989). TGFp1 is thought to act on early myeloid 
progenitors (Sing et al, 1988a; Aglietta et al, 1989). Holyoake et al, 1993 using 
a clonogeneic assay which detects the human counterpart of the murine 
colony-forming unit, the CFU-A assay showed that the early progenitors from 
CML samples were inhibited by TGF/^ but showed no response with MIP-lo;. 
In normal controls MIP-la and TGFjSj inhibited the proliferation of CFU-A 
colonies.
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In CML CP and AML samples G-CSF-induced CFU-C were augmented 
by the addition of IL-4. Other workers have shown that in normal MNC, IL-4 
increased G-CSF-induced CFU-GM (Broxmeyer et al, 1988; Sonoda et al, 
1990). Vellenga et al, 1990 showed that IL-4 augmented G-CSF-induced 
colony formation in normal and in 3/6 AML samples. By contrast IL-4 
inhibited IL-3-induced colony formation in both normal and AML samples. 
Similar results were obtained with and without T-cell, B-cell and adherent cell 
depletion, suggesting that the effects of IU4 were not mediated by accessory 
cells. By contrast IL-4 is thought to inhibit endogenous production of GM-CSF 
by blood mononuclear accessory cells (Sato et al, 1994). The possibility exists 
that IL-4 has different effects in association with different sources of accessory 
cells. The effect of IU 4 on G-CSF is on the early stages of proliferation 
(Sonoda et al, 1988). IL-4 inhibited G-CSF-induced proliferation of 2/4 CML 
myeloid cells. In mice with severe combined immunodeficiency (SCID) where 
in vivo growth of CML lymphoid blast transformation was established sub­
cutaneous administration of IL-4 caused regression of the leukaemia (De 
Lord, personal communication). IL-4 also inhibits the growth of T-acute 
lymphoblastic leukaemia (Lowenberg and Touw, 1992). In the only patient in 
lymphoid blast transformation (UPN26) IL-4 had no effect on G-CSF-induced 
colony formation. It is possible that cells in blast transformation are saturated 
with endogenous IL-4 and the addition of further exogenous IL-4 does not 
augment cell proliferation. This is supported by the observation that certain 
leukaemic cell lines proliferate in vitro in the absence of growth factors 
(G.Christie, personal communication).
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In CML chronic phase samples (see Table XXIII), TGF/^ reduced 
CFU-CML stimulated by G-CSF or by a combination of G-CSF and IU4. 
Interleukin-2 is a helper cytokine for IL-4 production, and since TGF/^ 
impairs signal transduction through the IU 2 receptor (Holter et al, 1994), it 
may inhibit any synergistic effect that IU4 and G-CSF have in combination.
In CML chronic phase mononuclear cells IL-4 augmented G-CSF- 
induced proliferation whilst TGFBj had an inhibitory effect. The data suggests 
that in CML there may be a genetic change in the malignant clone which 
changes its response to TGF/31 and IL-4 as maturation occurs. Alternatively 
inhibition of G-CSF-induced proliferation by TGF/^ and augmentation of 
CFU-CML by IL-4 may reflect the distribution of cells along the myeloid 
lineage and the expansion of a specific progenitor cell compartment which has 
characteristics of both early and late progenitors. This compartment of cells 
may behave like early progenitors in their response to TGFp1 but like later 
progenitors in their response to G-CSF. If this is so, then in normal 
haemopoiesis there may be an equivalent sub-population of progenitor cells 
which are also inhibited by TGFp1 when G-CSF is the proliferative stimulus. 
Since TGF/^ had no significant inhibitory effect on the G-CSF-induced 
proliferation of samples from normal donors it seems likely that such cells 
would represent a small population in normal haemopoiesis and that any 
inhibitory effects of TGFjSj on G-CSF-induced proliferation are masked but 
in CML patients they form a larger part of the myeloid compartment.
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Plate 1
Peripheral blood CFU-CML from UPN 31 (CML CP), magnification 
xlOO
Plate 2
Cytospin of CFU-CML colonies from UPN 31, stained with May- 
Grunwald Giemsa, magnification xlOOO
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Cytogenetic analysis on day 14 colonies from UPN 27 (CML BT).
The chromosomal abnormality was:- 
46,XX,t(9;22)inv(16)pl3ql2orl3,iso(17q)
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CHAPTER 4 
IMMUNOPHENOTYPIC STUDIES
Introduction
Immunophenotypic analysis in addition to morphological, cytogenetic 
and gene rearrangement studies have enabled more accurate characterisation 
of both normal and leukaemic cells.
In 1984, Civin et al, developed a mouse monoclonal antibody (anti- 
MY10) that bound to virtually all haemopoietic progenitors. Subsequently 
other groups discovered antibodies with similar specificities; 12.8, BI-3C5 and 
ICH-3 (Andrews et al, 1986; Tindle et al, 1985). These antibodies were 
subsequently assigned to the CD34+ cluster of differentiation (Hogg et al, 
1987).
The gene encoding CD34+ has been localised to the long arm of 
chromosome 1 (Molgaard et al, 1989; Tenen et al, 1990). The human CD34+ 
gene spans 26-28 kilobases and the coding sequences have 8 exons 
(Satterthwaite et al, 1992; He et al, 1992). The human CD34+ gene shares 
significant coding sequence with the murine CD34+ gene which has also been 
cloned (Brown et al, 1991).
The CD34+ antigen is a glycoprotein with a molecular weight of llOkD 
(Civin et al, 1984). To date, the CD34+ antigen has not been attributed with 
any specific functions. Electron microscopy studies have shown that the 
CD34+ molecule is found predominantly at the endothelial junctions (Fina et 
al, 1990). These sites are crucial for leucocyte binding and migration to the
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extravascular compartment. Thus CD34+ molecule may play a role in cell 
adhesion. The CD34+ molecule may also act as a binding site for lectins 
which are expressed on bone marrow stromal cells (Baumhueter at al, 1993). 
Hence the CD34+ molecule may play a role in early haemopoietic functions 
by mediating cell to cell or cell to stroma interactions.
The CD34+ antigen is expressed on 1-3% of normal bone marrow 
mononuclear cells (Andrews et al, 1986) and in about 0.1% of normal 
peripheral blood mononuclear cells (Bender et al, 1991). The CD34+ antigen 
is expressed early on in haemopoietic differentiation, all the colony-forming 
cells and both T and B-lymphocyte precursors express the CD34+ antigen 
(Civin et al, 1984; Andrews et al, 1986; Ryan et al, 1986; Srour et al, 1990). 
Subsets of CD34+ which do not coexpress any lineage associated antigens (lin- 
) have been identified, they do not form haemopoietic colonies in vitro but 
when cultured over irradiated stromal layers can give rise to multiple colonies 
of different cell types or alternatively to blast cell colonies (Sutherland et al, 
1989; Andrews et al, 1990; Brandt et al, 1988). Hence CD34+ is expressed 
throughout the whole spectrum of haemopoietic cells, the expression however 
seems stage specific rather than lineage specific and decreases with cellular 
maturation. Primitive progenitors express high levels of the CD34+ antigen 
whilst the expression is weak or undetectable on cell that have matured 
beyond the committed progenitor stage (Sutherland et al, 1989: Strauss et al, 
1986). CD34+ antigen is selectively expressed on haemopoietic stem cells and 
is not expressed on most non-haemopoietic cells, however it has been detected
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on osteoclasts, marrow stromal progenitor cells, peripheral nerve sheath cells, 
fibroblastic cells and vascular endothelial cells (Holyoake and Alcorn, 1994). 
The HLA-DR antigen is expressed on both immature haemopoietic cells 
giving rise to CFC and on mature cells such as monocytes and B-lymphocytes. 
All CD34+ cells express the HLA-DR antigen but only a small proportion of 
HLA-DR + cells are CD34+ (Civin et al, 1987), suggesting that the CD34+ 
antigen is expressed in early haemopoietic progenitors.
In AML, CD34 positivity predicts for a poorer outcome, with poorer 
response to induction treatment, lower response and survival rates (Vaughan 
et al,1988; Geller et al, 1990). Increased expression of the MDR-1 gene 
encoding for the P-170 glycoprotein, associated with drug resistance has been 
demonstrated in 50% of cases of AML. P-170 expression appears to be 
restricted to the CD34+ blast cell population and is significantly associated 
with lower remission rates (te Boekhorst et al, 1993). In B-ALL, CD34 
positivity is associated with longer event free survival (Holyoake and Alcorn,
1994) but in T-ALL is associated with a increased likelihood of CNS disease 
(Pui et al, 1993).
The identification of the CD34+ antigen has been a major development 
to our understanding of haemopoiesis. Identification of this antigen in AML, 
may select out patients with a poorer prognosis and direct more aggressive 
treatments (such as bone marrow transplantation) early. However the real 
advance in haematology and oncology is likely to occur in the next few years 
when purified CD34+ cell populations will be used to enhance bone marrow
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recovery after high dose chemotherapy and are likely to become targets for 
gene therapy. Transplantation using CD34+ cells has already been carried out 
(Shpall et al, 1994), but is likely to gain further popularity in the future.
Objective
The aims of immunophenotypic analyses in this study were 3 fold;
(1) to characterise surface antigen markers on CML and AML cell
(2) to isolate a primitive progenitor population (i.e CD34+) cells from 
patients with CML and AML and compare the effects of G-CSF, IL-4 and 
TGFjSj on these cells which have a higher clonogenecity with unmanipulated 
MNC (3) to quantitate the percentage of II^4R on CML and AML cells and 
to correlate this with the data obtained from in situ hybridisation.
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Results
The percentage of CD34+ cells from peripheral blood MNC, of patients with 
CML compared with disease stage, WBC count and CFU-CML obtained with 
15ng of G-CSF is shown in Table XXVI, below.
UPN STAGE OF DISEASE % CD34+ WBC xl07l CFU-CML
21 CML CP 1.0 87.2 8.0
22 CML CP 4.0 38.5 52.7
23 CML CP 20.0 69.0 23.0
24 CML CP 0.0 55.1 30.0
25 CML CP 4.0 48.0 15.3
30 CML CP 50.0 380.0 45.0
36 CML CP 2.0 123.0 104.0
38 CML CP 50.0 91.2 67.0
39 CML CP 2.0 250.0 0.0
51 CML CP 10.0 38.6 518.0
52 CML CP 90.0 98.9 0.0
53 CML CP 10.0 45.3 0.0
54 CML CP 20.0 350.0 0.0
55 CML CP 2.0 74.1 73.0
56 CML CP 10.0 38.4 0.0
26 CML lymphoid BT 10.0 26.5 11.0
34 CML myeloid BT 95.0 83.3 310.0
54b CML myeloid BT 50.0 96.0 334.3
57 CML myeloid BT 80.0 81.0 0.0
Twelve of the 15 patients in chronic phase had CD34 positive cells of 
<20%. Three of the 15 patients in chronic phase had CD34 positivity ranging
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from 50-95% (UPN30, 38 and 52). Plate 4 shows the appearance of CD34+  
cells in UPN 38. The increase in CD34 positivity was correlated with 
satisfactory in vitro growth in UPN 30 and 38, but cells from UPN 52 which
were 90% CD34+ did not grow in vitro. Among the 12 patients in CP with a
\
low percentage of CD34 counts (<  20%) 8 produced colonies in vitro (UPN21, 
22, 23, 24, 25, 36, 51, 55).
The 3 patients in myeloid blast transformation (UPN 34, 54b and 57) 
had a high percentage of CD34+ cells. Two of the 3 patients in myeloid blast 
transformation yielded satisfactory CFU-CML (UPN 34 and 54b). UPN 54b 
when in chronic phase (UPN 54) had a lower percentage of CD34 positivity, 
as might be expected.
A  CD34+ count of >50% correlated with satisfactory CFU-CML 
numbers in all but two patient (UPN 52 and 57). The lack of in vitro growth 
is difficult to reconcile with the expected increased proliferative potential of 
these cells and may be a reflect a sub-population of cells, within the expanded 
population, which may for instance be CD34+/CD33- and are less likely to 
respond to G-CSF than CD34+/CD33+ cells (Ema et al, 1990).
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The percentage of CD33, 34 and CD38 positive cells in CML PB MNC 
samples are shown in Table XXVII, below.
U PN STAGE
OF
DISEASE
% CD34+ %CD33 + %CD38+ WBCx
109/1
CFU-
CML
21 CP 1.0 10.0 70.0 87.2 8.0
22 CP 4.0 ND 90.0 38.5 52.7
23 CP 20.0 50.0 50.0 69.0 23.0
24 CP 0.0 50.0 1.0 55.1 30.0
25 CP 4.0 ND ND 48.0 15.3
30 CP 50.0 ND 95.0 380.0 45.0
36 CP 2.0 ND 40.0 123.0 104.0
38 CP 50.0 10.0 40.0 91.2 67.0
39 CP 2.0 95.0 2.0 250.0 0.0
54 CP 20.0 20.0 50.0 350.0 0.0
55 CP 2.0 20.0 50.0 74.1 73.0
56 CP 10.0 30.0 50.0 38.4 0.0
26 LY BT 10.0 ND ND 26.5 11.0
54b MY BT 50.0 90.0 20.0 96.0 334.3
57 MY BT 80.0 0.0 50.0 81.0 0.0
The percentages have been correlated to the WBC count and the CFU-CML 
obtained with 15ng of G-CSF. ND - not done; CP - chronic phase; LY BT - 
lymphoid blast transformation; MY BT - myeloid blast transformation.
CD38 is an 45kD antigen found on 40% of BM MNC including 
myeloblasts and promyelocytes. Cells that coexpress CD34+ and CD38+ 
belong to a subset of lineage committed progenitors (Holyoake and Alcorn,
1994). Patients with CML may be expected to have a high percentage of these 
cells. Nine out of 11 patients in chronic phase had a CD38 positive count of
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>40%. UPN 24 had both a low CD38 (1.0%) and a low CD34 count (0.0%) 
but produced 30 CFU-CML/5xl05 MNC with 15ng of G-CSF. UPN 39 too, 
had a low CD34 and CD38 count but unlike UPN 24 did not grow in vitro. 
Both these patients had not received any chemotherapy.
CD33 is a myeloid specific antigen, it binds strongly to monocytes and 
acute myeloid progenitor cells. It binds weakly to mature granulocytes. All 8 
patients in chronic phase had a CD33+ count of >10%. Patients in myeloid 
blast transformation might be expected to have a high CD33+ count. This was 
so in UPN 54b, but not in UPN 57, who was also in myeloid blast 
transformation but was negative for the CD33 antigen.
In-vitro effects of various cytokines on CD34 purified cell populations
CD34+ cells were purified from peripheral blood of CML patients as 
described in Chapter 2. The cells were plated at concentrations of between 
5xl03 and 8xl04/plate. The concentration of cytokines used were as follows: G- 
CSF 15ng; IL-4 5ng; TGF/3j 5ng; GM-CSF 50ng; IL-3 50ng. The results are 
shown in Table XXVIII, overleaf
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Table XXVIH below, shows the effect of G-CSF alone and in combination with IL-4
and TGFft on CD34 enriched MNC from CML PB MNC.
UPN STAGE CELL
NO
CD34% G-CSF G-CSF
+TGF&
G-CSF
+IL-4
G-CSF
+TGF/?!
+IL-4
21 CP 5xl04 1.0 1.0 0.0 5.3 2.3
22 CP 104 4.0 0.0 0.0 0.0 0.0
23 CP 2xl04 20.0 71.0 ND 110.5 47.5
55 CP 8xl04 2.0 160.3 24.0 136.0 48.67
25 CP 5x103 4.0 2.6 <1.0 1.6 1.6
24 CP 104 0.0 0.0 0.0 0.0 0.0
26 LY BT 5x103 10.0 0.0 0.0 0.0 0.0
36 CP 2x104 2.0 0.0 0.0 0.0 0.0
38 CP 2xl04 50.0 0.0 0.0 0.0 0.0
The percentage of CD34 positivity prior to enrichment and the number of cells/plate 
are also shown. CP - chronic phase; LY BT - lymphoid blast transformation.
Only 2/9 CML samples produced colonies in vitro when CD34+ 
enriched cells were used (UPN 23 AND 55). IL-4 augmented G-CSF-induced 
colony formation in UPN 23 but not in UPN 55. TGF/^ had an inhibitory 
effect on G-CSF and G-CSF plus IL-4 induced colony formation in UPN 55. 
It also inhibited CFU-CML in cultures from patient UPN 23 stimulated with 
a combination of G-CSF and IL-4. Though sample numbers are small the data 
suggests that there are expanded sub-populations within the CD34+ 
compartment that are less likely to respond to G-CSF. During the enrichment 
process the CD34+/CD33+ cells which are more likely to be responsive to G- 
CSF may have preferentially been removed, compared to the CD34+/CD33- 
cells which are less likely to respond to G-CSF (Ema et al, 1990).
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Enriched CD34+ cell population from UPN 55a gave rise to CFU-CML 
when stimulated by G-CSF, GM-CSF and IU3 (mean colony numbers being 
160, 118 and 75 respectively). In each instance TGFjSj reduced CFU-CML- 
stimulated by the 3 colony-stimulating factors (see Fig 17). The inhibitory 
effects of TGFjSj on G-CSF, GM-CSF or IL-3 stimulated, enriched CD34+ 
cells from CML patients was similar to its effects on non-enriched peripheral 
blood and bone marrow MNC from the same group of patients.
Figure 17, overleaf shows the effect of TG ¥p1 on G-CSF, GM-CSF and IL-3 
induced cell proliferation using CD34+ cells from UPN 55.
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Figure 17
G-CSF
G-CSF+TGFB
GM-CSF
GM-CSF+TGFB
IL-3 
IL-3+TGFB
0 50 1 0 0 4 150 200
CFU-CML/8X10 PB MNC 
G-CSF 15ng; GM-CSF 50ng; IL-3 50ng 
TGFB 5ng
Figure 17
The effects of TGFjSj on G-CSF, GM-CSF and IL-3-induced cell proliferation 
of CD34 positive cells from UPN 55a (CML CP) are shown.
TGFjGj inhibited G-CSF, GM-CSF and IU3-induced CFU-CML in each set 
of conditions.
I  160
24
1  118
50
UPN 55a75
CFU-CML
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Immunophenotyping in AML
The percentage of cells expressing the CD 33,34 and 38 antigen in AML 
peripheral blood MNC are shown in Table XXIX, below.
UPN FAB-TYPE %CD34 %CD33 %CD38 CFU-AML; 15ng 
G-CSF
40 21* AML 1.0 85.0 10.0 0.0
42 AML M3 90.0 50.0 90.0 0.0
44 AML Ml 2.0 50.0 95.0 26.3
47 AML M2 70.0 ND ND 58.7
48 217 AML 30.0 ND ND 134.0
In the AML samples in vitro growth of CFU-AML could not be 
correlated to the percentage of CD34+ cells or the FAB classification. 
Patients with AML M2 and M3 have cells that are more differentiated than 
M l and such cells may be expected to contain a low percentage of CD34+ 
cells, this was not reflected in the data. UPN44 a patient with AML M l had 
2% CD34+ cells whereas UPN42 and 47 who had AML M3 and M2 had 90% 
and 70% CD34+ respectively suggesting that the presence of the CD34 
antigen is not confined to early progenitor cells in this disease.
Detection of the IL-4 receptor on the surface of CML and AML cells
Idzerda et al cloned the high affinity receptor for IL-4 in 1990 (Idzerda 
et al, 1990). Since then there has been much evidence to suggest that in
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addition to the high affinity receptor there is a low affinity receptor for ID-4 
(Foxwell et al, 1989). This receptor has thus far not been cloned. To indirectly 
detect the presence of the receptor on the surface of leukaemic cells a goat 
anti-human IL-4 neutralising antibody was used as described in Chapter 2. 
This antibody would bind to any endogenous IL-4 already bound to the 
receptor.
Objective
Since IL-4 augmented G-CSF-induced colony formation from normal, 
AML and CML chronic phase cells but reduced G-CSF-induced colony 
numbers in CML BT MNC experiments were done to determine whether 
there was quantitative differences between the expression of the IL-4R in 
CML, AML and normal MNC.
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The percentage of cells expressing the receptor for IL-4 on CML MNC are 
shown in Table XXX, below. This number has been compared with CFU-CML 
numbers obtained with G-CSF, IL-4 and TGF/3. Normal or leukaemic MNC 
did not grow in vitro when stimulated with IL-4 alone. Samples were obtained
from peripheral blood.
UPN DISEASE G-CSF G-CSF+IL-4 G-CSF
+TGF/3
G-CSF
+IL-4
+TGFj8
% alL- 
4R
21 CML CP 8.3 13.6 3.0 8.0 5.0
22 CML CP 52.7 71.7 22.3 93.7 0.0
23 CML CP 23.0 55.0 8.0 16.0 10.0
24 CML CP 30.0 41.7 8.0 26.7 5.0
36 CML CP 104.0 169.0 23.3 76.7 2.0
38 CML CP 67.0 75.0 21.7 35.0 50.0
39 CML CP 0.0 0.0 0.0 0.0 30.0
54 CML CP 0.0 0.0 0.0 0.0 1.0
55 CML CP 73.0 81.3 24.0 43.7 1.0
56 CML CP 0.0 0.0 0.0 0.0 50.0
34 CML BT 310.0 210.0 17.5 3.5 50.0
54b CML BT 334.3 210.0 17.5 3.5 50.0
57 CML BT 0.0 0.0 0.0 0.0 10.0
Although IL-4 augmented G-CSF-induced colony formation CML cells 
in chronic phase there was no increase in CFU-CML in 3/4 patients in blast 
transformation (UPN 34, 35 and 54b, see Table XVIIIa). It could be 
speculated that in myeloid blast transformation clonogenic cells are saturated 
with endogenous IL-4 and that the addition of recombinant human IL-4 is 
unable to augment further CFU-CML. If this were the case the percentage
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of cells from patients in blast transformation which express the IL-4R would 
be expected to be greater than in cells in chronic phase. However the 
percentage of CML MNC expressing the IL-4R did not correlate with the 
disease stage or CFU-CML. The 3 patients in blast transformation (UPN 34, 
54b and 57) had 50%, 0% and 10% of MNC expressing the IL-4R. Three 
patients in chronic phase had a high percentage of cell expressing the IL-4R 
(UPN 38, 39 and 56). Plate 5 shows the expression of the IL-4R, in UPN 38. 
The data show that there was no correlation between the expression of IL-4R 
and enhanced colony numbers in cultures exposed to G-CSF and IL-4 
compared to G-CSF alone, or that the expression of IL-4R on a significant 
number of MNC was indicative of proliferative potential in vitro.
Discussion
The results show that in CML, neither CD34 positivity nor the white 
cell count at diagnosis correlated with the growth of CFU-CML in vitro using 
G-CSF as the stimulus. In contrast Silvestri et al showed that the percentage 
of CD34+ cells in CML peripheral blood correlated with the growth of CFU- 
GM, although the growth factors used were not mentioned (Silvestri et al, 
1991). Patients in blast transformation have more immature haemopoietic cells 
which would be expected to have a higher percentage of CD34+ cells. The 3 
patients in myeloid blast transformation (UPN 34, 54b and 57) had a high 
percentage of CD34 positive cells (95%, 50% and 80% respectively).
The LTC-IC in CML CP peripheral blood are present at a much higher
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concentration than in normal peripheral blood. Furthermore the LTC-IC in 
CML patients show features of proliferating or activated cells (CD34+ve, 
HLA-DR-ve, low Rhodamine-123 uptake and relative insensitively to 4- 
hydroperoxycyclophosphamide in vitro) compared with LTC-IC in normal 
peripheral blood which have features of a more quiescent cell population 
(Udomsakdi et al, 1992a; Udomsakdi et al, 1992b).
Nine of the 11 patients with CML >40% CD38+ cells and >10% 
CD33+ cells. Cells which express both the CD34 and CD33 antigens are 
committed to the myeloid lineage and can respond directly to G-CSF (Ema 
et al, 1990). Of the patients studied 5 had CD33 and 34 counts of >10% 
(UPN 23, 38, 54, 54b and 56). Three of these 5 patients produced CFU-CML 
in vitro (UPN 23, 38 and 56). However as the immunophenotyping was not 
done by dual staining it cannot be concluded that proliferation occurred from 
cells which were CD34+/CD33+. In normal bone marrow or peripheral blood 
only a minor subset of CD34+ cells coexpress CD33 antigen. The CD33 
antigen is a lineage marker which is coexpressed with HLA-DR and CD 13 on 
progenitors committed to the granulocyte-macrophage lineage (Pierelli et al, 
1993). These authors also found a correlation between the percentage of 
CD34+/HLA-DR+ cells and the number of colony forming cells in 
unfractionated samples of BM and PB from patients with malignancies where 
there was no bone marrow involvement.
Geller et al in 1990, in a series of 96 patients with acute myeloid 
leukaemia found that CD33 and CD34 were expressed in 73% and 60% of
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blasts respectively. Thus, a considerable proportion of AML blasts coexpress 
these antigens. The coexpression of CD33 and CD34 antigens on leukaemic 
blasts could reflect the neoplastic proliferation of a progenitor cell at the 
beginning of differentiation toward granulocyte-macrophage cells. This 
neoplastic clone retains a stem cell marker associated with a poor prognosis 
(Vaughan et al, 1988; Geller et al, 1990; Myint and Lucie 1992). Although 
spontaneous growth of AML cells in vitro has also been correlated to an 
adverse prognosis (Lowenberg et al, 1993) none of the AML samples in this 
study grew spontaneously in vitro.
Akashi et al have shown that IL-4 alone stimulated in vitro growth of 
both CD34+ve and CD34-ve blasts from AML patients. The effects of IU4  
were enhanced by the addition of IL-3, GM-CSF and G-CSF. Expression of 
the IL-4R was not studied in these patients (Akashi et al, 1991).
Seven of the 13 CML patients studied had MNC expressing the IL-4R 
(>  10.0%; of which 4 were in chronic phase and 3 in blast transformation). 
None of these samples grew in vitro when stimulated by IL-4 alone, although 
IU4 increased the number of colonies in cultures exposed to G-CSF in one 
of these patients (UPN 23). There was no colony formation with either G-CSF 
or G-CSF combined with IL-4 in 3/7 samples. Furthermore there was a 
reduction in colony numbers when IL-4 was added to G-CSF from one patient 
in myeloid blast transformation (UPN 34).
Of the 8 CML samples in chronic phase only 2/8 grew in vitro, from 
purified CD34+ cells although unmanipulated MNC from all 8 patients grew
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in vitro when stimulated by G-CSF or G-CSF plus IL-4. The data suggests that 
there may be significant inter-patient variation regarding the composition of 
the CD34+ compartment in CML. In normal haemopoiesis IL-4 synergizes 
with G-CSF to produce CFU-GM from CD34+ purified cells but inhibits GM- 
CSF and IL-3-induced colony formation (Snoeck et al, 1993). These effects 
were attributed predominantly to the differential response of CD34+/HLA- 
D R + + population compared with CD34+/HLA-DR+ cells to G-CSF (Snoeck 
et al, 1993). In CML there may be a similar population of CD34+/HLA- 
D R + +  cells that are more likely to proliferate in response to G-CSF and 
IL-4.
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Plate 4 - Immunophenotypic studies
Expression of CD34+ cells in PB MNC from UPN 38 (CML CP) 
magnification xlOOO
Plate 5
Expression of IL-4R on PB MNC from UPN 38, magnification xlOOO
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CHAPTER 5
IN-SITU  HYBRIDISATION
Introduction
Over the past 30 years techniques employing immunological and 
molecular biological methods have had an increasing impact on the biological 
sciences and have resulted in an unparalleled increase in the number of 
growth factors, oncogenes, enzymes, peptide hormones, cell surface receptors 
and other proteins for which amino acid sequences and corresponding 
nucleotide sequences are known.
The past 17 years has seen the development of recombinant DNA  
techniques and sensitive methods for detection of specific DNA or RNA  
sequences by molecular hybridisation. Hybridisation can either be performed 
in solid supports, in solution (in vitro) and on tissue sections or cell 
preparations (in situ). The hybridisation techniques on solid supports involve 
the immobilisation of DNA fragments onto a filter (nitrocellulose or nylon 
membrane) followed by hybridisation onto a specific DNA probe (Southern 
blotting, Southern, 1975). Similarly different types of extracted RNA can be 
identified after electrophoretic separation and transfer onto a solid support 
prior to hybridisation (Northern blotting, Alwine et al, 1979 ). A dot blot 
analysis enables specific DNA or RNA sequences to be quantitated regardless 
of their length. Although molecular hybridisation in vitro or to membrane- 
bound nucleic acids allows the identification of DNA or RNA, it does not 
reveal the distribution of specific sequences in individual cells. In situ
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hybridisation (ISH) was introduced in 1969 (Buongiorno-Nardelli and Amaldi 
1969; Gall and Pardue 1969; John et al, 1969). It is also referred to as 
hybridisation histochemistry or cytological hybridisation. In contrast to the 
other methods available it enables the morphological demonstration of specific 
DNA or RNA sequences in individual cells in tissue sections, single cells or 
chromosome preparations. Thus ISH is the only method that allows the study 
of cellular location of DNA or RNA sequences in a heterogeneous population.
ISH is based on the principle that labelled single-stranded fragments of 
DNA or RNA containing complementary sequences (probes) are hybridised 
to cellular DNA or RNA under appropriate conditions forming stable hybrids. 
The sensitivity of ISH depends on the following variables: (a) the effect of 
tissue preparations on retention and accessibility of cellular DNA or RNA, 
(b)type of probe construct, efficiency of probe labelling and sensitivity of the 
method used for signal detection and (c) the effect of hybridisation conditions 
on the efficiency of hybridisation.
Detection of mRNA
The use of ISH for the detection of DNA is now well established. In 
the past decade the technique has been used to detect mRNA. The precursors 
of mRNA are transcribed from DNA in the nucleus by RNA polymerase II 
and are known as heterogeneous nuclear RNA. These molecules are processed 
into mature mRNA by the addition of the 5’-methyl cap and a 3’-tail of 200 
adenyl residues (Perry, 1976). The transcripts are further processed by
186
removing the non-coding intron sequences by a process termed "splicing" in 
order to produce the complete mRNA which is transported from ribonuclear 
structures to the cytoplasm for translation. Therefore in situ hybridisation of 
mRNA can be sited within the nucleus or cytoplasm of the cell. mRNAs are 
generally very unstable being fairly readily degraded by RNAses. As 
cytoplasmic RNA represents only 3% of total cellular RNA their detection is 
dependent on the preservation of mRNAs by appropriate fixation of cells or 
tissue sections (Pringle et al, 1989)
Fixation
The process of fixation should retain the maximal level of cellular target 
DNA or RNA while maintaining morphological detail and allowing sufficient 
accessibility of probe. As mRNA is steadily synthesized and degraded 
enzymatically, for its localisation the type, time and concentration of the 
fixative are significant if loss of RNA is to be minimised. Paraformaldehyde 
a cross-linking fixative has been used in several studies using tissue sections 
(Brigati et al, 1983; Hafen et al, 1983; McAllister and Rock 1985, Hofler et al, 
1986; Crabbe et al, 1992), though to date it has not been used successfully on 
bone marrow or peripheral blood MNC. Unlike glutaraldehyde, 
paraformaldehyde does not cross-link proteins so extensively as to prevent 
penetration of probes. Acetic acid-alcohol mixtures or Bouin’s fixation are 
favoured by some workers (Gall and Pardue, 1971, Manuelidis et al, 1982; 
Berge-Lefranc et al, 1983). It must be emphasised that these fixatives were
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used on tissue sections. Tissue sections and single-cell preparations must 
adhere to specially treated glass slides to avoid loss of cells during 
hybridisation. Gelatin chrome alum coated glass slides (Gall and Pardue, 
1971), or treatment with poly-L-lysine (Huang et al, 1983) or 3- 
aminopropyltriethoxysilane (APES, Maddox and Jenkins, 1987) are the most 
commonly used.
Pretreatment of specimens with a detergent and/or proteinase digestion 
is standard procedure in most protocols, to increase probe penetration and 
accessibility. This process is of importance when dealing with paraffin 
embedded sections (Hofler, 1990). Triton X-100 and RNAse-free proteinase 
K are the most commonly used (Hofler, 1990). Lawrence and Singer 
(Lawrence and Singer, 1985) extensively studied the rate of RNA retention, 
influence of prolonged exposure to different fixatives and proteinase digestion 
on single-cell preparations. They concluded that paraformaldehyde fixation 
gave the highest specific signal and that detergent and proteinase pre­
treatment is not always necessary.
Probes and labelling
Labelled DNA and RNA probes can be used to localise DNA and 
mRNA. Broadly there are 3 different DNA probes, double stranded DNA (ds 
DNA), single stranded DNA (ss DNA) and synthetic oligonucleotides. RNA  
probes used for the detection of mRNA are single stranded complementary 
RNA probes.
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Double-stranded DNA probes: ds DNA probes are usually labelled by nick- 
translation or random priming. As the yield from random priming is low, it is 
not recommended for ISH where a large number of specimens are used. 
Synthetic oligodeoxyribonucleotides can be prepared from DNA synthesizers 
and have several advantages over cloned DNA probes, (a) a higher specificity 
(b) the possibility of synthesising probes from amino-acid sequences when the 
total DNA sequence is unknown and (c) the ability to generate discriminating 
sequences for similar genes (Hofler, 1990).
Single-stranded cDNA probes: With the introduction of the polymerase chain 
reaction (PCR) ssDNA probes with a high specificity can be generated 
(Gyllensten and Erlich, 1988). These probes have the theoretical advantage 
that re-annealing of the probe to the second strand cannot occur.
Single stranded anti-sense RNA probes: These probes can be synthesised using 
cDNA as a template in the presence of labelled or unlabelled ribonucleotides 
and RNA polymerase. These probes have a higher specificity and thermal 
stability than the DNA probes, in addition as they do not contain vector 
sequences they cause less non-specific binding (Hofler, 1990).
Antisense oligonucleotide probes: are made by sub-cloning of synthetic 
oligonucleotides (20-70 mers) into mRNA expression vectors. The probes are 
obtained by inserting specific cDNA sequences into an appropriate 
transcription vector containing an RNA polymerase promoter. Commonly used 
vectors include the plasmids pSP64 and pSP65, the Gemini vectors and 
Bluescript (Gibson and Polak, 1990). Sense and anti-sense probes can thus be
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obtained by either using 2 separate plasmids or into those containing 2 
different promoters on either side. This technique has several advantages, (a) 
it is easy to prepare large quantities of labelled probe (b) probes can be made 
for any gene whose protein sequence is known and (c) it has a high specificity 
(Chan and McGee 1990).
Labelling
There are 2 main types of labelling, direct labelling of a radioisotope 
onto the DNA or RNA and indirect where either a hapten (e.g digoxigenin or 
biotin) is attached to the probe and detected by a labelled binding protein 
(e.g. avidin) or the probe-hybrid is detected by a specific antibody. The most 
commonly used radioisotopes are 3H, 32P, 35S, 14C and 125I. As a result of 
problems of safety, waste disposal and reduced stability non-isotopic probes 
have become more popular, the most favoured haptens being biotin and 
digoxigenin. The relative merits of the radioisotopes and the haptens are given 
below (from Hofler, 1990).
Label Resolution Sensitivity Exposure
(days)
Stability
(weeks)
32p + + + 7 0.5
35s + + + + + 10 6.0
3H + + + + + + 14 >30
Biotin + + + + + 0.16 >52
Digoxigenin + + + + + + 0.16 >52
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Hybridisation conditions
One of the main advantages of ISH is that the degree of specificity of 
the hybridisation reaction can be accurately controlled by varying the reaction 
conditions. The degree of specificity depends on the probe construction, 
temperature, pH and salt and formamide concentrations (Hofler, 1990). 
Stringency refers to the degree to which reaction conditions favour the 
dissociation of nucleic acid duplexes. Under conditions of high stringency only 
probes with a high degree of homology to the target sequence will form stable 
hybrids. At low stringency (i.e. reactions carried out at low temperature or 
high salt or low formamide concentrations) a probe may bind to sequences 
with only 70-90% homology thus resulting in non-specific binding. In general 
the maximum rate of hybridisation takes place at the melting temperature (Tm) 
minus 10-25°C (Bonner et al, 1973). With oligonucleotide probes the rate of 
hybridisation rarely presents a problem, however it remains standard practice 
in most protocols to use overnight incubations and conditions approximating 
Tm-20°C.
Objective
The purpose of the ISH studies was as follows: (1) to determine 
whether the mRNA for IL-4R and/or G-CSFR could be detected in normal, 
CML and AML peripheral blood and bone marrow samples (2) to determine 
whether TGFjSj down regulates the expression of the G-CSFR when CML 
MNC are incubated with both cytokines, (3) to determine whether the G-CSF
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receptor is up-regulated by the addition of IH4 to cultures containing G-CSF 
and (4) to determine if the inhibitory effects of TGFjSj were mediated via by 
the down-regulation of II^4R mRNA in cultures of CML cells containing G- 
CSF, IL-4 and TGFft.
To date there has been no published data on ISH being carried out on 
bone marrow or peripheral blood MNC. Several problems were encountered 
which have been detailed in Chapter 2. In total 3 different methods were tried 
however the results have been variable. The commonest problem was the 
fragility of bone marrow and peripheral blood MNC which was more marked 
in CML samples than normal or AML samples. Secondly in all 3 methods 
there was some non-specific staining which occurs independently of the 
addition of probe or antibody and which was localised predominantly to 
mature granulocytes.
Results
The development of a suitable method to examine individual mRNA in 
situ from MNC from peripheral blood and bone marrow formed a major part 
of the work and is ongoing. The results from the ISH studies using the 3 
methods detailed in Chapter 2 are given below:
The results from ISH from Methods I, II and III are shown in Table XXXI, 
overleaf.
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UPN TYPE RESULTS
I 11 HI
C
E
L
L
S
EL-4R C
E
L
L
S
EL-4R G-CSFR C
E
L
L
S
G-CSFR IL-4R
21 CP/PB G + G + + G + +
22 CP/BM P U/A
23 CP/PB F N/S
24 CP/PB F N/S F U/A U/A
28 CP/BM P U/A
29 CP/PB P U/A G N/S N/S
39 CP/PB P U/A
51 CP/PB G N/S N/S
54 CP/PB P U/A
55 CP/PB F N/A G N/S N/S G N/S N/S
56 CP/PB G N/A P U/A U/A
34 BT/PB F - P U/A U/A
54b BT/PB F N/A F N/S N/S
57 BT/PB F N/S N/S
42 M3/PB P U/A
44 Ml/PB F +
47 M2/PB P U/A
18 NPB G + +
58 NBM F N/S
59 NBM P N/S
60 NPB P U/A
61 NBM P U/A G + +
Disease state CP/PB - CML chronic phase peripheral blood; CP/BM - CML 
chronic phase bone marrow; BT/PB - CML blast transformation peripheral
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blood; Ml/PB, M2/PB, M3/PB - are peripheral blood cells from patients with 
AML M l, M2 and M3; NBM - normal bone marrow; NPB - normal peripheral 
blood; Cells - describes the cellular integrity G - good, F - fair, P - poor; 
Expression of the mRNA for the IL-4R and G-CSFR was assessed as + - 
positive; - negative; U/A - unable to assess; N/S - non-specific binding. 
Briefly the differences in methods were due to the method of fixation and/or 
pre hybridisation/hybridisation conditions; in Method l a  1:1 mixture of 
acetone and methanol, followed by 0.2% paraformaldehyde was used, whereas 
in Methods II and III the slides were fixed in 1:1 mixture of acetone-methanol 
only. In both methods I and II samples were exposed to formamide and 
salmon sperm before hybridisation with the probes, in Method III the 
prehybridisation step was omitted and a thermal cycler was used to provide 
the required stringency.
Results I,II and III - results from methods I, II and III respectively.
Several problems were encountered doing ISH on PB and BM MNC. 
Non-specific binding was seen in all 3 methods but at a reduced intensity with 
Method III. Paraformaldehyde even at a low concentration of 0.2% caused 
cellular destruction. Of the various fixatives tried the combination of acetone 
and methanol was best at retaining cellular integrity.
Plates 7 shows the expression of the G-CSF receptor using ISH in UPN 
18 (normal PB), plate 6 shows the "no probe" negative control. Plate 9 and 10 
shows the expression of the G-CSF receptor and IL-4 receptor in UPN 21 
(CML CP PB) and plate 8 shows the "no probe" negative control.
To determine the effect of pre-incubation of MNC with growth factors, 
5ml liquid cultures containing 106 MNC/ml from UPN 21, 24, 29, 51 and 55 
were incubated with the following cytokines (1) 5ng G-CSF/ml, (2) 5ng G- 
CSF/ml and 5ng TGFjSj/ml, (3) 5ng G-CSF/ml and 5ng IL-4/ml and (4) 5ng G-
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CSF/ml, 5ng TGF/^/ml and 5ng IL-4/ml. After overnight incubation ISH was 
carried out as described in Chapter 2 (method III). In samples from UPN 21 
a positive signal was to IL-4R and G-CSFR was detected in samples exposed 
to antisense probes to the respective mRNA irrespective of pre-incubation 
conditions. In the 4 different culture conditions the expression of the G-CSF 
and IL-4 receptor were similar. In each instance a total of 200 cells were 
counted and the percentage expressing the relevant receptor calculated. The 
range of expression of the G-CSF receptor in the 4 culture media was 65% to 
71% and the range of expression of the IU4 receptor was 38% to 46%. The 
cells expressing the signal were mainly myelocytes and promyelocytes.
Discussion
The results from the clonogenic studies showed that IL-4 augmented G- 
CSF-induced proliferation of CML CP and AML cells but not CML blast 
transformation MNC. TGF/^ inhibited G-CSF-induced colony formation of 
both CML CP and BT MNC. G-CSF-induced colony-formation of normal and 
AML cells were not inhibited by TGFj8x. To try and determine the cause of 
this difference in situ hybridisation techniques were used to study the 
expression of the G-CSFR and IL-4R. As the cDNA sequence for the class 1 
and III receptors for TGF/^ have not been cloned, the expression of this 
receptor was not studied. Unfortunately the technical difficulties encountered 
with ISH meant that no consistent results were obtained.
Other workers have shown that the mRNA of gelsolin (an actin-binding
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protein that is also a constituent of normal plasma) in a megakaryocytic cell 
line could not be directly related by ISH but was detectable by reverse 
transcriptase polymerase chain reaction (PCR) in situ (Sninsky, personal 
communication). Thus the technique is limited by the number of copies of a 
particular mRNA and the ability to detect the mRNA using histochemical 
methods. Among the samples tested by each of the methods only cells from 
UPN21, who had CML in CP, were positive using each method and for both 
receptors. The morphology of the cells expressing both receptors indicated 
that they were mainly promyelocytes and myelocytes. The results from the 
clonogenic assays from UPN 21 are summarised below:
G-CSF G-CSF+ EL-4 G-CSF+TGFft G-CSF+IL-4+TGFft
8.3 13.6 3.0 8.0
The inhibitory effects by TGFjSj on G-CSF-induced proliferation of 
CFU-CML were partially reversed by IL-4. By ISH however the mRNA  
expression of G-CSFR and IL-4R were unchanged in cultures containing G- 
CSF, TGFjSj and/or IU 4 suggesting that the difference maybe due either to 
changes in translation or signal transduction rather than inhibition of mRNA  
synthesis. UPN 21 consistently gave a positive result regardless of the method 
used suggesting that the aberrant malignant clone in this patient produced 
multiple copies of mRNA for both the G-CSFR and IL-4R.
Peripheral blood from 2 normal donors, UPN 18 and 60, expressed the 
mRNA for the G-CSFR and IL-4R, the cells expressing the receptors were
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mature neutrophils.
The cellular architecture was best maintained using Method III which 
avoided the use of paraformaldehyde, formamide and salmon sperm. In 6/8 
samples studied using this method good cell morphology was retained, this 
contrasts with Method 1 where only 2/18 samples had good cellular integrity.
Although ISH studies using cytospin preparations of MNC is still at the 
developmental stage results suggest that in samples containing multiple copies 
of mRNA for specific receptors the use of DNA probes may enable their 
localisation within specific cells in heterogeneous populations. In summary, the 
effects of TGFjSj and IU 4 on G-CSF-induced stimulation of CFU-CML may 
be due to a difference in signal transduction or protein synthesis rather than 
down-regulation of the relevant receptor.
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Plate 6 - In situ hybridisation studies
(using Method III)
rft %
Negative control (No probe, no antibody) from normal PB MNC 
(UPN 18), magnification xlOOO
Plate 7
f t
Expression of G-CSFR on normal PB MNC (UPN 18) 
magnification xlOOO
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Plate 8 - In situ hybridisation studies
(using Method III)
m
Negative control (no probe, no antibody) from CML CP peripheral 
blood MNC (UPN 21), magnification xlOOO
Plate 9
*
%
>
Expression of G-CSFR in CML CP peripheral blood MNC from UPN 
21, magnification xlOOO
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Plate 10 - In situ hybridisation studies
(using Method III)
Expression of IL-4R from CML CP peripheral blood MNC (UPN 21), 
magnification xlOOO
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CHAPTER 6 
SUMMARY OF CONCLUSIONS
Table XXXII below, summarises the results from the clonogenic assays
Normal
MNC
CML CP 
MNC
CML BT 
MNC
AM L
MNC
G-CSF + + + + + +
GM-CSF + + + + +
IL-3 + + + +
G-CSF+TGF& 1 1 V
GM-CSF+ TGFjSj 1 1 -
IL-3+TG Fft — > I I -
G-CSF+IL-4 - t V t
f - colony numbers increased; j  - colony numbers decreased
- colony numbers unchanged; + and + + - increased proliferative response 
to the 3CSF’s. V - variable
Chronic myeloid leukaemia and acute myeloid leukaemia are 
pathologically and clinically distinct diseases. This study provides evidence 
that the proliferation of mononuclear cells from patients with CML are 
inhibited by TGFpt in vitro irrespective of the proliferative stimulus whereas 
there is no consistent inhibition in either normal or AML mononuclear cells. 
Although colony numbers from normal bone marrow and peripheral blood 
were low G-CSF, GM-CSF or IL-3 were equally effective in stimulating CFU- 
GM whereas with CML mononuclear cells G-CSF induced the best 
proliferative response in vitro.
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The inhibitory effects of TGFjSj on CML cells occurred independently 
of whether the cells were obtained in chronic phase or blast transformation or 
the nature of the colony-stimulating factor used. In contrast, TGFjSj had no 
consistent effect on normal MNC or those from patients with AML.
TGFjSj can be an activator or inhibitor of haemopoietic progenitors 
depending on the target cell population (Ottamann and Pelus, 1988; Sing et 
al, 1988; Keller et al, 1988a). In normal haemopoietic progenitor populations 
the earliest pluripotent cells are largely quiescent, while a larger proportion 
of later, lineage-restricted cells are in active phases of the cell cycle. Hatzfeld 
et al, 1991 have shown that anti-sense oligonucleotides to TGFjSj significantly 
enhanced the frequency of colony formation by multi-lineage, early erythroid 
and granulocyte-monocyte progenitors, but it did not affect colony formation 
by late progenitors. Using limiting dilutional analysis they showed that 
autocrine TGF/3j is produced by a sub-population of early progenitors. Anti­
sense oligonucleotides to retinoblastoma susceptibility gene (Rb) produced a 
similar effect to anti-sense oligonucleotides to TGF/31? releasing multi-lineage 
progenitors from quiescence. Furthermore, Rb anti-sense partially reversed the 
effects of exogenous TGF/3V Their data suggest that the inhibitory effects of 
TGFjSj may be mediated by interaction with the Rb gene. Hatzfeld et al, 1991, 
also showed that with a combination of growth factors including IL-3, IL-6, G- 
CSF and Epo, CFU-GEMM and early BFU-E could be enhanced 2-3 fold by 
antisense TGFjS1 oligonucleotides or by anti-TGF/^ serum. Antisense 
oligonucleotides to TGF/3j may have a role in the future of amplification of
202
normal haemopoietic stem cells by release of intracellular control mechanisms 
that prevent them from leaving G0. Li et al, 1994, showed that Steel Factor in 
combination with antisense oligonucleotides to TGF/31? in cultures of CD34+ 
bone marrow, enhanced colony formation that was more than additive 
compared to cultures containing the single agents, thus suggesting that Steel 
Factor and TGF/3j act through distinct pathways.
The effects of TGFjSj on CD34+ purified cells depend on the 
proliferative stimulus. Whilst early progenitors stimulated by IL-3 in 
combination with IL-1 or SCF, on addition of TGF/^ are arrested specifically 
in the Gj phase of the second cell cycle, more committed progenitors 
stimulated by IL-3 alone are either not arrested or undergo a slow retardation 
of growth (Lardon et al, 1994). The presence of a subset of CD34+ progenitor 
cells unaffected by the anti-proliferative effects of TGFp1 suggests the point 
at which cells become in sensitive to TGF-Bj is located within the CD34+  
compartment.
During the past 5 years there has been an escalation in the use of 
peripheral stem cell transplants (PBSCT) in association with high dose 
chemotherapy to facilitate the recovery from neutropenia. The rationale that 
higher doses of a cytotoxic agent might have greater anti-tumour effect than 
lower doses is self-evident, but the dose administered is usually limited by the 
toxicity of the cytotoxic agent used. For the majority of cytotoxic drugs the 
limiting toxicity is myelosuppression. In the early 1950s, clinical studies were 
performed to try and ameliorate myelosuppression (McFarland et al, 1959).
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By todays standard the dose of cytotoxics used was small and marrow 
inoculum inadequate. Enthusiasm was re-awaked in the 1970s, since when the 
number of autologous bone marrow transplants has risen exponentially each 
year (Armitage, 1994). Autologous bone marrow transplantation is not without 
its problems. In particular, there are protracted periods of pancytopenia with 
its attendant morbidity, mortality and financial costs. The administration of 
haemopoietic growth factors after autologous BMT has only made a minor 
impact on these parameters (Armitage, 1994). The use of stem cells collected 
from the peripheral blood instead of bone marrow represents a considerable 
further technical advance. Stem cells were first noted to be increased following 
chemotherapy in 1976 (Richman et al, 1976). In 1988, it was reported that 
administration of granulocyte-macrophage colony-stimulating factor and 
granulocyte colony-stimulating factor resulted in the mobilization of progenitor 
cells into the circulation (Dursten et al, 1988; Socinski et al, 1988). 
Chemotherapy induced mobilization may increase CFU-GM 100-fold over 
baseline values, the combination of chemotherapy plus either GM-CSF or IL-3 
expands (5 to 10 fold) the number of progenitors (Holyoake and Alcorn, 
1994). A number of issues concerning PBSC transplants still require 
resolution. The optimal mobilization schedules have yet to be determined, the 
quality and quantity of circulating haemopoietic progenitors required for rapid, 
complete and sustained engraftment is uncertain, and finally the degree of 
tumour mobilization and hence contamination is not known, tumour 
contamination however has been described (Bird et al, 1994; Moss et al, 1992).
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The benefits of PBSC transplants are clear and include avoidance of a 
general anaesthetic, more rapid haematological recovery (Peters et al 1989; 
Khwaja et al, 1992) and lower costs (as a result of shorter in-patient stays, less 
antibiotic use, lower blood and platelet support). In addition no operating 
theatre costs are incurred. Against these savings must be set the costs 
associated with priming chemotherapy if used, mobilizing growth factors, the 
leukapheresis procedures and any quality control assays. The cost savings using 
PBSC as compared to bone marrow in autologous transplants is estimated at 
£3500/patient (Ager et al, 1994).
PBSC can also be used for allogeneic transplants (Russell et al, 1993; 
Dreger et al, 1993). G-CSF (with no cytotoxics) appears to be safe for normal 
donors and the avoidance of a general anaesthetic is clearly an advantage. 
There is concern that PBSC collections would contain more T cells and give 
rise to more graft-versus-host disease. A  variant of using allogeneic peripheral 
stem cells for transplant is the use of umbilical cord blood. Several studies 
indicate that human umbilical cord blood contains a higher proportion of 
primitive haemopoietic progenitors than bone marrow (Broxmeyer et al, 1992; 
Hows et al, 1992). The place of human umbilical cord blood as a source of 
marrow repopulating cells remains to be established, but the emerging data 
from related and unrelated umbilical cord blood transplants is encouraging. 
To date, 35 such transplants have been performed. Comprehensive data is 
available on 26 patients. The median duration to neutrophil recovery
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(0.5xl09/l) was 23 days (range 12-46), and the median time to platelet recovery 
(50xl09/l) was 44.5 days (range 15-105). There were 4 cases of graft failure. 
(Nichol et al, 1994).
The quantity and quality of circulating haemopoietic progenitors 
required for rapid and sustained engraftment is unclear, though a threshold 
dose of approximately 15-5Qxl04/kg CFU-GM has been recommended 
(Holyoake and Alcorn, 1994). Accurate measurement of CD34+ cell numbers 
may help to more accurately predict the most effective time to initiate 
apheresis procedures and also to avoid undesirable collections. The number 
of CD34+ progenitors obtained from mobilized peripheral blood may exceed 
that obtained from bone marrow 10 to 20-fold. Several groups have now 
shown that there also appears to be a correlation between CFU-GM numbers 
and CD34+ cell numbers obtained (Holyoake and Alcorn, 1994).
A  further interest is the possibility of expanding PBSC in vitro. The 
potential advantages of ex vivo expansion are; reducing harvest time, expanding 
the most primitive cells required for long-term engraftment, which may be 
useful when performing autologous transplants from heavily pre-treated 
patients, the possibility of expanding normal haemopoiesis at the expense of 
the malignant clone and finally ex vivo expanded haemopoietic cells may be 
candidate cells for retroviral transduction and genetic manipulation. Brugger 
et al, 1993 studied the effects of several combinations of cytokines on a 
population of CD34+ enriched cells. Stem cell factor, epo, IL-1B, IL-6, IL-3 
and interferon-gamma were identified as the optimal combination of growth
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factors for expanding both the total number of nucleated cells as well as 
clonogenic progenitor cells. The number of multilineage colonies increased 
250-fold as did the absolute number of early progenitors (CD34+/HLA-DR-; 
CD34+/CD38-). Hence large scale expansion from small numbers of CD34+  
cells is feasible and may be sufficient for repetitive use after multiple cycles 
of high-dose chemotherapy.
To demonstrate the potential for combined modality mobilization of 
PBSCs, Brugger et al, 1992, studied the effects of GM-CSF alone and in 
combination with IL-3. A  greater number of progenitors were mobilized using 
GM-CSF and IL-3. Ganser et al, 1992 too showed that the number of 
progenitors giving rise to CFU-GM and BFU-E was enhanced when IL 3  was 
used with GM-CSF. Stem cell factor and G-CSF together or in combination 
with IL-3 may have a similar effect. Synergistic effects of combinations of 
growth factors is a rapidly expanding area and may show clinical benefit in the 
future.
In this study G-CSF and IL-4 had a synergistic colony-forming effect 
when CML cells in chronic phase were used. IL-4 had no effect on normal 
MNC stimulated by G-CSF (colony numbers however were low in all 
instances). In AML, the addition of IL-4 increased G-CSF-induced colony 
numbers. The number of AML samples studied were too small for this to be 
definitive. Further studies are required to determine the effects of IL-4 on G- 
CSF-induced CFU-GM of normal MNC, before G-CSF plus IL-4 can be used 
to mobilise PBSCs.
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In CML, autologous transplants were carried out using unmanipulated 
peripheral blood cells collected at diagnosis, from patients in chronic phase 
(Hoyle et al, 1994). Recently autografts involving either in vivo or in vitro 
manipulations have evolved in the treatment of CML. Such approaches have 
been developed in an attempt to select benign haemopoietic progenitors and 
therefore restore normal, Ph negative haemopoiesis. The in vivo methods have 
involved giving chemotherapy and then collecting PBSCs mobilized into the 
circulation during the recovery phase. Various mobilizing regimens have been 
used including cyclophosphamide 5-7gm/m2, ICE (idarubicin, cytarabine and 
etoposide), (Tringali et al, 1994, Carella et al,1991). The optimum mobilization 
regimen has yet to be defined and the follow up period is too short in this 
group of patients. What is interesting, is that normal progenitors appear to 
predominate over CML cells, when PBSCs are collected after chemotherapy, 
the reasons for this are not apparent. M lP-la has an inhibitory effect on 
normal but not CML progenitors (Eaves et al,1993; Holyoake et al, 1993). 
Appropriate scheduling of MIP-la together with intensive chemotherapy might 
may have future clinical application in the treatment of CML, that results in 
improved anti-leukaemic effect without the associated risks of severe marrow 
aplasia. In this study TGF^1 had no apparent effect on normal progenitors, 
however others have reported an inhibitory effect of TGF/^ on normal 
haemopoietic cells (Sing et al, 1988). If the effects of TGF/^ are not 
preferential it is unlikely to have a role in the treatment of CML. In CML part 
of the genetic lesion could be loss of sensitivity to inhibitory signals leading to
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deregulated proliferation of primitive progenitor cells. If the effects of negative 
inhibitors such as TGFBj are preferential then drug regimens designed to 
ablate or reduce the leukaemic progenitors becomes a real possibility. Other 
potential uses of the negative regulatory proteins include MIP-la to protect 
stem cells against myelotoxic treatments and antisense TGFi^ oligonucleotides 
to amplify the normal haemopoietic compartment either following 
chemotherapy or to enhance mobilization of stem cells for transplantation.
The Vancouver group have recently published their results for 
autografting for CML using cultured marrow cells (Barnett et al, 1994). 
Thirteen of 16 patients autografted in first chronic phase are alive 1.0 to 5.7 
years after the autograft. 4/13 are in complete cytogenetic remission. Thus 
autografting with cultured marrow cells may result in Ph negative 
haemopoiesis in some patients.
Okabe et al, 1992 have shown that IL-4 has an inhibitory effect in vitro 
on Ph positive acute lymphoblastic leukaemia cells (encoding a 190kD tyrosine 
kinase). This inhibitory effect was not mediated by the induction of TNF-o: or 
interferon but was associated with a decreased activity of intracellular protein- 
tyrosine kinase. A  phase 1 study of daily i.v bolus IL-4 in patients with 
refractory malignancies (colon, renal, sarcoma) produced an array of side 
effects the most prominent of which were nasal congestion, periorbital 
oedema, fatigue, diarrhoea and capillary leak syndrome (Atkin et al, 1992). 
The side effects were dose related and became severe at a dose of 15pg/kg.
In this study, IL-4 had a variable effect on G-CSF-induced colony
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formation from CML myeloid blast transformation mononuclear cells. In 2/4 
patients colony numbers were reduced, in 1/4 it was increased and in the 
remaining patient CFU-CML induced by G-CSF were unchanged by the 
addition of IL-4. IL-4 inhibits the production of granulocyte-macrophage 
colony-stimulating factor by blood mononuclear accessory cells in normal 
human peripheral blood (Sato et al, 1994). As a negative regulator, this 
mechanism of action is different from TGF(3l which directly inhibits 
haemopoietic progenitor cells (Sing et al, 1988; Keller et al, 1988a). IU 4  
suppresses the spontaneous proliferation of chronic myelomonocytic leukaemia 
by inhibiting their production of IL-6 and/or GM-CSF, both of which could act 
as an autocrine growth factor for chronic myelomonocytic cells (Akashi et al, 
1991a). IL-4 could similarly have an inhibitory effect on CML blast 
transformation cells by inhibiting accessory cells or autocrine growth factors. 
As the prognosis for patients with CML in blast crisis is so poor (Goldman, 
1989b) and as IL-4 may potentially be of benefit further in vitro studies of the 
effects of this cytokine on CML blast transformation MNC are justified.
In patients with CML, the degree of CD34 positivity did not correlate 
with the WBC at diagnosis or the growth of CFU-CML in vitro. Patients in 
chronic phase have the whole spectrum of myeloid progenitors and these more 
mature cells are less like to express the CD34+ antigen. By contrast, 3/3 
patients in myeloid blast transformation had a high percentage of CD34+ 
cells. In AML cells the degree of CD34+ positivity at diagnosis correlates with 
a poorer prognosis (Geller et al, 1990).
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In normal haemopoiesis cells expressing CD34+ antigen, constitute a 
heterogeneous population, many of the cells of which are already committed 
to a particular lineage (Sutherland et al, 1989). The antigens that define 
lineage commitment include CD10 and CD19 on pre-B lymphoid cells, CD5 
and CD7 on pre-T lymphoid cells, CD13, CD33 and CD45RA on myeloid 
progenitors, CD41 on megakaryocytic progenitors and CD71 and CD45RO on 
erythroid precursors (Holyoake and Alcorn, 1994). A more primitive 
progenitor population can be defined that does not coexpress any lineage 
antigens and is CD34+, lin-, HLA-DR-, RhoduU, CD45RO. The primitive 
nature of these cells is confirmed by their ability to establish haemopoiesis on 
fibroblast feeder layers (LTC-IC), (Sutherland et al, 1989). Recently Huang 
and Terstappen, 1992 reported the presence of 2 distinct subsets of stem cells 
from foetal human bone marrow. One subset was CD34+, CD38-, HLA-DR+ 
and could differentiate into all haemopoietic lineages. The other subset was 
more primitive and had the immunophenotype CD34+, CD38-, HLA-DR-. 
These cells could differentiate into haemopoietic precursors and could form 
stromal structures capable of supporting the differentiation of these 
precursors. These cells were termed "common (haemopoietic/stromal) stem 
cells". They could represent the first identification of a single cell capable of 
reconstituting haemopoietic cells and their microenvironment.
CD34+ cell populations can be isolated by fluorescence activated cell 
sorting (FACS), giving yields of high purity. Because of the large cell numbers 
required this technology is not suitable for collecting cells for transplantation
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(Holyoake and Alcorn, 1994). Adequate numbers of cells for this purpose can 
be purified using several commercially available devices that are available. The 
most widely used system (CellPro) exploits the high affinity interaction 
between the protein avidin and the vitamin biotin. For positive selection cells 
are labelled with an biotinylated anti-CD34+ and then passed through a 
column of avidin-coated polyacrylamide beads. CD34+ cells are retained and 
can be recovered by gentle agitation (Holyoake and Alcorn, 1994).
Brenner et al, 1993 first showed using an neomycin resistance gene 
marker, that in autologous transplantation for AML or neuroblastoma an 
apparent remission marrow can contribute to relapse. Since then other 
workers have shown that there is tumour contamination of PBSC collections 
and this depends on the type of primary tumour, its stage and prior 
chemotherapy (Bird et al, 1994; Moss et al, 1992). A  major advantage in using 
CD34+ cells for transplantation would be the possible reduction in 
contaminating tumour cells. In the majority of tumours, malignant cells 
contaminating the blood or bone marrow do not express the CD34+ antigen. 
Lebkowski et al, 1992 showed that CD34+ cells enriched from bone marrow 
to which defined numbers of radiolabelled tumour cells were added, were 
99.9% depleted of tumour cells. The tumour cells studied included AML, 
neuroblastoma, breast cancer and small cell lung cancer. The potential benefits 
of selected CD34+ for transplantation include reduced tumour contamination, 
faster neutrophil and platelet engraftment times, reduced storage 
requirements, smaller volumes being re-infused to the patient thus reducing
212
the effects of DMSO toxicity and fluid overload. Positively selected PBSC 
transplants have now been carried out (Berenson et al, 1991, Shpall et al, 
1994). It is likely that in the next decade the use of CD34+ will significantly 
reduce the period of pancytopenia following high-dose chemotherapy so that 
the procedure may be carried out in the out-patient clinic.
Dubois et al, 1990 showed that specific binding of IL-1 to growth factor 
dependent myeloid progenitor cell lines was inhibited by incubation with 
TGFjSj. TGFjSj inhibits the ability of IL-3 to up-regulate IL-1 receptors and 
the expression of ID-1 receptors on lymphoid cells (Ruscetti et al, 1992). Thus 
the mechanism of growth inhibition by TGF/^ could be relevant to other 
surface receptors as well. Attempts to elucidate the mechanisms by which 
TGFjSj inhibited G-CSF and G-CSF plus IL-4-induced CFU-CML using in situ 
hybridisation was largely unsuccessful. The expression of the G-CSFR and ID  
4R were established in one CML sample and 2 normal donor peripheral blood 
samples. In the CML sample the expression of the G-CSFR and IL-4R were 
unchanged in cultures stimulated with G-CSF, G-CSF and IL-4, and G-CSF 
in combination with both IL-4 and TGF/^. Clearly definitive results cannot be 
drawn from this data. It does however suggest that the inhibitory effects of 
TGFjSj may be mediated by a difference in signal transduction or protein 
synthesis rather than at the level of transcription.
Over the past decade the haemopoietic growth factors have 
provided new insights into the mechanisms of haemopoiesis and the 
differentiation of blood cells. Cytokines such as erythropoietin, G-CSF, GM-
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CSF, IL-2 and IL-3 have been used in clinical trials and G-CSF, GM-CSF and 
erythropoietin have found niches in different clinical situations. Other growth 
factors such as IL^4 and TGF/^ have not been studied extensively in humans 
but hold promise for the future.
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APPENDIX
TABLE Is CLINICAL DETAILS OF PATIENTS WITH CML
UPN AGE SEX DISEASE Hb
£/dl
WBC
1071
Plat
1071
Treatment
21 39 M Ph CML CP 14.4 87.2 210 Nil
22 49 F Ph CML CP 12.9 38.5 702 Nil
23 38 F Ph CML CP 9.8 69 519 Nil
24 43 F Ph CML CP 13.1 55.1 310 Nil
25 53 F Ph** CML 12.0 48.0 170 Nil
26 11 M Ph CML BT 11.1 26.5 54 Yes chemo
27 31 F Ph CML BT 9.0 2.9 115 Yes chemo
28 36 F Ph CML CP 13.6 9.0 424 Nil
29 29 M Ph CML CP 8.9 35.0 102 Yes Bus
30 39 M Ph've CML 7.7 380 207 Nil
31 31 M Ph CML CP 10.2 22.6 496 Nil
32 47 M Ph CML CP 11.5 65.1 371 Nil
33 32 M Ph CML CP 123 53.0 222 Nil
34 24 M Ph CML BT 15.1 83.3 688 Yes chemo
35 46 M Ph CML BT 11.3 51.8 43 Yes A/G
36 34 F Ph CML CP 11.4 123 348 Nil
37 36 M Ph CML CP 14.0 52.0 253 Nil
38 49 M Ph CML CP 12.9 91.2 127 Nil
39 33 M Ph CML CP 13.8 250 589 Nil
51 37 F Ph CML CP 10.1 38.6 946 Yes OH 
urea
52 48 M Ph CML CP 15.1 98.9 490 Yes OH 
urea
53 41 F Ph CML CP 13.2 45.3 380 Yes OH 
urea
54 49 F Ph CML CP 7.2 350 98 No
54b 49 F Ph CML CP 11.2 96.1 54 Yes chemo
55 31 F Ph CML CP 13.0 74.1 298 No
56 46 M Ph CML CP 10.0 38.4 378 Yes OH 
urea
57 36 M Ph CML BT 9.9 81.0 32 Yes, chemo
transformation
UPN 25 & 30 - Ph‘ve CML; A/G - autograft; Bus - busulphan; OH urea - hydroxyurea
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TABLE II: CLINICAL DETAILS OF PATIENTS WITH AML
UPN AGE SEX FAB TYPE Hb
g/dl
WBC
io9/i
Plat
io7i
Treatment
40 35 F 2^ AML 14.1 72.5 73.0 Yes
42 23 M AML M3 4.5 137.0 71.0 Nil
44 69 4 AML Ml 14.5 71.6 23.0 Nil
46 33 M AML M4 9.5 43.8 10.0 Nil
47 21 F AML M2 8.8 76.0 78.0 Nil
48 59 M 2^ AML 10.5 4.1 15.0 Yes
49 41 M AMLM4 8.1 3.2 61.0 Nil
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TABLE III: Composition o f Eagles minimal essential medium (alpha-medium)
INGREDIENT MEM
mg/litre
INGREDIENT MEM
mg/litre
L-Alanine 25.00 L-Tyrosine 45.00
Lr Arginine 126.4 L-Valine 46.90
Lr Asparagine 50.00 Ascorbic acid 50.00
LrAspartic acid 30.00 Biotin 0.10
I^Cysteine 89.74 Folic acid 1.00
I^Cystine 30.22 i-Inositol 2.00
L-Glutamic acid 75.00 Nicotinamide 1.00
L-Glutamine 292.00 Pyridoxin e 1.00
Glycine 50.00 Riboflavin 0.10
L-Histidine 41.90 Thiamin HC1 1.00
L-Isoleucine 52.50 Vitamin B12 1.36
I^Leucine 52.50 CaCl2 264.90
L-Lysine HC1 73.06 KC1 400.00
L-Methionine 14.90 MgS04.7H2O 200.00
L-Phenylalanine 33.02 NaCl 6000.800
I^Proline 40.00 N aH C 03 2000.00
L-Serine 25.00 NaH2P04.2H2O 158.3
L-Threonine 47.64 D-Glucose 1000.00
L-Tryptophan 10.20 Phenol red sodium 
salt
10.00
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TABLE IV: COMPOSITION OF RPMI 1640 CULTURE M EDIUM
INGREDIENT RPMI 1640 
mg/litre
INGREDIENT RPMI 1640 
mg/litre
L-Arginine 200.00 L-Tyrosine 24.83
L-Asparagine 56.82 L-Valine 20.00
L-Aspartic acid 20.00 Biotin 0.20
L-Cystine 62.92 D-Calcium
pantothenate
0.25
L-Glutamic acid 20.00 Choline Chloride 3.00
Glutathione 1.00 Folic acid 1.00
UGlutamine 300.00 i-Inositol 35.00
Glycine 10.00 Nicotinamide 1.00
DHistidine 15.00 p-Aminobenzoic acid 1.00
U-Hydroxyproline 20.00 Pyridoxine HC1 1.00
DIsoleucine 50.00 Riboflavin 0.20
L-Leucine 50.00 Thiamin HC1 1.00
L-Lysine HC1 40.00 Vitamin B12 0.005
DMethionine 15.00 C a(N 03)2 69.48
L-Phenylalanine 15.00 KC1 400.00
L-Proline 20.00 MgS04.7H2O 100.00
L-Serine 30.00 NaCl 6000.00
L-Threonine 20.00 D-Glucose 800.7
L-Tryptophan 5.00 Phenol red sodium 
salt
5.00
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Figure 2
ctggactgca gctggtttca ggaacttctc ttgacgagaa gagagaccaa ggaggccaag 
eaggggetgg gccagaggtg ccaacatggg gaaactgagg ctcggctcgg aaaggtgaag 
taacttgtcc aagatcacaa agctggtgaa catcaagttg gtgctatggc aaggctggga 
aactgcagcc tgacttgggc tgccctgatc atcctgctgc tccccggaag tctggaggag 
tgcgggcaca tcagtgtctc agcccccatc gtccacctgg gggatcccat cacagcctcc 
tgcatcatca agcagaactg cagccatctg gacccggagc cacagattct gtggagactg 
ggagcagagc ttcagcccgg gggcaggcag cagcgtctgt ctgatgggac ccaggaatct 
atcatcaccc tgccccacct caaccacact caggcctttc tctcctgctg cctgaactgg 
ggcaacagcc tgcagatcct ggaccaggtt gagctgcgcg caggctaccc tccagccata 
ccccacaacc tctcctgcct catgaacctc acaaccagca gcctcatctg ccagtgggag 
ccaggacctg agacccacct acccaccagc ttpaclctga agagtttcaa gagccggggc 
aactgtcaga cccaagggga ctccatcctg gactgcgtgc ccaaggacgg gcagagccac 
tgctgcatcc cacgcaaaca cctgctgttg taccagaata tgggcatctg ggtgcaggca 
gagaatgcgc tggggaccag catgtcccca caactgtgtc ttgatcccat ggatgttgtg 
aaactggagc cccccatgct gcggaccatg gaccccagcc ctgaagcggc ccctccccag 
gcaggctgcc tacagctgtg ctgggagcca tggcagccag gcctgcacat aaatcagaag 
tgtgagctgc gccacaagcc gcagcgtgga gaagccagct gggcactggt gggccccctc 
cccttggagg cccttcagta tgagctctgc gggctcctcc cagccacggc ctacaccctg 
cagatacgct gcatccgctg gcccctgcct ggccactgga gcgactggag ccccagcctg 
gagctgagaa ctaccgaacg ggcccccact gtcagactgg acacatggtg gcggcagagg 
cagctggacc ccaggacagt gcagctgttc tggaagccag tgcccctgga ggaagacagc 
ggacggatcc aaggttatgt ggtttcttgg agaccctcag gccaggctgg ggccatcctg 
cccctctgca acaccacaga gctcagctgc accttccacc tgccttcaga agcccaggag 
gtggcccttg tggcctataa ctcagccggg acctctcgcc ccaccccggt ggtcttctca 
gaaagcagag gcccagctct gaccagactc catgccatgg cccgagaccc tcacagcctc 
tgggtaggct gggagccccc caatccatgg cctcagggct atgtgattga gtggggcctg 
ggccccccca gcgcgagcaa tagcaacaag acctggagga tggaacagaa tgggagagcc 
acggggtttc tgctgaagga gaacatcagg ccctttcagc tctatgagat catcgtgact 
cccttgtacc aggacaccat gggaccctcc cagcatgtct atgcctactc tcaagaaatg 
gctccctccc atgccccaga gctgcatcta aagcacattg gcaagacctg ggcacagctg 
gagtgggtgc ctgagccccc tgagctgggg aagagccccc ttacccacta caccatcttc 
tggaccaacg ctcagaacca gtccttctcc gccatcctga atgcctcctc ccgtggcttt 
gtcctccatg gcctggagcc cgccagtctg tatcacatcc acctcatggc tgccagccag 
gctggggcca. ccaacagtac agtcctcacc ctgatgacct tgaccccaga ggggtcggag 
ctacacatca tcctgggcct gttcggcctc ctgctgttgc tcacctgcct ctgtggaact 
gcctggctct gttgcagccc caacaggaag aatcccctct ggccaagtgt cccagaccca 
gctcacagca gcctgggctc ctgggtgccc acaatcatgg aggaggatgc cttccagctg 
cccggccttg gcacgccacc catcaccaag ctcacagtgc tggaggagga tgaaaagaag 
ccggtgccct gggagtccca taacagctca gagacctgtg gcctccccac tctggtccag 
acctatgtgc tccaggggga cccaagagca gtttccaccc agccccaatc ccagtctggc 
accagcgatc aggtccttta tgggcagctg ctgggcagcc ccacaagccc agggccaggg 
cactatctcc gctgtgactc cactcagccc ctcttggcgg gcctcacccc cagccccaag 
tcctatgaga acctctggtt ccaggccagc cccttgggga ccctggtaac cccagcccca 
agccaggagg acgactgtgt ctttgggcca ctgctcaact tccccctcct gcaggggatc 
cgggtccatg ggatggaggc gctggggagc ttctagggct tcctggggtt cccttcttgg 
gcctgccttt taaaggcctg agctagctgg agaagagggg agggtccata agcccatgac 
taaaaactac cccagcccag gctctcacca tctccagtca ccagcatctc cctctcctcc 
caatctccat aggctgggcc tcccaggcga tctgcatact ttaaggacca gatcatgctc 
catccagccc cacccaatgg ccttttgtgc ttgtttccta taacttcagt att
Sequence of human mRNA coding for granulocyte colony-stimulating factor receptor. 
Source tissue: placenta 
Source clone: HuGCSFR-25-1
From: Larsen, A., Davis, T., Curtis, B.M., Gimpel, S., Sims, J., Cosman, D., Park, L., 
Sorensen, E., March, C.J., Smith, C. (1990) Expression cloning of a human granulocyte 
colony-stimulating factor receptor: a structural mosaic of hematopoietin receptor, 
immunoglobulin and fibronectin domains. Journal of Experimental Medicine, 172,1559-1570. 
Submitted on 02-0ct-1990 on tape to the EMBL Data Library.
219
Figure 3
1 GGCGAATGGA GCAGGGGCGC GCAGATAATT AAAGATTTAC ACACAGCTGG AAGAAATCAT 
61  AGAGAAGCCG GGCGTGGTGG CTCATGCCTA TAATCCCAGC ACTTTTGGAG GCTGAGGCGG 
12 1  GCAGATCACT TGAGATCAGG AGTTCGAGAC CAGCCTGGTG CCTTGGCATC TCCCAATGGG 
1 8 1  GTGGCTTTGC TCTGGGCTCC TGTTCCCTGT GAGCTGCCTG GTCCTGCTGC AGGTGGCAAG 
24 1 CTCTGGGAAC ATGAAGGTCT TGCAGGAGCC CACCTGCGTC TCCGACTACA TGAGCATCTC 
3 0 1  TACTTGCGAG TGGAAGATGA ATGGTCCCAC CAATTGCAGC ACCGAGCTCC GCCTGTTGTA 
3 6 1  CCAGCTGGTT TTTCTGCTCT CCGAAGCCCA CACGTGTATC CCTGAGAACA ACGGAGGCGC 
4 2 1  GGGGTGCGTG TGCCACCTGC TCATGGATGA CGTGGTCAGT GCGGATAACT ATACACTGGA 
4 8 1  CCTGTGGGCT GGGCAGCAGC TGCTGTGGAA GGGCTCCTTC AAGCCCAGCG AGCATGTGAA 
5 4 1  ACCCAGGGCC CCAGGAAACC TGACAGTTCA CACCAATGTC TCCGACACTC TGCTGCTGAC 
6 0 1  CTGGAGCAAC CCGTATCCCC CTGACAATTA CCTGTATAAT CATCTCACCT ATGCAGTCAA 
6 6 1  CATTTGGAGT GAAAACGACC CGGCAGATTT CAGAATCTAT AACGTGACCT ACCTAGAACC 
7 21 CTCCCTCCGC ATCGCAGCCA GCACCCTGAA GTCTGGGATT TCCTACAGGG CACGGGTGAG 
7 8 1  GGCCTGGGCT CAGTGCTATA ACACCACCTG GAGTGAGTGG AGCCCCAGCA CCAAGTGGCA 
84 1 CAACTCCTAC AGGGAGCCCT TCGAGCAGCA CCTCCTGCTG GGCGTCAGCG TTTCCTGCAT 
9 0 1  TGTCATCCTG GCCGTCTGCC TGTTGTGCTA TGTCAGCATC ACCAAGATTA AGAAAGAATG 
9 6 1  GTGGGATCAG ATTCCCAACC CAGCCCGCAG CCGCCTCGTG GCTATAATAA TCCAGGATGC 
1 0 2 1  TCAGGGGTCA CAGTGGGAGA AGCGGTCCCG AGGCCAGGAA CCAGCCAAGT GCCCACACTG 
1 0 8 1  GAAGAATTGT CTTACCAAGC TCTTGCCCTG TTTTCTGGAG CACAACATGA AAAGGGATGA 
1 1 4 1  AGATCCTCAC AAGGCTGCCA AAGAGATGCC TTTCCAGGGC TCTGGAAAAT CAGCATGGTG 
1 2 0 1  CCCAGTGGAG ATCAGCAAGA CAGTCCTCTG GCCAGAGAGC ATCAGCGTGG TGCGATGTGT 
1 2 6 1  GGAGTTGTTT GAGGCCCCGG TGGAGTGTGA GGAGGAGGAG GAGGTAGAGG AAGAAAAAGG 
1 3 2 1  GAGCTTCTGT GCATCGCCTG AGAGCAGCAG GGATGACTTC CAGGAGGGAA GGGAGGGCAT 
1 3 8 1  TGTGGCCCGG CTAACAGAGA GCCTGTTCCT GGACCTGCTC GGAGAGGAGA ATGGGGGCTT 
14 4 1  TTGCCAGCAG GACATGGGGG AGTCATGCCT TCTTCCACCT TCGGGAAGTA CGAGTGCTCA 
1 5 0 1  CATGCCCTGG GATGAGTTCC CAAGTGCAGG GCCCAAGGAG GCACCTCCCT GGGGCAAGGA 
1 5 6 1  GCAGCCTCTC CACCTGGAGC CAAGTCCTCC TGCCAGCCCG ACCCAGAGTC CAGACAACCT 
16  21  GACTTGCACA GAGACGCCCC TCGTCATCGC AGGCAACCCT GCTTACCGCA GCTTCAGCAA 
1 6 8 1  CTCCCTGAGC CAGTCACCGT GTCCCAGAGA GCTGGGTCCA GACCCACTGC TGGCCAGACA 
1 7 4 1  CCTGGAGGAA GTAGAACCCG AGATGCCCTG TGTCCCCCAG CTCTCTGAGC CAACCACTGT 
1 8 0 1  GCCCCAACCT GAGCCAGAAA CCTGGGAGCA GATCCTCCGC CGAAATGTCC TCCAGCATGG 
1 8 6 1  GGCAGCTGCA GCCCCCGTCT CGGCCCCCAC CAGTGGCTAT CAGGAGTTTG TACATGCGGT 
19 2 1  GGAGCAGGGT GGCACCCAGG CCAGTGCGGT GGTGGGCTTG GGTCCCCCAG GAGAGGCTGG 
19 8 1  TTACAAGGCC TTCTCAAGCC TGCTTGCCAG CAGTGCTGTG TCCCCAGAGA AATGTGGGTT 
2 0 4 1  TGGGGCTAGC AGTGGGGAAG AGGGGTATAA GCCTTTCCAA GACCTCATTC CTGGCTGCCC 
2 1 0 1  TGGGGACCCT GCCCCAGTCC CTGTCCCCTT GTTCACCTTT GGACTGGACA GGGAGCCACC 
2 1 6 1  TCGCAGTCCG CAGAGCTCAC ATCTCCCAAG CAGCTCCCCA GAGCACCTGG GTCTGGAGCC 
2 2 2 1  GGGGGAAAAG GTAGAGGACA TGCCAAAGCC CCCACTTCCC CAGGAGCAGG CCACAGACCC 
2 2 8 1  CCTTGTGGAC AGCCTGGGCA GTGGCATTGT CTACTCAGCC CTTACCTGCC ACCTGTGCGG 
2 3 4 1  CCACCTGAAA CAGTGTCATG GCCAGGAGGA TGGTGGCCAG ACCCCTGTCA TGGCCAGTCC 
2 4  0 1  TTGCTGTGGC TGCTGCTGTG GAGACAGGTC CTCGCCCCCT ACAACCCCCC TGAGGGCCCC 
2 4 6 1  AGACCCCTCT CCAGGTGGGG TTCCACTGGA GGCCAGTCTG TGTCCGGCCT CCCTGGCACC 
2 5 2 1  CTCGGGCATC TCAGAGAAGA GTAAATCCTC ATCATCCTTC CATCCTGCCC CTGGCAATGC 
2 5 8 1  TCAGAGCTCA AGCCAGACCC CCAAAATCGT GAACTTTGTC TCCGTGGGAC CCACATACAT 
2 6 4 1  GAGGGTCTCT TAGGTGCATG TCCTCTTGTT GCTGAGTCTG CAGATGAGGA CTAGGGCTTA 
2 7  0 1  TCCATGCCTG GGAAATGCCA CCTCCTGGAA GGCAGCCAGG CTGGCAGATT TCCAAAAGAC 
2 7  6 1  TTGAAGAACC ATGGTATGAA GGTGATTGGC CCCACTGACG TTGGCCTAAC ACTGGGCTGC 
2 8 2 1  AGAGACTGGA CCCCGCCCAG CATTGGGCTG GGCTCGCCAC ATCCCATGAG AGTAGAGGGC 
2 8 8 1  ACTGGGTCGC CGTGCCCCAC GGCAGGCCCC TGCAGGAAAA CTGAGGCCCT TGGGCACCTC 
2 9 4 1  GACTTGTGAA CGAGTTGTTG GCTGCTCCCT CCACAGCTTC TGCAGCAGAC TGTCCCTGTT 
3 0 0 1  GTAACTGCCC AAGGCATGTT TTGCCCACCA GATCATGGCC CACGTGGAGG CCCACCTGCC 
3 0 6 1  TCTGTCTCAC TGAACTAGAA GCCGAGCCTA GAAACTAACA CAGCCATCAA GGGAATGACT 
3 1 2 1  TGGGCGGCCT TGGGAAATCG ATGAGAAATT GAACTTCAGG GAGGGTGGTC ATTGCCTAGA 
3 1 8 1  GGTGCTCATT CATTTAACAG AGCTTCCTTA GGTTGATGCT GGAGGCAGAA TCCCGGCTGT 
3 2 4 1  CAAGGGGTGT TCAGTTAAGG GGAGCAACAG AGGACATGAA AAATTGCTAT GACTAAAGCA 
3 3 0 1  GGGACAATTT GCTGCCAAAC ACCCATGCCC AGCTGTATGG CTGGGGGCTC CTCGTATGCA 
3 3 6 1  TGGAACCCCC AGAATAAATA TGCTCAGCCA CCCTGTGGGC CGGGCAATCC AGACAGCAGG 
34  2 1  CATAAGGCAC CAGTTACCCT GCATGTTGGC CCAGACCTCA GGTGCTAGGG AAGGCGGGAA
Sequence of mRNA coding for human interleukin-4 receptor.
Source: peripheral blood T-cells 
Source clone: T22-8
From: Idzerda, R.L., March, C.J., Mosley, B., Lyman, S.D., Gimpel, S.D., Din, W.S., 
Grabstein, K.H., Widmer, M.B., Park, L.S., Cosman, D., Beckmann, M.P. (1990) Human 
interleukin-4 receptor confers biological responsiveness and defines a novel receptor 
superfamily. Journal of Experimental Medicine, 171, 861-873.
Submitted to EMBL Data Library on 02-Nov-1990.
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